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ABSTRACT 
Injectable Cell-Laden Hydrogel Composites for Osteochondral Tissue Engineering 
By 
Xuan Guo 
This work investigated an injectable, biodegradable hydrogel composite of 
oligo(poly(ethylene glycol) fumarate) (OPF) and gelatin microparticles (MPs) as a cell 
and growth factor carrier for osteochondral tissue engineering applications. An in vitro 
study first investigated chondrogenic differentiation of rabbit marrow mesenchymal stem 
cells (MSCs) encapsulated in single-layer hydrogel composites of different swelling 
ratios with or without transforming growth factor-pl (TGF-pi). The results showed that 
hydrogel composites containing TGF-pi -loaded MPs and of higher swelling ratios 
supported MSC chondrogenic differentiation. When implanted in a rabbit osteochondral 
defect, these hydrogel composites containing MSCs facilitated subchondral bone 
formation in the presence of TGF-pi. However, the delivery of MSCs either with or 
without TGF-pi did not improve cartilage morphology. Accordingly, a bilayered 
OPF/MP hydrogel composite consisting of a chondrogenic layer and an osteogenic layer 
was fabricated. In vitro culture of the construct demonstrated that MSCs encapsulated in 
the chondrogenic layer differentiated into chondrocyte-like cells in the presence of 
TGF-pi-loaded MPs. In the osteogenic layer, osteogenically precultured MSCs 
maintained their osteoblastic phenotype, and synergistically enhanced chondrogenic 
differentiation of the MSCs in the chondrogenic layer with TGF-pi. In a following study 
investigating similar hydrogel composites, TGF-P3-loaded MPs in the chondrogenic layer 
showed a more effectively stimulatory effect on MSC chondrogenic differentiation than 
TGF-pi -loaded MPs. Furthermore, encapsulated cells of different degrees of osteogenic 
differentiation in the osteogenic layer were found to significantly influence the 
chondrogenic gene expression of co-cultured MSCs in both the presence and absence of 
TGF-|33. Overall, this study demonstrated the fabrication of hydrogel composites that 
mimic the structure and function of osteochondral tissue, along with the application of 
these composites as cell and growth factor carriers for osteochondral tissue engineering. 
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CHAPTER I: SPECIFIC AIMS 
The objective of this work focuses on the development of a biodegradable 
hydrogel composite as a cell and growth factor carrier for osteochondral tissue 
engineering applications. In particular, hydrogel composites of oligo(poly(ethylene glycol) 
fumarate) (OPF) encapsulating gelatin microparticles (MPs) and rabbit marrow 
mesenchymal stem cells (MSCs) were investigated, towards the following specific aims: 
1. Fabricate OPF/transforming growth factor-pi (TGF-pi)-loaded MP hydrogel 
composites for chondrogenic differentiation of encapsulated MSCs in vitro, and 
determine the effect of swelling ratio of the hydrogel composites on cell 
differentiation; 
2. Evaluate the capacity of these hydrogel composites containing MSCs and TGF-pi for 
cartilage and bone tissue repair in an osteochondral defect in vivo; 
3. Generate a bilayered OPF/MP hydrogel composite consisting of a chondrogenic layer 
and an osteogenic layer, and evaluate cell differentiation in each layer in vitro; 
4. Investigate the combined effect of a chondrogenic growth factor and osteogenic cells 
of different preculture periods on the chondrogenic differentiation of the co-cultured 
MSCs in the chondrogenic layer of the bilayered OPF hydrogel composites. 
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CHAPTER II: BACKGROUND -- APPROACHES FOR OSTEOCHONDRAL TISSUE 
ENGINEERING 
Abstract 
Articular cartilage is an avascular tissue in the articular joint with a limited 
self-repair potential once injured. Injured articular cartilage also leads to degenerative 
changes in subchondral bone, resulting in severe pain and loss of mobility of the joint. 
Tissue engineering has become a promising strategy for tissue regeneration, by 
combining scaffolds, cells, and bioactive molecules. In this review, different scaffold 
materials, cells and bioactive factors for engineering of both cartilage and bone tissues 
are discussed. Furthermore, the review emphasizes tissue engineering strategies to 
fabricate a well-integrated construct consisting of both cartilage-like and bone-like tissues, 
which can mimic the structure and fulfill the functions of native osteochondral tissue. 
Abbreviations 
ALP, alkaline phosphatase; BMP, bone morphogenetic protein; dw, dry weight; ECM, 
extracellular matrix; FGF, fibroblast growth factors; GAG, glycosaminoglycan; IGF, 
insulin-like growth factor; MMP, matrix metalloproteinase; MP, gelatin microparticles; 
MPC, mesenchymal progenitor cell; MSC, mesenchymal stem cell; OPF, 
oligo(poly(ethylene glycol) fumarate); PCL, poly(s-caprolactone); PEG, poly(ethylene 
glycol); PEG-DA, poly(ethylene glycol)-diacrylate; PGA, poly(glycolic acid); PLA, 
poly(lactic acid); PLGA, poly(lactic-co-glycolic acid); PNIPAAm, 
poly(N-isopropylacrylamide); PPO, poly(propylene oxide); PPF, poly(propylene 
fumarate); TCP, tricalcium phosphate; TGF, transforming growth factor; VEGF, vascular 
endothelial growth factor; ww, wet weight; 3D, three dimensional. 
Motivation 
In the articular joint, articular cartilage and subchondral bone are two distinct 
tissues that contribute to the unique and important functions of the joint. Articular 
cartilage protects bone from high stresses and allows for low-friction movements within 
the joint, while subchondral bone serves as a mechanical support for the articular surface 
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[1-3]. However, articular cartilage has limited ability to regenerate once injured due to its 
complex structure and poor access to progenitor cells [1]. Furthermore, injured articular 
cartilage can lead to degenerative changes of the subchondral bone, resulting in severe 
pain and loss of mobility of the affected joint [1, 2]. Osteoarthritis, a disease caused by 
degeneration of osteochondral tissue, has been reported to affect about 10% United States 
population older than 30, and most of the people older than 65, leading to a total direct 
cost of $28.6 billion each year [3]. 
Current treatments for cartilage injury often involve surgical interventions to 
remove affected tissues and insert transplanted osteochondral plugs as replacement [1,3, 
4]. The most common methods include: 1) arthroscopic drilling, to get assess to bone 
marrow for cartilage repair; 2) mosaicplasty, to replace both cartilage and subchondral 
bone with an osteochondral graft; 3) autologous cell transplantation, to inject 
pre-expanded cells under an autologous periosteal flap sutured on the cartilage; and 4) 
prosthetic replacement, to remove the joint and replace it with a mechanical device [1,3, 
4], While these procedures may provide relief from pain and restore joint mobility, they 
can present long-term complications. Tissue engineering strategies, integrating the 
elements of cells, scaffolds and bioactive factors, provide a potential solution for repair 
and regeneration of native osteochondral tissues [5-7]. 
Anatomy of Osteochondral Tissues 
Articular Cartilage 
Articular cartilage covers the ends of long bones in synovial joints, and this tissue 
provides elasticity, distribution of load, resistance to compressive forces, as well as a 
smooth articulating surface during joint movement. Articular cartilage has a highly 
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specialized composition and structure which is adapted to serve its many important 
functions [5, 8, 9]. 
Chondrocytes are the only type of cells in articular cartilage. These specified cells 
originate from mesenchymal cells during fetal development, and are responsible in 
generating and maintaining the large amount of matrix. However, chondrocytes were 
found to be scattered throughout the matrix in mature tissue, occupying less than 10% of 
the total tissue volume [10]. 
The extracellular matrix (ECM) in cartilage is composed of approximately 75% 
water and 25% solid matrix. The solid matrix consists of 50-73% collagens and 15-30% 
proteoglycans as well as a lesser amount of glycoproteins [11, 12]. Additionally, 90-95% 
of the collagen in articular cartilage is type II, and the collagen fibers form a complex 
network that is essential for maintaining the tissue's volume and shape [11]. Other 
collagens, such as collagen type IX, X, XI, and VI, also contribute to the unique function 
of the tissue [13, 14]. Proteoglycans, a diverse group of heterogenous complex 
macromolecules with one or more covalently bound glycosaminoglycan (GAG), are 
embedded within the fibrillar network of collagens [10]. The negatively charged GAG 
chains of proteoglycans interact with water, forming a high molecular weight complex, 
which generates swelling pressure to counter the high compressive loads at the joint [15]. 
Previous studies on the morphology and biology of articular cartilage have 
revealed its elaborate, highly ordered structure, consisting of four distinct zones: 
superficial, middle, deep and calcified zone [9, 11, 16, 17]. The chondrocytes in each 
zone demonstrate differences in density, morphology as well as mitotic and metabolic 
activity [18, 19]. The ECM components they assemble also vary in concentration and 
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orientation with depth from the articular surface [10, 19, 20]. The superficial zone (first 
10-20% of the full-thickness), forming the gliding surface, contains elongated cells and 
densely packed collagen fibrils (diameter, 20nm) oriented tangentially to the articular 
surface [21]. The middle zone next (40-60% of the full-thickness) contains less aligned 
collagen fibers with a larger diameter, and chondrocytes with a more rounded appearance. 
Directly beneath is the deep zone, in which columns of ellipsoid hypertrophic 
chondrocytes are distributed between thicker collagen fibers (diameter, 120nm) oriented 
perpendicular to the articulating surface [21]. Finally, the calcified zone contains rather 
small cells, an abundance of calcium salts and a thin vasculature network as the tissue 
transitions from cartilage to mineralized bone. Moving through these zones from the 
articulating surface towards the subchondral bone, water content decreases linearly, from 
approximately 84% wet weight (ww) to 40-60% ww, and collagen content falls from 
86% dry weigh (dw) to 67% dw, while proteoglycan content increases from 15% dw in 
the superficial zone to a peak of 25% dw in the middle zone, then falls to 20% dw in the 
deep zone [9]. 
Articular cartilage has a poor capacity to repair itself due to many reasons, such as 
a low cell density, the lack of blood supply, and the lack of access to progenitor cells that 
can promote tissue repair [1, 3]. Partial thickness defects, which are confined in the 
cartilage region, do not have access to the progenitor cells from bone marrow, therefore 
do not heal spontaneously. Full thickness defects penetrate to the subchondral bone and 
have access to the bone marrow. This triggers a wound healing response with progenitor 
cell infiltration from the bone marrow, however, the defects heal with hyaline cartilage or 
fibrocartilage instead of articular cartilage, which undergoes degenerative changes [1, 3]. 
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In general, both lesions do not result in complete tissue regeneration [1,4]. 
Subchondral Bone 
Bone tissue lies directly under the calcified zone of cartilage, and provides 
mechanical support for the cartilage. The bone tissue contains multiple cell types, 
including osteoblasts, osteocytes and osteoclasts [22, 23]. Osteoblasts and osteocytes are 
immature and mature bone-forming cells, respectively, that produce and maintain bony 
matrix, while osteoclasts are multinucleated cells responsible for bone resorption. It is 
known that there is a balance between bone formation and resorption regulated by the 
cells, allowing for bone remodeling [24]. 
The bony matrix is composed of about 5% water, 25% organic matrix and 70% 
inorganic matrix [22]. The organic matrix contains mainly collagen type I (90%), 
although other molecules such as proteoglycans, osteocalcin, osteopontin, and growth 
factors also serve important roles structurally and biochemically [22]. The inorganic 
phase contains minerals in the form of hydroxyapatite [22]. They are deposited in the 
collagen framework, giving the bone stiffness and strength. 
Compared to cartilage, bone tissue has a higher healing ability. Due to abundant 
vascularization and access to progenitor cells, the bony part of any injury at the joint 
usually heals readily [25]. 
Cells 
Marrow Mesenchymal Stem Cells 
Tissue engineering strategies sometimes involve introducing cells to the site of 
injury in order to help ECM production and remodeling. This is especially important for 
articular cartilage, which has limited self-repair ability. 
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Different cell types are available for osteochondral tissue engineering, including 
differentiated cells (such as chondrocytes and osteoblasts), and progenitor stem cells (like 
MSCs) [4, 5]. Previous research has demonstrated that autologous chondrocytes serve as 
a reliable cell source with no concern of an immune response [4], However, the sources 
for chondrocyte harvest are limited, and the harvest process usually involves invasive 
surgeries and results in further injury to a healthy cartilage [4, 26]. Additionally, the 
subsequent in vitro expansion of the isolated chondrocytes leads to de-differentiation of 
the cells. In the monolayer culture, these chondrocytes become fibroblastic and lose their 
chondrocytic characteristics [27], which affects their success in cartilage repair upon 
implantation. 
In contrast, the use of pluripotent stem cells for tissue repair is a viable alternative 
for tissue engineering. Although there are political and ethical concerns with the use of 
embryonic stem cells, there are no such worries concerning adult stem cells. 
Mesenchymal stem cells (MSCs) are self-renewable and multipotent stem cells that can 
differentiate into a variety of cell types of connective tissues, such as cartilage, bone, 
tendon, and muscle, when given specific environmental cues [28-30]. Although MSCs 
reside in many tissues throughout the adult organism, bone marrow is considered to be 
the most accessible and enriched source [31, 32], Recent research has demonstrated that 
MSCs can be easily isolated from bone marrow and expanded in vitro without losing 
their pluripotency [33-35]. Therefore, MSCs have become a popular cell source for 
regeneration of connective tissues, especially an osteochondral tissue consisting of both 
cartilage and bone. 
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MSC Differentiation during Skeletal Development 
During skeletal development in vivo, cartilage and bone are formed by a complex 
and sequential event, where chondrogenesis first results in the formation of a cartilage 
intermediate, and then long bone is developed from the cartilage by endochondral 
ossification [24, 26, 36, 37]. More specifically, endochondral development begins with 
condensation of MSCs, which results in chondrogenesis of MSCs to chondrocytes. The 
differentiating chondrocytes proliferate, secrete a cartilaginous matrix, and subsequently 
progress to a more mature phenotype, hypertrophic chondrocytes. At this stage, 
cartilaginous matrix becomes calcified, and the chondrocytes undergo apoptosis. 
However, these hypertrophic chondrocytes produce vascular endothelial growth factor 
(VEGF) before apoptosis, which stimulates vascular invasion into the cartilaginous 
matrix. Followed by chondrocyte apoptosis and angiogenesis, osteoblasts differentiated 
from osteoprogenitor cells invade into the cartilaginous matrix and lay down a collagen 
matrix. The matrix is eventually mineralized while osteoclasts resorb the original 
calcified cartilage, resulting in bone formation. The whole process is regulated by 
numerous growth factors, transcription factors, as well as matrix molecules [38, 39]. 
MSC Chondrogenic Differentiation 
As mentioned above, chondrogenic differentiation of MSCs passes through 
sequential stages, including MSC condensation, chondrocyte differentiation, and 
maturation. Each stage is characterized by specific gene expression and ECM production 
[14, 36, 37, 40]. The undifferentiated MSCs produce ECM rich in collagen type I, 
hyaluronan and fibronectin. As the cells differentiate into chondrocytes, they begin to lay 
down a cartilage specific ECM, including collagen type II, IX and XI, large chondroitin 
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sulfate rich proteoglycans, aggrecans and link proteins. Meanwhile, the expression of 
collagen type I is turned off. After further maturation and hypertrophy, these cells express 
another cadre of ECM components including type X collagen and matrix 
metalloproteinase (MMP)-13. The expression of collagen type II decreases at the 
maturation stage. 
Recent studies on MSC chondrogenic differentiation in vitro demonstrated that 
the chondrogenesis process depends on coordinated activities of many factors, including 
the protein-based growth factors, extracellular maxtix, nonproteinaceous chemicals, 
biophysical parameters, mechanical stimuli, and cell density [41]. For example, a 
serum-free medium condition is commonly used to enhance MSC chondrogenic 
differentiation [41, 42]. Some chemical compounds supplemented to the medium, such as 
dexamethasone and ascorbic acid have also been shown to induce chondrogenesis and to 
encourage cartilaginous matrix production [41, 42]. The delivery of exogenous cytokines 
and growth factors also play crucial roles for directing cell differentiation, which will be 
detailed in a later section. Other culture conditions conductive for MSC chondrogenesis 
include a high cell density. Many studies have pelleted MSCs to mimic their 
condensation in vivo, and cultured these pellets in defined medium for chondrogenesis 
[42-44]. However, the disadvantages of the pellet culture system are its small size and 
poor mechanical properties, making it impractical for articular cartilage repair. On the 
other hand, polymer scaffolds can provide a three-dimensional (3D) environment for cells 
to grow and differentiate, synthesize ECM and other biological molecules. Therefore, in 
vitro and in vivo studies of chondrogenic differentiation of MSCs in a polymer scaffold 
with bioactive molecules have been increasingly active [45-48]. 
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MSC Osteogenic Differentiation 
Similar to chondrogenic differentiation, osteogenic differentiation of MSCs also 
contains a sequence of three principle stages, including proliferation, matrix maturation 
and mineralization [49]. In the first stage, cells are actively proliferating, with expression 
of cell-cycle and cell-growth- regulated genes (such as histone), as well as genes 
associated with ECM formation (such collagen type I, fibronectin and transforming 
growth factor-P (TGF-|3)). As the cells start to differentiate, their proliferation rate slows 
down. Cells in this stage increasingly secrete alkaline phosphatase (ALP), a protein 
associated with the bone phenotype. ALP usually peaks during the ECM maturation stage 
prior to the onset of mineralization. Meanwhile, the ECM undergoes a series of 
modifications in composition and organization that renders it competent for 
mineralization. With the onset of mineralization, other bone-related genes, such 
osteopontin and osteocalcin, become induced. Both of the proteins contribute to 
hydroxyapatite binding and are maximally expressed during the mineralization period. 
Induction of osteogenic differentiation of MSCs in vitro has also been extensively 
investigated recently [50]. Similar to chondrogenic differentiation, it requires the 
combined use of a supplemented culture medium, a 3D environment, the presence of 
growth factors and mechanical stimuli [50]. 
Varying the culture period of MSCs in an osteogenic medium has resulted in the 
development of osteogenic cells of different maturity stages [49, 51]. Many studies have 
underscored the importance of investigating the stages of MSC osteogenic differentiation, 
since they found that the in vitro osteogenic preculture period of MSCs significantly 
affected their osteogenic potential when implanted in vivo [51-53]. This is probably 
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related to various components and amount of extracellular matrix and soluble growth 
factors secreted by the cells at different stages. 
Scaffolds 
Scaffolds provide a 3D environment for cell attachment and growth, however, for 
cartilage and bone tissue engineering the scaffold should fulfill the requirements below 
[54]. First, the scaffold should be biocompatible, meaning that the material and its 
degradation products (if degradable) must not elicit an unresolved inflammatory response 
nor demonstrate extreme immunogenicity or cytotoxity. Second, the material is 
preferably biodegradable so that a second surgery will not be required for removing the 
implant. Third, the scaffold should also have the ability to promote cartilage and bone 
regeneration. The scaffold should be porous with high surface to volume ratio, which 
allows for cell attachment, extracellular matrix growth as well as nutrient exchange. The 
architecture of the scaffold should mimic natural ECM in order to enhance cell growth. 
Furthermore, the scaffold material should offer sufficient temporary mechanical support 
as cartilage and bone tissues regenerate. More specifically for articular cartilage, the 
scaffold will need to withstand not only compressive loads but also shear forces at the 
joint surface. In addition to these, ease of handling and sterilization is also important for 
clinical use. 
Usually, scaffold materials can be classified as naturally based and synthetically 
based [54, 55]. Natural materials, such as collagen/gelatin, fibrin, alginate, hyaluronate, 
and chitosan, have demonstrated their applications in a variety of orthopedic tissues due 
to their adequate biocompatibility and biodegradability. However, they generally possess 
low mechanical properties, which limit their use in clinical applications [54, 55]. 
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Ceramics, such as P-tricalcium phosphate (TCP), hydroxyapatite, are natural materials 
specific for bone tissue engineering. Although they are stronger than many other natural 
materials, studies have found that their tensile strengths are still below those of native 
bone [54]. 
In contrast, synthetic materials are controllable in formulations, and therefore 
have adjustable mechanical and degradation properties [54, 55]. Many synthetic materials, 
such as poly(esters), poly(anhydrides), poly(acrylamides) and derivatives of 
poly(ethylene glycol) (PEG), have been successfully utilized in cartilage and bone tissue 
engineering in a variety of physical forms (fibers, meshes, gels) [54, 55]. Based on 
implantation method, scaffolds can be divided as preformed scaffolds and injectable 
scaffolds. 
Preformed Scaffolds 
Preformed scaffolds can be fabricated via various methods, including phase 
separation, solvent casting/particulate leaching or electrospinning [56]. Interconnected 
pore structures formed in these scaffolds are important to provide sites for cell attachment 
and also void spaces for nutrient exchange [57, 58]. 
Poly(a-hydroxy esters), such as poly(glycolic acid) (PGA), poly(lactic acid) 
(PLA), and their copolymer poly(lactic-co-glycolic acid) (PLGA) are commonly used for 
preformed scaffolds in both cartilage and bone tissue engineering [54, 57, 59]. These 
polymers undergo bulk degradation via hydrolytic cleavage of the ester bonds. By 
varying the ratio of lactic acid and glycolic acid in copolymer formulations, the 
mechanical and degradation properties of the material can be tailored [54]. Recent work 
has demonstrated the efficacy of using such biomaterials, in cell-based cartilage and bone 
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tissue engineering. For example, PGA porous nonwoven scaffolds seeded with bovine 
chondrocytes and cultured for 12 weeks showed hyaline-like cartilage formation [54]. 
Similarly, electrospun PLA scaffolds supported osteogenic differentiation of 
osteoprogenitor cells in vitro, and the fiber diameter of the scaffolds was found to affect 
cell spreading and proliferation [60]. Additionally, the implantation of PLGA scaffolds 
with or without cells in a rabbit osteochondral defect resulted in both cartilage and bone 
tissue regeneration [61, 62]. 
Poly(s-caprolactone) (PCL) is a semicrystalline polymer, which is biodegradable 
and bioresorbable. Compared to PLGA, PCL has a slower degradation rate [63]. Recently, 
PCL was used to fabricate three-dimensional nano- or micro- fibrous scaffolds with 
structural similarity to natural collagen networks using the electrospinning technique [64]. 
These scaffolds have large surface area, which leads to a faster degradation time than the 
homopolymer, about 6 months [65]. Furthermore, they support the attachment, 
proliferation and differentiation of many cell types, including chondrocytes, osteoblasts, 
and MSCs, suggesting their potential in both soft and hard tissue engineering [47, 58, 
66] . 
Injectable Scaffolds 
Compared to preformed scaffolds, injectable materials enable the transplantation 
of cells and bio active factors within a polymer mixture in a minimally invasive manner. 
This type of materials are especially convenient in dealing with irregular-shaped defects 
commonly found in articular cartilage [6, 7, 67, 68]. Hydrogels, which are insoluble 
hydrophilic polymer networks formed by crosslinking water soluble monomers, have 
great potential among various injectable scaffolds. The aqueous environment of 
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hydrogels not only allows diffusion of nutrients and bioactive factors [69, 70], but also 
mimics the natural extracellular matrix of soft tissues, thus supporting the growth of cells 
encapsulated in the hydrogels [7]. 
Many natural polymers mentioned previously, such as fibrin and alginate, are 
widely used as hydrogel scaffolds for cartilage tissue engineering [6, 67]. A variety of 
synthetic hydrogels have also been developed. Among those, poly(acrylamides), such as 
poly(N-isopropylacrylamide) (PNIPAAm), and PEG derivatives, have been actively 
investigated for cartilage tissue engineering [54, 55, 71]. 
PNIPAAm and a triblock copolymer of PEG and poly(propylene oxide) 
(PEG-PPO-PEG) (also know as Pluronic), can form thermally reversible gels without any 
permanent crosslinks, thus demonstrating good biocompatibility for cell encapsulation 
[54]. A study by Cao et al. compared the use of different polymers for autologous 
chondrocyte implantation in a porcine model, and found that Pluronic resulted in more 
cartilage-like tissue formation than either alginate or PGA [72]. However, both 
PNIPAAm and Pluronic are not degradable [54]. 
Acrylated or methacrylated PEG allows for the formation a hydrogel via chemical 
crosslinking, either by radical initiation or photo initiation [7, 55]. For example, Williams 
et al. encapsulated both MSCs and TGF-(31 in a poly(ethylene glycol)-diacrylate 
(PEG-DA) photopolymerizing hydrogel [7, 45]. In vitro culture of the constructs after 6 
weeks showed marked increases in cellularity and cartilaginous matrix production, 
suggesting chondrogenesis of the cells in the hydrogel. Similarly, Elisseeff et al. injected 
a PEG-dimethacrylate/chondrocytes solution subcutaneously in mice. The hydrogel that 
was formed by photopolymerization resulted in cartilage tissue formation after 7 weeks in 
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vivo [7]. 
Another PEG-derived injectable material, oligo(poly(ethylene glycol) fumarate) 
(OPF) has been developed in our laboratory recently [73, 74]. OPF is synthesized from 
fumaryl chloride and PEG. The fumarate double bonds in the macromer chains allow this 
material to chemically crosslink to form a hydrogel network, and the hydrolysis of ester 
linkages results in the degradation of the crosslinked hydrogel [73]. Previous work in our 
laboratory has demonstrated the cytocompatibility of OPF hydrogels with various cell 
types, including fibroblasts, chondrocytes and MSCs [74-78]. For example, rat MSCs 
encapsulated in OPF hydrogels and cultured in an osteogenic medium have been shown 
to be viable and to differentiate down the osteogenic lineage. The cells produced various 
amounts of calcium after 4 weeks, depending on the swelling and degradation properties 
of the hydrogels [76]. Additionally, the encapsulation of both cells and particulate drug 
delivery systems within the hydrogels demonstrated the potential of the hydrogels for 
cartilage tissue engineering applications [70, 74, 75]. Hydrogel composites containing 
TGF-pi-loaded microparticles (MPs) enabled controlled release of the growth factor [69, 
79], and enhanced the chondrogenesis of the co-encapsulated bovine chondrocytes or 
rabbit MSCs in vitro [74, 75]. In vivo, these hydrogel composites underwent 
biocompatible degradation and supported neo-tissue formation in a rabbit osteochondral 
defect after 14 weeks [80, 81]. These results suggested the potential of OPF as a cell and 
growth factor carrier for orthopedic tissue engineering. 
Composite Scaffolds for Osteochondral Tissue Engineering 
Due to the significant difference in the composition and properties of articular 
cartilage and subchondral bone, composite scaffolds containing a chondrogenic and an 
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osteogenic compartment have been recently developed in order to mimic the native 
osteochondral tissue structurally and functionally. Different approaches have been 
reported in the literature involving the use of both preformed and injectable materials [3, 
26, 82]. 
In one of the approaches, an osteochondral construct was fabricated from the 
same or similar biomaterials, but having a porosity/pore size gradient with depth. For 
example, Woodfield et al. reported the fabrication of a poly(ethylene 
glycol)-terephthalate-poly(butylene terephthalate) copolymer scaffold with a pore size 
gradient with depth (200-1650 urn), using a 3D fiber deposition technique [21]. The 
culture of chondrocytes on theses scaffolds demonstrated a zonal distribution of cells and 
extracellular matrix similar to those in native articular cartilage. Similarly, Sherwood et al. 
utilized a 3D printing process to fabricate an osteochondral scaffold of varied 
composition and properties between layers [83]. The cartilage region made of 
PLGA/PLA had a higher porosity of 90%, which allowed cartilage formation after the 
culture of chondrocytes for 6 weeks. The bone portion made of PLGA/TCP had a 
porosity of 55%, which demonstrated similar tensile strength as native bone tissue. 
Another approach involves independent fabrication or culture of chondrogenic 
and osteogenic layers, and a subsequently joining of the two layers by suturing or gluing 
[48, 84, 85]. For example, in some studies, an engineered cartilage cultured from 
chondrocytes seeded on a PGA scaffold, was sutured on an engineered bone to form a 
composite. These composites showed characteristic architectural features of an 
osteochondral tissue in both in vitro co-culture and upon implantation in vivo, with GAG 
production in the chondrogenic layer and mineralization in the osteogenic layer [48, 84]. 
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However, the integration between layers was dependent on the maturity/preculture period 
of each layer, and poor integration with host cartilage was generally observed in the in 
vivo cases [3, 48]. 
In order to improve the integration between layers, other researchers have 
combined the use of both preformed scaffolds and injectable scaffolds for the fabrication 
of an osteochondral composite [86, 87]. More specifically, a polymer solution with cells 
is loaded on a porous scaffold as an osteogenic base. Crosslinking of the solution forms a 
chondrogenic hydrogel layer on top the osteogenic layer, resulting in an integrated 
osteochondral composite. Cao et al. reported that fibrin glue containing chondrocytes was 
able to coagulate on a precultured PCL scaffold containing osteoblasts, to form a 
composite [86]. Scanning electron microscopy on the co-cultured constructs revealed cell 
proliferation and matrix production within each compartment, as well as matrix 
integration at the interface. However, in a similar study by Lima et al., the incorporation 
of devitalized bone under a chondrocyte-seeded-agarose was found to reduce the 
biochemical and mechanical properties of the chondrogenic layer, although good 
integration between layers was observed [87]. 
Integrated osteochondral composites have also been fabricated using hydrogels in 
both layers [80, 81, 88, 89]. Compared to other approaches, this technique is 
advantageous because it can achieve spatial control of cell types and bioactive factor 
release in a minimally invasive way. A previous study in our laboratory has demonstrated 
the successful fabrication of a laminated hydrogel composite with OPF macromer, using 
a two-step crosslinking procedure [90]. Mechanical testing on these hydrogels revealed 
that the presence of an interfacial area did not significantly alter their tensile properties, 
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indicating a good integration between layers. Similar hydrogel composites encapsulating 
gelatin microparticles in both layers were implanted in a rabbit osteochondral model [80, 
81]. The results demonstrated degradation of the composites at 14 weeks after 
implantation, and the formation of cartilaginous and bony tissue in the respective region 
of the defects. In another study, an osteochondral construct was fabricated in the shape of 
an articular condyle using PEG-DA hydrogels [88, 89]. In vitro cultured chondrogenic 
cells and osteogenic cells were encapsulated in the cartilage and bone compartments, 
respectively. The implantation of the construct in vivo demonstrated not only stratified 
layers of cartilaginous and osseous tissues, but also a mutual infiltration of the tissues into 
each other. 
Despite promising results from the in vivo studies above, challenges still remain 
for the in vitro culture of an osteochondral construct. Further investigations are required 
to construct a well-integrated bilayered scaffold that can guide the chondrogenic and 
osteogenic differentiation of cells in different regions of the same scaffold. Additionally, 
a single set of cell culture conditions that can maintain the appropriate chondrogenic and 
osteogenic phenotype need to be further explored. 
Bioactive Factors 
Bioactive Molecules 
In native osteochondral tissue, both insoluble and soluble components of the ECM 
play important roles in regulating cell attachment, proliferation and differentiation [36, 
37]. Insoluble ECM can interplay with the embedded cells in many ways. Some 
components signal to the cells directly. For example, previous studies have showed that 
collagen type II, a major cartilaginous matrix component, is superior to collagen type I 
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for inducing chondrogenesis of stem cells, when added to culture medium or used as a 
hydrogel scaffold [91, 92]. This again suggests it is important to mimic the native ECM 
structurally and functionally when we design a scaffold. In addition to direct signaling, 
ECM can also regulate cellular behavior by binding, storing, and releasing soluble 
mediators. In fact, studies in our lab have demonstrated the presence of different growth 
factors in the ECM generated by in vitro culture of MSCs on a polymeric scaffold [93]. 
After decellularization the ECM showed a great potential in inducing osteogenic 
differentiation of reseeded MSCs on the scaffolds [94-96]. 
Soluble growth factors, such as transforming growth factors (TGFs), bone 
morphogenetic proteins (BMPs), and insulin-like growth factor (IGF) are known to play 
important roles in cartilage and bone formation during embryonic development and 
during tissue repair in vivo [97-99]. 
The transforming growth factor (TGF) family includes a number of polypeptides 
involved in the regulation of cell growth and differentiation in wound healing [11]. 
TGF-Ps have been widely investigated and shown to exert various effects on different 
cell types [11]. In vitro, TGF-(31 is crucial to promote the chondrogenic differentiation of 
MSCs and to enhance cartilaginous matrix synthesis, in combination with a serum-free 
and chemically defined medium condition [42, 75]. In vivo, the delivery of TGF-pi to a 
chondral or osteochondral defect has been shown to improve neo-cartilage and bone 
morphology in many studies [80, 100, 101]. However, a higher concentration of TGF-pi 
resulted in side effects, such as inflammatory synovitis, cartilage erosion, and osteophyte 
formation [100, 102]. Recently, other isoforms of TGF-Ps, such as TGF-P2 and -P3, have 
also been investigated [103, 104]. Due to a similar amino acid sequence as TGF-pi, both 
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TGF-P2 and TGF-P3 also demonstrated a stimulatory effect on MSC chondrogenic 
differentiation [103, 105]. In a comparative study, TGF-P2 and -P3 led to an earlier and 
greater GAG and collagen type II production for human MSCs than TGF-pi in vitro 
[103]. The effects of TGF-Ps on osteogenic differentiation are controversial. While some 
researchers reported TGF-pi induced and accelerated osteogenic differentiation of bone 
marrow cells [106, 107], others showed that TGF-Ps inhibited osteogenesis of MSCs or 
MSC derived osteoblasts in vitro [104, 108]. 
BMPs, a subfamily of the TGF superfamily, have been shown to have the ability 
to induce both chondrogenesis and osteogenesis [109-111]. For example, BMP-2, -4, -6, 
and -7 were shown to enhance the chondrogenesis of MSCs with an increase in type II 
collagen and proteoglycan synthesis. BMP-2, -6, and -9 also significantly promoted 
osteogenic differentiation of MSCs, as evidenced by increased alkaline phosphatase 
activity, osteocalcin expression and calcium deposition [111]. 
Some other growth factors, such as IGFs, fibroblast growth factors (FGFs), and 
vascular endothelial growth factor (VEGF) also play important roles in cartilage and bone 
formation [11, 112, 113]. Although these growth factors may not directly promote MSC 
chondrogenic or osteogenic differentiation [102], the combination of these growth factors 
with TGF-Ps was shown to have a synergistic effect on the chondrogenic differentiation 
of MSCs and on cartilage-like matrix synthesis [43, 44, 114-116]. The synergistic effect 
could be due to regulatory cross-talks between different signaling pathways. 
The challenge in the application of signaling molecules to optimize cartilage and 
bone regeneration is that their regulatory effects depend on the dose and timing of 
administration, therefore, different drug delivery systems have been investigated for 
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controlled release of the growth factors [70]. Particulate drug delivery systems, such as 
microparticles (MPs) made of gelatin and PLGA, are of great attention recently [117]. 
Previous work in our lab has shown that growth factors, like TGF-pi, BMP-2, IGF-1, can 
be loaded on gelatin MPs through polyionic complexation [69, 70,19]. The encapsulation 
of growth factor-loaded MPs in OPF hydrogels enabled a sustained release of the growth 
factors in vitro, where the release kinetics can be tailored simply by varying the 
crosslinking density of the gelatin MPs and formulation of the OPF hydrogels [69, 70, 
79]. This system has been successfully used for both cartilage and bone tissue 
engineering. Studies in our laboratory by Park et al. have shown that OPF hydrogel 
composites encapsulating TGF-J31 -loaded MPs supported the proliferation and matrix 
synthesis of co-encapsulated bovine chondrocytes [74]. Similar hydrogel composites 
releasing TGF-pi or releasing both TGF-pi and IGF-1, enhanced chondrogenic 
differentiation of co-encapsulated rabbit MSCs [75, 114]. For bone tissue engineering, 
Patel et al. investigated dual delivery of VEGF and BMP-2 from a poly(propylene 
fumarate) (PPF)-MP composite for in vivo bone regeneration [118]. Although a similar 
amount of bone growth was observed in both BMP-2 release and dual release groups at 
12 weeks, bone formation appeared most abundant in the dual release group at 4 weeks, 
indicating an interplay between these growth factors for early bone regeneration. 
Mechanical Stimuli 
Both articular cartilage and subchondral bone reside in a dynamic environment 
with various mechanical stimuli [119, 120]. Therefore, to mimic this environment, a 
variety of bioreactors such as spinner flasks, rotating wall vessel reactors and flow 
perfusion bioreactors, have been designed for in vitro generation of cartilage and bone 
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tissues [119, 120]. These bioreactors not only provide relevant mechanical signals for cell 
proliferation and differentiation, but also allow for more uniform distribution of cells 
throughout the scaffold and better mass transfer between the cells and culture medium. 
The effects of mechanical stimuli, including direct compression, shear stress and 
hydrostatic pressure, on chondrocyte proliferation and ECM production have been 
examined using different types of bioreactors [119]. In general, moderate levels of 
mechanical loading show a positive stimulus to chondrogenesis [120]. Compression has 
been found to increase cartilage-like ECM synthesis through a mechanism that 
potentially involves increased localized fluid flow [121]. Hydrostatic pressure helps 
maintain chondrocyte phenotype and upregulate the expression of genes associated with 
chondrogenesis [120]. Studies with low shear, generated either by flow perfusion or 
rotating wall bioreactors, demonstrated enhanced cartilage-specific ECM deposition 
[120]. There is also increasing evidence that biomechanical stimuli can promote the 
differentiation of progenitor cells into a chondrogenic phenotype. Cyclic compressive 
loading was found to induce the synthesis of TGF-|31 and promote the chondrogenesis of 
MSCs and proteoglycan synthesis in vitro [122, 123]. Hydrostatic pressure was also 
shown to enhance the chondrogenic differentiation of MSCs in the presence of other 
bioactive factors in vitro, as evidenced by increased proteoglycan production and 
chondrogenic gene expression [124]. 
Similarly, different bioreactors have been utilized for bone tissue engineering. In 
our laboratory, a perfusion bioreactor has been developed [125], in which MSCs were 
able to undergo osteogenic differentiation under shear stress [126, 127]. By changing the 
amount of shear stress applied or scaffold architecture, the differentiation of MSCs into 
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osteoblasts can be modulated [126, 128]. In addition, bioactive molecules introduced to 
the bioreactor have been shown to have a synergistic effect with flow shear on the 
osteogenic differentiation of MSCs. For example, direct addition of dexamethasone into 
culture media or the use of a biomimetic scaffold containing bone-like ECM in the 
bioreactor, both showed an enhanced osteogenic differentiation of rat MSCs [95, 127]. 
Co-culture 
In addition to the delivery of bioactive factors and application of mechanical 
stimuli, co-culture has become another important tool to regulate cell growth and 
differentiation. Understanding how cells of different types interact with each other and 
how signaling cascades exist and contribute to cell proliferation, differentiation, and 
distribution are important to generate a complex tissue. Recently, different co-culture 
models have been developed for osteochondral tissue engineering applications [82, 129]. 
Two dimensional models are utilized to investigate the interactions between 
different cell types, such as chondrocytes, osteoblasts and progenitor cells [130]. One 
simple method is to mix two or more types of cells together, allowing their direct contact. 
The results are commonly compared to those of an insert/trans-well system, which 
prevents direct contact of the cells but allows for exchange of growth factors secreted by 
them. In one study involving the co-culture of chondrocytes and osteoblasts, Nakaoka et 
al. found active interactions between the two cell types with or without direct contact (in 
plates or trans-well) [130]. Osteoblasts produced growth factors that enhanced 
chondrocyte proliferation, and the differentiation level of the osteoblasts significantly 
influenced the differentiation level of the co-cultured chondrocytes. On the other hand, 
chondrocytes regulated osteogenic differentiation of the osteoblasts through both soluble 
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growth factors and direct contact. Similarly, in another study by Ahmed et al, rat MSCs 
embedded in alginate beads were cultured with cartilage chips in trans-wells without 
addition of growth factors [39]. Chondrogenesis of the MSCs was induced by paracrine 
factors released from the cartilage, as evidenced by a sustained expression of an early 
chondrogenic marker, Sox9. Additionally, the co-culture was found to suppress collagen 
X expression of MSCs, indicative of a hypertrophic phenotype. 
Based on these studies, some three-dimensional co-culture systems have been 
developed. Different types of cells were either pelleted, or seeded in a scaffold 
(preformed or injectable), and subsequently co-cultured to generate an osteochondral 
construct. 
Jiang et al. has developed a co-culture system with a high density chondrocyte 
micromass and a monolayer of osteoblasts adhering to it [131]. Their results showed that 
chondrocytes in the co-culture significantly reduced proteoglycan production; while 
osteoblasts maintained their ALP activity, but delayed in mineralization. However, the 
authors were not sure whether the regulatory interactions were due to cell-cell contact or 
paracrine signaling. Tuli et al. press-coated a mesenchymal progenitor cell (MPC) pellet 
on a PLA scaffold and induced chondrogenesis using a chondrogenic medium [132]. 
After 2 or 5 weeks, osteogenic precultured mesenchymal progenitor cells were loaded on 
the PLA scaffold and co-cultured with the pellet in a cocktail medium. Analyses on the 
osteochondral construct showed the formation of cartilage-like and bone-like tissues in 
the respective layers. The co-culture did not negatively affect cell differentiation in the 
other layer, and furthermore supported the formation an interface resembling the native 
osteochondral junction. 
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In another study by Mahmoudifar et al., chondrocytes seeded on PGA scaffolds 
were co-cultured with either seeded chondrocytes or osteoblasts, or with ex vivo cartilage 
or bone, to investigate the effect of co-culture on osteochondral tissue formation [133]. 
Cartilage and bone compartments were sutured together and then cultured in a 
recirculation bioreactor. The work revealed that the engineered bone (seeded with 
osteoblasts) had the most stimulatory effect on GAG and collagen synthesis of the 
chondrocytes in the engineered cartilage compared to the other formulations. 
Additionally, they reported that the presence of chondrocytes did not prevent osteoblast 
differentiation and mineralization in the engineered bone during the co-culture. In 
contrast, some other studies involving the co-culture of chondrogenic and osteogenic 
cells showed that the co-culture with chondrogenic cells inhibited osteocalcin expression 
or calcium deposition of the osteogenic cells in an osteochondral construct [84, 86]. 
Co-culture has also been performed in layered hydrogel systems. Compared to 
other 3D systems, layered hydrogels demonstrated better integration between layers, and 
additionally prevented significant cell migration within the system [20, 134]. For 
example, Lee et al. constructed a layered PEG-DA hydrogel by photopolymerization of 
polymer and cell solution [134]. The hydrogels consisted of a top-layer encapsulating 
embryonic stem cells, an acellular layer in the middle, and a bottom layer encapsulating 
hepatic cells. The co-culture showed enhanced chondrogenic differentiation of embryonic 
stem cells, probably due to growth factors secreted by the hepatic cells. The same group 
also reported the co-culture of chondrocytes with MSCs, osteoblasts and fibroblasts in a 
similar bilayered hydrogel [7]. Their results showed that the cells maintained their 
phenotypes in each layer during the co-culture, however, they interacted with each other 
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through paracrine signaling. In the top layer, chondrocyte matrix production was 
enhanced by the co-cultured MSCs, but not by the co-cultured osteoblasts or the 
fibroblasts; whereas in the bottom layer, MSC mineralization was suppressed by the 
chondrocytes in the adjacent layer. 
Although various results were found from the studies mentioned above due to 
different co-culture systems selected, all the cases indicate active interactions between 
different cell types. For osteochondral tissue engineering, we should take advantage of 
co-cultures, not only to include both chondrogenic and osteogenic cells, but also to guide 
and support cartilage formation through cellular interactions with other cell types. 
Summary 
Tissue engineering, integrating the use of cells, scaffolds and bioactive factors, 
provides a promising solution for osteochondral tissue repair. Exciting results have been 
shown using MSCs along with different biomaterials to generate both cartilage-like and 
bone-like tissues. Further research should focus on the development of a well-integrated 
composite scaffold that can induce and support chondrogenic and osteogenic 
differentiation of MSCs in the respective layers. Furthermore, 3D co-culture systems 
which allow for cellular interactions between different cell types should also be further 
investigated and utilized to improve the quality of an engineered osteochondral tissue. 
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CHAPTER III: EFFECT OF SWELLING RATIO OF INJECTABLE HYDROGEL COMPOSITES 
ON CHONDROGENIC DIFFERENTIATION OF ENCAPSULATED RABBIT MARROW 
MESENCHYMAL STEM CELLS IN VITRO + 
Abstract 
An injectable, biodegradable hydrogel composite of oligo(poly(ethylene glycol) 
fumarate) (OPF) and gelatin microparticles (MPs) has been investigated as a cell and 
growth factor carrier for cartilage tissue engineering applications. In this study, hydrogel 
composites with different swelling ratios were prepared by crosslinking OPF macromers 
with poly(ethylene glycol) (PEG) repeating units of varying molecular weights from 
1,000 ~ 35,000. Rabbit marrow mesenchymal stem cells (MSCs) and MPs loaded with 
transforming growth factor-|31 (TGF-pi) were encapsulated in the hydrogel composites 
in order to examine the effect of the swelling ratio of the hydrogel composites on the 
chondrogenic differentiation of encapsulated rabbit marrow MSCs both in the presence 
and absence of TGF-J31. The swelling ratio of the hydrogel composites increased as the 
PEG molecular weight in the OPF macromers increased. Chondrocyte-specific genes 
were expressed at higher levels in groups containing TGF-pi-loaded MPs and varied 
with the swelling ratio of the hydrogel composites. OPF hydrogel composites with PEG 
repeating units of molecular weight 35,000 and 10,000 with TGF-pi-loaded MPs 
exhibited a 159 ± 95 and a 89 ± 31 fold increase in type II collagen gene expression at 
day 28, respectively, while OPF hydrogel composites with PEG repeating units of 
molecular weight 3,000 and 1,000 with TGF-p 1-loaded MPs showed a 27 ± 10 and a 17 
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± 7 fold increase in type II collagen gene expression, respectively, as compared to the 
composites with blank MPs at day 0. The results indicate that chondrogenic 
differentiation of encapsulated rabbit marrow MSCs within OPF hydrogel composites 
could be affected by their swelling ratio, thus suggesting the potential of OPF composite 
hydrogels as part of a novel strategy for controlling the differentiation of stem cells. 
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Introduction 
Articular cartilage tissue often lacks the ability of self-repair and is difficult to 
fully regenerate with currently available treatments [2]. Therefore, tissue engineering 
strategies have been investigated as an alternative to treat articular cartilage defects [2, 
135]. The success of a tissue engineering approach relies on the proper selection of cells, 
bioactive molecules, and scaffolding materials [2]. One attractive candidate for cells in 
this approach is mesenchymal stem cells (MSCs), since MSCs may be easily isolated 
from the bone marrow and expanded without losing their capacity to differentiate into 
cells of various mesenchymal lineages, including chondrocytes [136]. Numerous studies 
have demonstrated the successful transplantation of autologous MSCs for cartilage and 
bone tissue engineering applications [137-139]. 
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Recently, various hydrogel materials have been developed for use as delivery 
vehicles of bioactive molecules and cells in tissue engineering [140-143]. Hydrogels are 
physically or chemically crosslinked three-dimensional polymers swollen in water that 
allow the controlled release of bioactive molecules [55]. Among those, injectable 
hydrogel materials, which can gel under physiological conditions, have held great 
potential. Cells and bioactive factors can be easily incorporated in the system and injected 
to the defect site, which allows minimally invasive procedures for tissue repair [67, 71]. 
Moreover, depending on the selection of crosslinking molecules, the mechanical 
properties of hydrogels can be easily tailored [144]. 
A novel, degradable fumarate-based macromer, oligo(poly(ethylene glycol) 
fumarate) (OPF), has been developed in our laboratory as an injectable hydrogel carrier 
for growth factors for orthopedic tissue engineering. Previous studies have demonstrated 
the potential of degradable OPF hydrogels for in vitro osteogenesis by rat MSCs. OPF 
hydrogels with two different OPF formulations of varying poly(ethylene glycol) (PEG) 
molecular weight were prepared for encapsulation of rat marrow mesenchymal stem cells 
and cultured for 4 weeks both with and without osteogenic supplements [76]. That study 
demonstrated that the molecular weight of the PEG repeating unit in the macromer 
affected the hydrogel swelling ratio and that changes in the swelling ratio of OPF 
hydrogels resulted in different amounts of calcium deposition by encapsulated rat marrow 
MSCs. In addition, OPF hydrogels have been recently investigated as a cell and growth 
factor delivery system for cartilage tissue engineering [75]. In that study, rabbit marrow 
MSCs encapsulated with TGF-pM-loaded MPs in OPF hydrogels showed an increase in 
gene expression of type II collagen and aggrecan, demonstrating that the incorporation of 
30 
gelatin microparticles into a hydrogel matrix is a promising strategy for localized and 
sustained release of a growth factor. Additional studies have demonstrated the 
degradation of OPF hydrogel composites with encapsulated MPs both in vitro and in vivo 
[79, 80]. 
The present study asked whether the swelling ratio of OPF hydrogel composites 
affected the proliferation and chondrogenic differentiation of encapsulated rabbit marrow 
MSCs. OPF hydrogel composites of different swelling ratios encapsulating rabbit marrow 
MSCs and gelatin MPs loaded with or without TGF-pi were prepared and cultured for 4 
weeks to investigate the effect of hydrogel swelling on the chondrogenic differentiation 
of encapsulated rabbit marrow MSCs as measured by gene expression of two 
chondrogenic markers, collagen type II and aggrecan. 
Materials and Methods 
OPF Synthesis and Characterization 
OPF was synthesized from fumaryl chloride and PEG according to a previously 
established method [73]. PEG of four different nominal molecular weights (35,000 g/mol, 
10,000 g/mol, 3,300 g/mol and 1,000 g/mol) was used to prepare OPF macromers of four 
different repeating units (namely OPF 35K, OPF 10K, OPF 3K and OPF IK). Macromer 
molecular weight was determined by gel permeation chromatography (GPC; Model 410; 
Waters, Milford, PA) using a refractive index detector (n=3). The purified macromer was 
stored at -20°C and sterilized prior to use by exposure to ethylene oxide for 14 h. 
Gelatin Microparticle Preparation 
Gelatin microparticles were fabricated from acidic gelatin (Nitta Gelatin Inc., 
Osaka, Japan) following established procedures [74]. Briefly, a gelatin solution was 
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prepared by dissolving 5 g of gelatin in 45 ml of distilled, deionized water (ddH20) at 
60°C. Then, this solution was added dropwise to 250 ml of chilled olive oil while stirring 
at 500 rpm. After 30 min, 100 ml of chilled acetone (4°C) was added to the emulsion. 
After an additional 60 min, the microspheres were collected by filtration and washed with 
acetone. These microparticles were then crosslinked in 0.1 wt % Tween 80 (Sigma, St. 
Louis, MO) solution with 10 mM glutaraldehyde (GA) (Sigma, St. Louis, MO) while 
stirring at 500 rpm at 15°C. After 15 h, crosslinked microparticles were collected by 
filtration, washed with ddH20, and then agitated in 25 mM glycine solution for 1 h to 
inactivate any unreacted GA. These microparticles were collected by filtration, washed 
with ddH20, and then lyophilized overnight. Finally, dried microparticles were sieved to 
obtain particles of 50-100 jam in diameter and sterilized with ethylene oxide for 14 h. 
OPFHydrogel Composite Swelling and Degradation Experiment 
For swelling studies, OPF 35K, OPF 10K, OPF 3K and OPF IK hydrogel 
composites encapsulating gelatin microparticles were prepared in the same manner as 
would be used for cell encapsulation. Briefly, 0.1 g of OPF and 0.05 g of the crosslinking 
agent poly(ethylene glycol) diacrylate (PEG-DA; nominal MW 3400, Nektar 
Therapeutics, Huntsville, AL) and 0.0219 g of microparticles were combined in 578 ul of 
phosphate buffered saline (PBS). Equal volumes (46.8 ul) of the thermal radical initiators, 
25 mM ammonium persulfate (APS) and 25 mM N,N,N\NMetramethylefhylenediamine 
(TEMED) in PBS, were then added. After gentle mixing, the suspension was quickly 
injected into Teflon molds (6 mm diameter, 1 mm thickness) followed by incubation at 
37°C for 8 min. Hydrogel composites were transferred to PBS and cultured statically at 
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37°C for 4 weeks. At day 1, 7, 14, 21 and 28, the swelling ratio and sol fraction of OPF 
hydrogel composites were then determined by the following equations. 
W - W Swelling ratio = — 
Wd 
W- -W 
Sol fraction = —* d-
Wl 
Here, W\, Ws, and Wd represent the weight of dried hydrogel composites after 
crosslinking, the weight of hydrogel composites after swelling in PBS, and the weight of 
dried hydrogel composites after swelling, respectively. The swelling ratio is defined as 
the fractional increase in the weight of the hydrogel due to water absorption. The sol 
fraction represents the fraction of the polymer following a crosslinking reaction that is 
not part of a crosslinked network. A decrease in sol fraction over time reflects polymer 
loss and characterizes the extent of hydrogel degradation. 
Rabbit Marrow MSC Isolation and Pre-culture 
Rabbit marrow MSCs were isolated from the tibias of 4 month old New Zealand 
white rabbits as previously described [75]. Briefly, after anesthesia, rabbit bone marrow 
was collected into a 10 ml syringe containing 5000 U of heparin. The bone marrow was 
then filtered through a cell strainer (40 urn) and cultured in Dulbecco's modified Eagle's 
medium-low glucose (DMEM-LG) supplemented with 10% v/v fetal bovine serum (FBS; 
Gemini, Calabasas, CA), 250 (j.g/1 fungizone, 100 mg/1 ampicillin, and 50 mg/1 
gentamicin (Invitrogen) for 2 weeks. In an effort to reduce any interanimal variation, a 
pool of rabbit marrow MSCs from a total of 6 rabbits was collected together, placed in 
medium containing 20% FBS and 10% dimethyl sulfoxide (DMSO), and cryopreserved 
in liquid nitrogen prior to use. For experiments, cryopreserved cells were thawed at 37°C, 
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seeded in T-75 flasks, and expanded for 14 days of culture in DMEM supplemented 
medium containing 10% v/v FBS, 250 \xg/\ fungizone, 100 mg/1 ampicillin, and 50 mg/1 
gentamicin. Cells from one preparation were used in all experiments and were cultured 
up to passage three before the encapsulation process. 
Microparticle and Rabbit Marrow MSC Encapsulation 
Before encapsulation, OPF 35K, OPF 10K, OPF 3K and OPF IK were combined 
with PEG-DA at a 2:1 ratio of OPF to PEG-DA by weight. These polymer mixtures and 
gelatin microparticles were sterilized with ethylene oxide for 14h. Then, sterilized MPs 
were loaded with TGF-pi (R&D Systems, Minneapolis, MN) by immersing them in 
aqueous TGF-(31 solution at pH 7.4 and incubating them at 4°C for 15h according to 
established methods [69]. At this pH, there is ionic complexation of gelatin 
microparticles and TGF-pi due to the negative charge of the acidic gelatin (isoelectric 
point (IEP) of 5.0) and positive charge of TGF-pi (IEP of 9.5) [145]. The total TGF-pi 
loading of the microparticles in each gel was 25 ng, which resulted in a concentration of 
10 ng TGF-pi/ml relative to the medium (2.5 ml) used for culturing each gel. 
TGF-pi-free MPs were also prepared for comparison. 
For encapsulation of isolated rabbit marrow MSCs and gelatin microparticles in 
OPF hydro gel composites, a combination of OPF and PEG-DA were dissolved in 300 ul 
PBS and mixed with the 110 ul microparticle swelling solution. Equal volumes (46.8 ul) 
of the thermal radical initiators, 0.3 M APS and 0.3 M TEMED in PBS, were then added. 
After this mixture was vortexed, a 168 ul PBS suspension containing 6.7 million cells 
was added to achieve a cell concentration of 10 million cells/ml in the final suspension. 
After gentle mixing, the suspension was quickly injected into Teflon molds (6 mm 
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diameter, 1 mm thickness) followed by incubation at 37°C for 8 min. Final gel constructs 
were transferred into 12 well tissue culture plates. Each well contained one gel construct 
and 2.5 ml chondrogenie medium, which was DMEM supplemented with ITS+ Premix 
(6.25 ug/ml insulin, 6.25 ug/ml transferrin, 6.25 ug/ml selenous acid, 5.35 ug/ml 
linoleic acid and 1.25 ug/ml bovine serum albumin) (BD Biosciences, Franklin Lakes, 
NJ), 1 mM sodium pyruvate, 50 ug/ml ascorbate 2-phosphate (Sigma-Aldrich), 10"7M 
dexamethasone (Sigma-Aldrich), 250 mg/1 fungizone, 100 mg/1 ampicillin and 50 mg/1 
gentamicin. The medium was changed every 3 days. For the comparison with 
TGF-pl-loaded MP groups (noted as +), the same OPF cell-hydrogel composites with 
blank MPs (noted as -) were also prepared and cultured exactly as described above. At 
day 7, 14, and 28, samples were collected from each group for biochemical assays (n=4) 
and quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) (n=4). 
Samples at day 0 were collected immediately after the encapsulation process, including 
four samples from each OPF formulation (OPF 35K, OPF 10K, OPF 3K and OPF IK) for 
biochemical assays and a total of four samples from TGF-pi-free groups used as a 
control for all groups for RT-PCR analysis. In addition, cell-free hydrogel composites 
(n=3) were also prepared following the same methods. These cell-free hydrogel 
composites were analyzed with samples to establish any background contribution from 
the hydrogel to fluorescence and absorbance measurements in the biochemical assays. 
Biochemical Assays for Cell Proliferation and Glycosaminoglycan Production 
At each time point, samples and cell-free hydrogels were removed from medium, 
rinsed in 2 ml PBS, homogenized with a pellet grinder (Fisher Scientific) and digested in 
500 ul of a proteinase K solution (1 mg/ml proteinase K (Sigma-Aldrich), 10 fig/ml 
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pepstatin A (Sigma-Aldrich), and 185 ug/ml iodoacetamide (Sigma-Aldrich) in 
tris-EDTA solution (6.055 mg/ml tris(hydroxymethyl aminomethane) (Sigma-Aldrich), 
0.372 mg/ml EDTA (Sigma-Aldrich), pH 7.6 adjusted by HC1)) at 60°C for 16 h. After 
collection and digestion of all samples and cell-free hydrogels, specimens underwent 
three repetitions of a freeze/thaw/sonication cycle (1 h at -80°C, 30 min at room 
temperature, 30 min of sonication) for complete extraction of DNA from the cell 
cytoplasm. DNA and glycosaminoglycan (GAG) assays were then run for samples at 
each time point (n=4). 
DNA content was calculated by measuring double-stranded DNA (dsDNA) 
content using the PicoGreen assay (Molecular Probes, Eugene, OR) according to the 
manufacturer's instructions. The PicoGreen dye binds to dsDNA and results in 
fluorescence corresponding to the concentration of dsDNA, which was measured by a 
plate reader (FLx800, Bio-Tek Instrument, Winooski, VT) at a wavelength of 490 nm. 
The fluorescence of negative, cell-free hydrogels was subtracted from the fluorescence 
values of experimental groups to account for fluorescence of the material alone. 
Similarly, glycosaminoglycan content was also determined using a biochemical 
assay, the dimethylmethylene blue dye (DMMB) assay (Sigma-Aldrich), as previously 
described [146]. Upon DMMB binding to GAG, a pink color is produced, allowing for 
quantification of GAG by measuring absorbance at 520 nm. GAG content in hydrogels 
was calculated by comparison to a curve generated from standards of known amounts of 
porcine chondroitin sulfate B (Sigma-Aldrich). A microplate reader (BIO-TEK 
Instrument, Winooski, VT) was utilized for the absorbance measurements. 
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Real-time PCR 
Total RNA was extracted from hydrogel composites at each time point via the 
RNeasy Mini Kit (Qiagen, Valencia, CA). Briefly, hydrogels were transferred into RNA 
lysis buffer solution and homogenized by gentle pipetting. The homogenized solution 
was purified using a Qiagen shredder column and total RNA was extracted with the 
RNeasy Mini Kit. RNA samples were then reverse-transcribed to cDNA using Oligo dT 
primers and superscript III transcriptase. The final cDNA transcripts were then subjected 
to real-time PCR (7300 Real-Time PCR System, Applied Biosystems, Foster City, CA) 
to determine the expression of genes for type II collagen and aggrecan. Gene expression 
data were analyzed using the 2"AACt method as reported previously [137, 147]. Briefly, all 
gene expression data were normalized to the expression of the house-keeping gene, 
glyceraldehyde-3-phosphatase dehydrogenase (GAPDH) and expressed as the fold ratio 
as compared with those of a control group. For this study, the control group contained 
rabbit marrow MSCs embedded in OPF with blank MPs (n=4, one sample from each 
OPF formulation) that were analyzed immediately after encapsulation (day 0). The 
sequence of primers for GAPDH, type II collagen, and aggrecan were as follows [75]: 
GAPDH: 5'-TCACCATCTTCCAGGAGCGA-3', 
5'-CACAATGCCGAAGTGGTCGT-3'; type II collagen: 
5'-AACACTGCCAACGTCCAGAT-3', 5 '-CTGCAGC ACGGTATAGGTGA-3'; 
Aggrecan: 5 '-GCTACGGAGACAAGGATGAGTTC-3', 
5 '-CGTAAAAGACCTC ACCCTCCAT-3'. 
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Statistical Analysis 
Swelling ratio, sol fraction, DNA, GAG, and gene expression were reported as 
means ± standard deviation. Repetitive ANOVA and Tukey's multiple comparison test 
were used to determine possible significant differences (p < 0.05) in the DNA, GAG, and 
gene expression between groups. 
Results 
OPF Characterization 
The number average molecular weight (Mn) and weight average molecular weight 
(Mw) of OPF macromers and the parent PEG for the synthesis were determined by GPC 
and are shown in Table III-l. 
OPF Hydrogel Composite Characterization 
Swelling studies indicated that equilibrium swelling of the hydrogel composites 
had been reached after being immersed in PBS overnight. Swelling ratios of the 
hydrogels remained the same afterwards for the 28 day culture period (data not shown). 
The equilibrium fold swelling of OPF hydrogel composites is shown in Figure III-l (A). 
OPF 35K had a swelling ratio of 15.1 ± 0.3, which was statistically higher than that of all 
the other OPF formulations. In addition, OPF 1 OK hydrogel composites had a statistically 
higher swelling ratio (13.9 ± 0.2) than either OPF 3K (13.0 ± 0.4) or OPF IK (12.7 ± 0.3). 
There was no statistical difference between OPF 3K and IK. The results indicated that 
swelling ratio increased as the PEG molecular weight in the OPF formulation increased. 
Sol fraction of OPF hydrogel composites over time is shown in Figure III-l (B). For each 
OPF formulation, there was little change in sol fraction over time. However, OPF 10K 
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had a significantly lower sol fraction than OPF 35K, OPF 3K and OPF IK at each time 
point. 
Biochemical Assays 
DNA content at each time point is depicted in Figure III-2. All groups showed a 
trend of decreasing DNA content over the culture period. A significant decrease in DNA 
content was seen for all the treatments at day 28 as compared to day 0. Differences were 
also found between groups with different swelling ratios at the same time point. More 
specifically, when blank MPs were encapsulated, a statistically higher DNA content was 
observed in both OPF 35K- and OPF 10K- hydrogel composites compared with OPF 3K-
or OPF IK- hydrogel composites at day 7, 14 and 28. While in groups with 
TGF-(31 -loaded MPs, significantly higher DNA content was observed in samples for OPF 
35K+ at day 28 as compared to those for OPF 3K+ or OPF 1K+. 
As shown in Figure III-3, for all of the eight treatments, there was a higher 
GAG/DNA content at later time points (day 7, 14 and 28) as compared to day 0. 
Especially in the TGF-pi treated groups, a significant increase in GAG/DNA content was 
observed in OPF 35K+ samples at day 14 and day 28, OPF 10K+ samples at day 7, OPF 
1K+ samples at day 28 as compared to day 0. No significant difference was found in the 
groups loaded with blank MPs during the culture period except for OPF 10K- at day 28. 
Additionally, swelling ratio was determined to have an influence on GAG/DNA content, 
as evidenced by the significantly higher GAG/DNA values for OPF 35K+ hydrogel 
composites than both OPF 3K+ and OPF 1K+ hydrogel composites at day 14. 
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Real-time PCR 
Results of collagen type II gene expression over time are presented in Figure III-4. 
Statistical analysis revealed significantly higher collagen type II gene expression levels 
for the OPF 35K+ and OPF 10K+ samples (158.8 ± 95.4 and 89.1 ± 31.5 fold increase, 
respectively) at day 28 than their corresponding TGF-pi-free groups OPF 35K- and OPF 
10K- (62.2 ± 34.4 and 29.9 ±11.3 fold increase, respectively). However, there was no 
significant change in collagen type II gene expression level for the OPF 3K and IK 
samples over the culture period regardless of the presence of TGF-pi. At day 28, the OPF 
35K+ samples were determined to have a significantly higher level of collagen type II 
gene expression than other treatments. OPF 10K+ samples had a significantly higher 
collagen type II gene expression level than OPF 3K+ and OPF 1K+ samples at day 28. 
Similar to collagen type II gene expression, aggrecan gene expression for all the 
treatments showed an increasing trend during the culture period, as shown in Figure III-5. 
The results demonstrated a significantly higher aggrecan gene expression level for the 
OPF 35K+ (23.7 ± 12.0 fold increase), OPF 10K+ (14.2 ± 7.4 fold increase) and OPF 
35K- (12.8 ± 6.4 fold increase) samples at day 28 compared with day 0. Additionally, 
significant differences were also seen between OPF 35K+ samples and OPF 3K+ or OPF 
1K+ samples in the presence of TGF-p 1-loaded MPs at day 28, while there was no 
significant change between the groups with blank MPs. 
Discussion 
The objective of this study was to examine the effect of the swelling ratio of OPF 
hydrogel composites with gelatin MPs on the chondrogenic differentiation of 
encapsulated rabbit marrow MSCs. This study was designed to assess how OPF hydrogel 
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composites with gelatin MPs of four different swelling ratios (OPF 35K, OPF 10K, OPF 
3K, and OPF IK) affected chondrocyte-specific gene expression of encapsulated rabbit 
marrow MSCs. For each OPF formulation, composites encapsulating MSCs and 
TGF-pl-loaded MPs (noted as '+') and composites encapsulating MSCs and blank MPs 
(noted as '-') were included. 
The synthesis of OPF from PEG was characterized by GPC. The results indicated 
a decrease in the number of PEG chains incorporated in the macromer as the PEG 
molecular weight increased, which was probably due to steric hindrance of large PEG 
molecules thus affecting the addition of a fumarate unit to the end of the chain [73]. 
Although many factors, such as molecular weight of macromer, concentration of 
macromer, crosslinker and initiator as well as crosslinking extent, can influence the 
swelling ratio of a crosslinked composite, in the current study the swelling ratio of OPF 
hydrogel composites was adjusted by changing the initial PEG molecular weight for OPF 
synthesis based on previous reports [76, 78]. Theoretically, as the PEG molecular weight 
increases, the spacing between the crosslinks becomes larger and therefore the resulting 
hydrogel will have a larger mesh size, exhibiting as a higher swelling ratio. A previous 
study has proved that OPF 10K hydrogels had a significantly larger swelling ratio (17.5 ± 
0.2) than OPF 3K hydrogels (13.4 ± 0.4) [78]. The results of this study, as expected, 
demonstrated a significant difference in composite swelling ratio between OPF 
formulations even though MPs were present. Specifically, OPF 35K and OPF 10K 
hydrogel composites were shown to have a statistically higher swelling ratio than that of 
OPF 3K and OPF IK composites. 
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Sol fraction of the hydrogel composites represents the fraction of the polymer that 
is not involved in the crosslinked network. The sol fraction of OPF hydrogel composites 
was measured over time to evaluate the degradation of hydrogel composites and its 
potential influence on cell behavior. The results revealed no significant change in sol 
fraction over a 28-day culture period for each OPF formulation, suggesting little hydrogel 
degradation occurred. The results further indicated that hydrogel degradation may not be 
a factor that would affect cell behavior in the present study. OPF 10K hydrogel 
composites had a lower sol fraction as compared to that of other OPF formulations at all 
the time points, which was probably due to the varied molar ratios of fumarate double 
bonds to acrylate double bonds for the OPF formulations examined because the same 
weight ratios of OPF to PEG-DA were used. However, this result did not present any 
concern since the goal of this study was to examine hydrogel composites with different 
swelling ratios. 
Cell encapsulation was performed using a thermal radical initiation system 
(APS/TEMED), which enables crosslinking in situ. Compared to photoinitiation, a 
thermal initiation system would be beneficial in areas where there is limited light 
penetration. Although it is known that the radical initiators may elicit some toxicity to the 
cells, the initiator concentration used in the present study has been previously shown to 
be cytocompatible for MSCs in OPF hydrogels [76]. 
DNA assay results showed a trend of decreasing DNA content in all groups 
during the culture period. As we previously reported, the cell loss may be attributed to the 
encapsulation process which resulted in some cell death, especially over the first few 
days of cell culture [75, 76]. Additionally, the decrease in DNA content may also be due 
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to the culture of cellular constructs in chondrogenic medium, which is chemically defined 
and serum free. The absence of serum in the medium was shown to be beneficial for 
chondrogenic differentiation of MSCs but not for cell attachment and growth [42, 148]. 
In fact, a previous study involving encapsulation of bovine chondrocytes in similar 
OPF/MP composites showed a significant increase in DNA content after culture in a 
serum-containing medium for 14 days [74]. OPF swelling ratio was determined to have a 
significant influence on DNA content in the hydrogel composites. At day 7, 14 and 28, a 
significant difference in DNA content was observed between higher swelling ratio 
composites (OPF 35K- and 10K-) and lower swelling ratio composites (OPF 3K- and 
1K-). In addition, in the presence of TGF-pi-loaded MPs, OPF 35K hydrogel composites 
(OPF 35K+) also had a higher DNA content than OPF 3K as well as OPF IK hydrogel 
composites (OPF 3K+ and 1K+) at day 28. OPF 35K and 10K had comparatively higher 
swelling ratios, indicative of larger mesh sizes, which possibly facilitated nutrient and 
growth factor diffusion and resulted in higher DNA content. 
GAG is a marker of chondrocytic phenotype, and therefore GAG deposition in the 
hydrogel composites was measured to evaluate MSC chondrogenic differentiation. The 
results revealed that GAG/DNA content increased after day 0 and remained similar after 
day 7 for all the formulations (Figure III-3), which provided evidence of MSC 
chondrogenic differentiation in the hydrogel composites. Significant increase in GAG 
production as compared to day 0 was seen more frequently in the groups with TGF-pi 
(OPF 35K+ at day 14 and 28, OPF 10K+ at day 7 and OPF 1K+ at day 28) than those 
without TGF-pi (only OPF 10K- at day 28), suggesting the stimulative effect of TGF-pl 
on chondrogenic differentiation. However, a generally low GAG production by rabbit 
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marrow MSCs encapsulated in a hydrogel composite was seen and this may be explained 
by the tight polymer network surrounding cells, thus limiting the deposition of GAGs 
only in the pericellular space. Alternatively, rabbit marrow MSCs may need additional 
signaling to sustain GAG production following chondrogenic differentiation. Further 
study is needed to elucidate the relationship between encapsulated rabbit marrow MSC 
differentiation and extracellular matrix production. 
To further characterize the in vitro chondrogenesis by rabbit marrow MSCs as a 
function of the swelling ratio of hydrogel composites, gene expressions of two 
chondrogenic-specific markers, collagen type II and aggrecan, were measured by 
quantitative RT-PCR [137, 147]. 
The RT-PCR results showed that the presence of TGF-pl in the hydrogel 
composites significantly promoted collagen type II gene expression. For each OPF 
formulation, samples cultured with TGF-pi-loaded MPs expressed more collagen type II 
than those with blank MPs. Additionally, significant increases were found in OPF 35K+ 
and OPF 10K+ samples compared with OPF 3K+ or OPF 1K+ samples at day 28, 
indicating that chondrogenic differentiation was accelerated in hydrogel composites with 
higher swelling ratios. This result may be due to better diffusion of signaling molecules 
and nutrients in hydrogel samples with a higher swelling ratio. However, it could also be 
due to the different local concentrations of TGF-pi in the hydrogel phase after its release 
from the gelatin MPs. A previous study investigating the release kinetics of TGF-pi from 
OPF 10K and OPF 3K hydrogel composites prepared with different crosslinking agents 
in the absence of encapsulated cells showed that both composites exhibited a burst 
release after 3 days followed by a sustained release for a period of 25 days. However, the 
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relative amount of TGF-pi released from each hydrogel composite was different, 
suggesting a different local concentration of TGF-pi inside the corresponding hydrogel 
[79]. 
Aggrecan gene expression demonstrated a similar trend as that for collagen type II. 
Upregulation of the gene expression was seen over time for all the treatments, especially 
when TGF-pi was present. Samples in OPF 35K+, with a higher swelling ratio, resulted 
in a significantly higher level of aggrecan gene expression at day 28 than all the other 
formulations. Interestingly, some extent of chondrogenic differentiation was also 
observed in OPF 35K- hydrogel composites since both collagen type II and aggrecan 
gene expression were upregulated at day 28. This could be due to the chondrogenic 
potential of chemically defined medium. Previous literature reports indicated that 
chondrogenic differentiation was achieved in only 25% of the samples cultured in 
chondrogenic medium without addition of TGF-pi, while in the presence of TGF-|31 
chondrogenic differentiation was induced for all the samples [42]. 
Both collagen type II and aggrecan gene expressions suggested that hydrogel 
composites of higher swelling ratios, including OPF 35K and OPF 10K hydrogel 
composites, promoted chondrogenic differentiation of encapsulated rabbit marrow MSCs. 
This result was consistent with the findings of a previous study concerning the osteogenic 
differentiation of rat marrow MSCs encapsulated in OPF hydrogels. OPF 10K hydrogels 
promoted osteopontin production and calcium deposition over OPF 3K hydrogels in the 
presence of dexamethasone [76]. Both studies suggested that the swelling ratio of 
hydrogel composites, which is related to the hydrogel mesh size, may affect nutrient 
transport and drug delivery throughout the hydrogels and thus influence the proliferation 
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and differentiation of encapsulated cells. Although hydrogel degradation may also affect 
MSC differentiation, this was not the case in the present study since equilibrium swelling 
of the hydrogel composites was reached within one day and little change in swelling ratio 
or degradation was seen during the culture period. 
Conclusions 
Rabbit marrow MSCs were encapsulated in hydrogel composites of crosslinked 
OPF and MPs of different swelling ratios and cultured over a 28-day culture period. 
Real-time RT-PCR demonstrated chondrocyte-specific gene expression in hydrogel 
composites containing TGF-|31 -loaded microparticles. Additionally, enhanced 
upregulation of chondrocyte-specific genes such as collagen type II and aggrecan was 
observed in OPF hydrogel composites with higher swelling ratios, which is indicative of 
larger mesh sizes. The results suggest that chondrogenic differentiation in this system 
was affected by the swelling ratio (or mesh size) of surrounding hydrogels. Taken 
together, these results indicate that OPF hydrogel composites of tailored swelling 
characteristics can be used as part of a novel strategy for controlling the differentiation of 
MSCs. 
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Figures 
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Figure III-l: Swelling ratio (A) of OPF 35K, 10K, 3K and IK hydrogel composites after 
swelling in PBS overnight and sol fraction (B) of OPF hydrogel composites after 
immersion in PBS for up to 28 days. The symbol (#) indicates a significant difference as 
compared to other OPF formulations (p<0.05). Error bars represent means ± standard 
deviation for n = 4. 
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Figure III-2: DNA content of OPF 35K, 10K, 3K and IK hydrogel composites 
encapsulating rabbit marrow MSCs with TGF-pi-loaded MPs (+) or blank MPs (-) over a 
28-day culture period. Samples marked by (*) exhibited significant DNA decrease 
compared to samples at day 0 (p<0.05). The day 0 samples from each blank formulation 
served as the controls for all samples (blank and TGF-pi-loaded) associated with the 
respective OPF (OPF 35K, 10K, 3K or IK). The symbol (#) indicates a significant 
difference in DNA content as compared to other OPF formulations at the same time point 
(p<0.05). Error bars represent means ± standard deviation for n = 4. 
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Figure III-3: GAG/DNA content of OPF 35K, 10K, 3K and IK hydrogel composites 
encapsulating rabbit marrow MSCs with TGF-pi-loaded MPs (+) or blank MPs (-) over a 
28-day culture period. Samples marked by (*) exhibited significantly higher GAG/DNA 
compared to samples at day 0 (p<0.05). The day 0 samples from each blank formulation 
served as the controls for all samples (blank and TGF-pi-loaded) associated with the 
respective OPF (OPF 35K, 10K, 3K or IK). The symbol (#) indicates a significant 
difference in GAG/DNA content as compared to other OPF formulations at the same time 
point (p<0.05). Error bars represent means ± standard deviation for n = 4. 
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Figure III-4: Quantitative collagen type II gene expression for OPF 35K, 10K, 3K and 
IK hydrogel composites encapsulating rabbit marrow MSCs and TGF-J31 -loaded MPs (+), 
or rabbit marrow MSCs and blank MPs (-). Data are presented as a fold ratio after being 
normalized to GAPDH values. The average expression level of controls (Day 0) is 
represented as one and is shown with the OPF 35K- group. Within a given hydrogel 
formulation, significantly higher (p<0.05) gene expression than the day 0 value (control) 
is noted with (*). Samples indicated with (#) had significantly higher gene expression 
than other OPF formulations at the same time point (p<0.05). Error bars represent means 
± standard deviation for n = 4. 
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Figure III-5: Quantitative aggrecan gene expression for OPF 35K, 10K, 3K and IK 
hydrogel composites encapsulating rabbit marrow MSCs and TGF-|31 -loaded MPs (+), or 
rabbit marrow MSCs and blank MPs (-). Data are presented as a fold ratio after being 
normalized to GAPDH values. The average expression level of controls (Day 0) is 
represented as one and is shown with the OPF 35K- group. Within a given hydrogel 
formulation, significantly higher (p<0.05) gene expression than the day 0 value (control) 
is noted with (*). Samples indicated with (#) had significantly higher gene expression 
than other OPF formulations at the same time point (p<0.05). Error bars represent means 
± standard deviation for n = 4. 
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Tables 
Table III-l: Number (Mn) and weight (Mw) average molecular weights of PEG and OPF 
as determined by GPC. 
PEG 35K 
PEG 10K 
PEG3K 
PEG IK 
Mn 
38,380± 1,310 
8,870 ±280 
2,900 ±90 
860 ± 30 
Mw 
62,170 ±2,110 
11,570 ±360 
3,390 ± 100 
1,000 ±30 
OPF 35K 
OPF 10K 
OPF3K 
OPF IK 
M„ 
41,520 ±1,570 
9,230 ± 300 
4,290 ±140 
2,930 ± 90 
Mw 
125,580 ±4,750 
64,970 ±2,110 
39,540 ±1,250 
15,560 ±490 
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CHAPTER IV: REPAIR OF OSTEOCHONDRAL DEFECTS WITH BIODEGRADABLE 
HYDROGEL COMPOSITES ENCAPSULATING MARROW MESENCHYMAL STEM CELLS IN 
A RABBIT MODEL + 
Abstract 
This work investigated the delivery of marrow mesenchymal stem cells (MSCs), 
with or without the growth factor transforming growth factor-pM (TGF-|31), from 
biodegradable hydrogel composites on the repair of osteochondral defects in a rabbit 
model. Three formulations of oligo(poly(ethylene glycol) fumarate) (OPF) hydrogel 
composites containing gelatin microparticles (GMPs) and MSCs were implanted in 
osteochondral defects, including (1) OPF/GMP hydrogel composites; (2) OPF/GMP 
hydrogel composites encapsulating MSCs; and (3) OPF hydrogel composites containing 
TGF-(31 loaded GMPs and MSCs. At 12 weeks, the quality of new tissue formed in 
chondral and subchondral regions of defects was evaluated based on subjective and 
quantitative histological analysis. OPF hydrogel composites were partially degraded and 
the defects were filled with newly formed tissue at 12 weeks with no sign of persistent 
inflammation. With the implantation of scaffolds alone, newly formed chondral tissue 
had an appearance of hyaline cartilage with zonal organization and intense staining for 
glycosaminoglycans, while in the subchondral region hypertrophic cartilage with some 
extent of bone formation was often observed. The addition of MSCs, especially with 
TGF-(31 loaded GMPs, facilitated subchondral bone formation, as evidenced by more 
trabecular bone appearance. However, the delivery of MSCs with or without TGF-(31 at 
+
 This chapter was published as the following article: Guo X §, Park H s, Young S, Kretlow JD, van den 
Beucken JJ, Baggett LS, Tabata Y, Kasper FK, Mikos AG, Jansen JA. Repair of osteochondral defects with 
biodegradable hydrogel composites encapsulating marrow mesenchymal stem cells in a rabbit model. Acta 
Biomater 2010; 6:39-47. § These authors contributed equally to this work. 
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the dosage investigated did not improve cartilage morphology. While OPF-based 
hydrogel composites supported osteochondral tissue generation, further investigations are 
necessary to elucidate the effects of MSC seeding density and differentiation stage on 
new tissue formation and regeneration. 
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Introduction 
Although articular cartilage has a complex, highly organized structure responsible 
for its important function, it lacks an intrinsic capability to repair itself and is difficult to 
fully regenerate with current treatments [2]. Recently, tissue engineering strategies 
combining cells, scaffolds and bioactive factors have been investigated for the 
replacement of structural and functional aspects of native cartilage [2, 135]. Among the 
different cell populations investigated for cartilage tissue engineering applications, 
mesenchymal stem cells (MSCs) hold great promise for the generation of constructs as 
MSCs can be easily isolated from bone marrow and expanded in vitro [136]. Numerous 
studies have demonstrated the successful transplantation of autologous MSCs for bone 
and cartilage tissue engineering [138, 149, 150]. 
Various types of scaffolds made of synthetic and natural polymers have been 
found to provide a favorable environment for small cartilage lesions [151]. However, the 
repair of extended osteochondral lesions may require a suitable scaffold that can carry 
both growth factors and cells [82]. A novel oligomer, oligo(poly(ethylene glycol) 
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fumarate) (OPF), has been recently developed as a cell carrier and growth factor delivery 
system for cartilage tissue engineering [74, 76]. OPF can be synthesized by esterification 
of fumaryl chloride and poly(ethylene glycol) (PEG). The double bonds in the main chain 
enable this material to crosslink into a hydrogel, and the hydrolysis of ester linkages 
along the chain leads to degradation of a crosslinked hydrogel [73]. Previous work in our 
laboratory has shown that incorporation of gelatin microparticles (GMPs) into hydrogels 
is a promising strategy for controlled release of growth factors [69, 70]. The GMPs 
encapsulated in the hydrogel composites function as both a digestable porogen and a drug 
delivery vehicle, which have been shown to improve the sustained release of loaded drug 
compared to hydrogels or GMPs alone, and to enhance the proliferation of cells 
co-encapsulated [69, 74, 79]. In vivo studies also demonstrated the therapeutic effect of 
insulin-like growth factor-1 (IGF-1) released from hydrogel composites implanted into 
osteochondral defects in rabbits [80, 81]. However, fibrous tissue was observed in the 
neo-surface with the delivery of transforming growth factor-pi (TGF-pi) from 
OPF/GMP hydrogel composites [80, 81]. 
A previous study in our laboratory also investigated the encapsulation of rabbit 
marrow MSCs in OPF-based hydrogel composites containing growth factor-loaded 
GMPs and measured in vitro chondrogenesis [75]. Rabbit MSCs encapsulated in 
hydrogels combined with TGF-pi-loaded GMPs showed an increase in gene expression 
of type II collagen and aggrecan, which are characteristic of chondrocytes, indicating that 
MSCs undergo chondrogenic differentiation in this approach [75]. Therefore, in this 
study, we hypothesized that the combined delivery of MSCs and TGF-pi would enhance 
the quality of new cartilage formation in a rabbit osteochondral defect model by 
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influencing not only host cells but also implanted cells. More specifically, this study 
investigated (1) the effect of MSC delivery on the quality of new cartilage and bone 
tissue formation; and (2) the effect of the combined delivery of MSCs and TGF-pi on the 
quality of new cartilage and bone tissue formation, both involving MSCs in a rabbit 
osteochondral defect model. 
Materials and Methods 
Three different formulations were designed for the present study and implanted in 
rabbits, including (1) OPF/GMP hydrogel composites without cells or growth factors 
(OPF group); (2) OPF hydrogel composites encapsulating blank GMPs and MSCs (10 
million cells/ml hydrogel) (OPF/MSC group); and (3) OPF hydrogel composites 
containing TGF-J31 loaded GMPs (600 ng/ml hydrogel) and MSCs (10 million cells/ml 
hydrogel) (OPF/MSC/TGF group). 
OPF Synthesis 
OPF macromer was synthesized from PEG (Sigma, St. Louis, MO) with nominal 
molecular weight of 10,000 according to a method developed in our laboratory [73]. The 
resulting OPF was sterilized by exposure to ethylene oxide gas for 14 h. 
Gelatin Microparticle Fabrication and Loading 
Gelatin microparticles were fabricated from acidic gelatin (Nitta Gelatin Inc., 
Osaka, Japan) and crosslinked in 10 mM glutaraldehyde (Sigma, St. Louis, MO) 
according to previously established methods [152]. After lyophilization, the GMPs were 
sieved to obtain particles 50-100 um in size and then sterilized with ethylene oxide. 
Sterile GMPs were then loaded with recombinant human TGF-pi (R&D Systems, 
Minneapolis, MN) by swelling in an aqueous solution of the growth factor at pH 7.4 for 
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15 hrs before composite fabrication according to established methods [79]. In particular, 
110 ul of TGF-J31 loading solution (volume needed for equilibrium swelling of the GMPs) 
was combined with 22 mg of GMPs. The loading solution had a concentration of 3.6 ug 
TGF-pi/ml phosphate buffered saline (PBS) to achieve a final loading of 600 ng 
TGF-pi/ml crosslinked scaffolds. This growth factor concentration has been shown to 
promote the chondrogenic differentiation of rabbit MSCs encapsulated in hydrogel 
composites in vitro [75]. Blank GMPs were loaded with PBS in a similar fashion and 
served as control. 
Rabbit Marrow MSC Isolation and Pre-culture 
Rabbit marrow MSCs were isolated from the tibias of 6-month-old New Zealand 
White rabbits (specified-pathogen-free, different rabbits from those used for implantation) 
as previously described [75, 138]. Two isolations were performed in this study, 
respectively, for the two groups treated with cells (OPF/MSC and OPF/MSC/TGF 
groups). Each isolation involved 3 rabbits in an effort to minimize any interanimal 
variation. Specifically, harvested bone marrow from each rabbit was cultured in 
Dulbecco's modified Eagle's medium-low glucose (DMEM-LG; Invitrogen, Carlsbad, 
CA) supplemented with 10% fetal bovine serum (Gemini, Calabasas, CA), 250 u,g/l 
fungizone, 100 mg/1 ampicillin, 50 mg/1 gentamicin. After 2 weeks, the cells were lifted 
with a trypsin-EDTA solution (passage one cells) and mixed with cells from the other 
two rabbits of an isolation for composite fabrication. Previously, rabbit MSCs isolated 
and cultured using this method have been tested for their multi-potentiality to 
differentiate into osteoblast-like cells and chondrocyte-like in vitro [75]. 
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Hydrogel Composite Fabrication 
Before implantation, hydrogel composites were fabricated according to the 
formulations shown in Table IV-1 following established methods [74]. Briefly, 0.1 g of 
sterile OPF and 0.05 g of sterile poly(ethylene glycol) diacrylate (PEG-DA; nominal MW 
3400, Nektar Therapeutics, Huntsville, AL) in 300 ul of PBS were transferred to a vial 
containing the swelling microparticle solution (either blank or TGF-pi-loaded). For 
crosslinking, equal parts (46.8 ul) of initiator solutions, 0.3 M ammonium persulfate 
(APS) and 0.3 M N,N,N',N',-tetramethylethylenediamine (TEMED), were first mixed 
with the polymer solution, followed by the addition of 168 ul of a cell suspension 
containing 6.7 million rabbit MSCs to reach a final concentration of 10 million cells/ml 
solution. The solution was then quickly injected into Teflon molds (2.2 mm in diameter x 
2.2 mm in depth) and incubated at 37°C for 8 minutes. Cell-free constructs were 
fabricated in a similar fashion using PBS instead of the cell suspension. After 
crosslinking, hydrogel constructs with or without MSCs were transferred in PBS before 
they were implanted in the osteochondral defects in rabbits within 2 h. The final 
dimensions of the scaffolds after swelling were 3 mm in diameter and 3 mm in height, 
which match the dimensions of the osteochondral defect. 
Animal Surgery 
A total of 18 specified-pathogen-free New Zealand white rabbits (6-month-old) 
were used for the implantation study based on a well-established rabbit osteochondral 
(full-thickness) defect model [81, 138]. Rabbits 6 months in age were selected for this 
study since they are skeletally mature; a previous study has shown histologically and 
radiographically that their growth plates in the distal femur closed at 19-24 weeks [153]. 
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All in vivo work was conducted in accordance with ISO standards, and protocols of the 
Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands. National 
guidelines for the care and use of laboratory animals were observed, and approval of the 
Experimental Animal Ethical Committee was obtained (RUDEC 2007-019). 
Animal surgeries were performed as described previously [81]. Briefly, bilateral 
osteochondral defects (3 mm in diameter x 3 mm in depth) were first created on the 
weight-bearing surface of medial femoral condyles. Then a prefabricated hydrogel 
composite, which had similar dimensions of the defect, was press-fit into the defect. 
Subsequently, the muscle and skin were closed. Each rabbit received 2 hydrogel 
composites with the same formulation, one per knee, and the procedure was repeated for 
6 rabbits per formulation, resulting in n=12 implants per group. To minimize 
post-operative discomfort, Fynadyne® was administered for two days postoperatively. 
The animals were returned to their cages after surgery and allowed unrestricted 
weight-bearing activity. Signs of pain, infection and proper activity were monitored and 
carefully recorded. 
Tissue Processing 
Rabbits were euthanized at twelve weeks after surgery by intravenous 
administration of Nembutal (pentobarbital). The tissue surrounding the medial femoral 
condyle was retrieved en bloc. Specimens were fixed in 10% buffered formalin (pH 7.4) 
for 1 week, decalcified in Formical2000 (Decal Corporation, Congers, NY, USA) for 2 
weeks, dehydrated through a graded series of ethanol, and then embedded in paraffin. 
Longitudinal sections of 6 urn were taken from the center (within the central 1 mm), 
lateral edge (within the lateral 1 mm) and medial edge (within the medial 1 mm) of each 
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defect. Two sections from each region were then stained with hematoxylin and eosin 
(H&E), Safranin O/Fast green as well as Masson's trichrome separately, and 
subsequently scored [80]. 
Histological Scoring 
Histological sections were blindly and independently scored by three evaluators 
(FKK, SY, JDK) using an established scoring system consisting of 11 parameters for 
osteochondral repair, as shown in Table IV-2 [80, 81, 138, 154-157]. Analysis was done 
over the whole defect for both chondral (within the upper 1 mm of the defect) and 
subchondral regions (within the bottom 2 mm of the defect). In particular, the chondral 
region was scored for its morphology, thickness, regularity, and chondrocyte clustering, 
as well as cell and glycosaminoglycan (GAG) content. The cell and GAG content of the 
cartilage tissue adjacent to the defect was also examined to assess possible tissue 
degeneration near the implant site. Additionally, bone filling, integration, and 
morphology in the subchondral region of defects were assessed during this evaluation. 
Statistical Analysis 
Prior to the study, the number of defects needed in each group (n=12) was 
determined by power analysis and consideration of previous studies [80, 81]. For 
histological data analysis, ordered logistic regression was performed on each of the 
parameters in the scoring system to determine the potential effects of implant formulation, 
location within the defect (lateral, medial edges and center) and knee joint (left and right) 
on tissue regeneration following previous methods [80, 81]. A significance level of 0.05 
was used for the statistical analysis. 
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Results 
Macroscopic Observation 
All animals regained full movement within one week, and they continued to 
exhibit normal behavior and movement during the 12-week period. No gross signs of 
inflammation, infection or swelling were observed upon visual inspection of the joint 
surface at the time of tissue retrieval. Migration of the hydrogel composites from the 
defect was not found. 
Histological Observation 
For all three treatments, complete degradation of the implanted hydrogel 
composites was seen in approximately half of the specimens. More specifically, the 
frequency for complete implant degradation was 5/12, 6/12 and 7/12 for the OPF, 
OPF/MSC and OPF/MSC/TGF groups, respectively. However, in the cases where the 
hydrogels were not completely degraded, less degradation was seen in the defects when 
TGF-(31 was not present. Four out of twelve specimens had less than 50% degradation in 
the OPF and OPF/MSC groups, whereas only one was found in the OPF/MSC/TGF 
group. A similar extent of implant degradation and tissue filling was seen in the left and 
right knees of each rabbit. 
In the OPF group, the defects were filled with newly formed cartilage tissue in the 
superficial part and bone tissue in the deep part. In seven out of twelve specimens, 
cartilage developed in the subchondral bone area and occupied more than 2/3 of the 
whole defect. Neo-formed cartilage tissue on the surface had an appearance of hyaline 
cartilage, evidenced by an intense Safranin O staining as shown in Figure IV-1 (b). At 
higher magnification, the cells were round, clustered, and surrounded by extracellular 
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matrix, resembling well differentiated chondrocytes [Figure IV-1 (d)]. In some sections, 
chondrocytes were even arranged with a zonal organization, indicative of true articular 
cartilage. As also shown in Figure IV-1 (d), slightly elongated cells were located near the 
articular surface. Below these cells, more rounded cells were clustered in columns, as 
expected for the cells in middle and deep zones of articular cartilage. 
Although trabecular bone was present in some areas of the subchondral region, 
the bone regeneration seemed incomplete because of incomplete degradation of the 
hydrogel composites and the presence of cartilage tissue. Hypertrophic cartilage was seen 
and appeared calcified in some sections, indicative of the process of cartilage resorption 
and bone formation. In most specimens, tissue in the subchondral region integrated well 
with the surrounding host tissue and cartilage tissue. 
Similarly, in the OPF/MSC group, the subchondral region contained remaining 
hydrogel composite material, hypertrophic cartilage, and some trabecular bone. Cartilage 
had an appearance of hyaline cartilage and fibrocartilage with varying thickness, as seen 
in Figure IV-2. 
In the group with TGF-pi, neo-cartilage tissue exhibited a fibrocartilage-like 
appearance. In particular, a thicker fibrous layer with faint staining for GAG and intense 
staining for collagen was seen near the articular surface as compared to the other two 
groups [Figure IV-3 (a-c)]. At higher magnification, the cells in this layer appeared as 
small dots and were surrounded by fibrillar matrix [Figure IV-3 (d)]. In the subchondral 
region, although remaining hydrogel and hypertrophic cartilage were still observed in 
some sections, more trabecular bone formation could be seen as compared to the groups 
without TGF-pl. 
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Histological Scoring 
Figure IV-4 displays the quantitative scoring of 11 parameters of osteochondral 
restoration. Statistical analysis was performed to determine the effects of implant 
formulation, position in the defect site (lateral, center or medial), and knees (left and right) 
on each of the 11 parameters. The analysis revealed that implant formulation affected 
significantly the surface morphology, cartilage thickness, surface regularity, and cell and 
GAG content of the neo-surface. Position within the defect was determined to be a 
significant factor affecting only cell and GAG content of the adjacent surface, but not for 
any of the other parameters. No significant difference was found between left and right 
knees for all the parameters except bone bonding. 
Mean scores for overall tissue filling and scaffold degradation were around two 
[Figure IV-4 (a)], indicating that more than 50% of the implant was degraded and filled 
with tissue [according to the scoring system, Table IV-2 (a)] over the 12-week period. 
However, no significant difference existed between the various implant formulations. 
Similarly, no significant difference was observed for bone filling, subchondral 
morphology or bone bonding among the implant formulations [Figure IV-4 (b)]. Bone 
filling scored slightly above two, indicating that more than 50% of the subchondral 
region was filled with tissue at 12 weeks. Bone bonding had an average score between 
two and three, which was consistant with the histological apprearence that the 
neo-formed tissue in the subchodral region was well integrated with the surrounding host 
tissue. The detailed differences in subchondral bone morphology are shown in Figure 
IV-5 (a). In the OPF/MSC/TGF group, more sections scored 'normal, trabecular bone' 
(score 4), indicative of the formation of normal trabecular bone, than the other two 
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groups. These findings corroborate the subjective histological observation that more 
remodeling of bone tissue was seen in the subchondral region of the defects treated with 
TGF-pl. 
Further, the OPF group had a higher score in cartilage morphology as well as cell 
and GAG content of neo-cartilage than the other two groups [Figure IV-4 (c)]. 
Specifically, the score for the cartilage morphology of the OPF group was 2.9 ± 1.3, 
reflecting the majority of hyaline cartilage near the joint surface. In the OPF/MSC group, 
the mean score was 2.4 ± 1.3, which was consistent with the histological appearance of a 
mixture of hyaline cartilage and fibrocartilage. When TGF-J31 was incorporated, the 
neo-formed tissue had a score of 1.9 ± 1.2 in cartilage morphology, indicating the fibrous 
nature of the neo-surface. A detailed score distribution of cartilage morphology for each 
formulation is displayed in Figure IV-5 (b). Scoring for cell and GAG content 
demonstrated the same trend and additional statistical evaluation revealed that for both of 
the two markers, significant differences were observed between the OPF and 
OPF/MSC/TGF groups. 
For neo-cartilage thickness, the OPF group had a mean value around two [Figure 
IV-4 (c)], suggesting thicker neo-cartilage formed than host cartilage accroding to the 
scoring system. Although the scores of this group were significantly higher than those of 
both the OPF/MSC and OPF/MSC/TGF groups, the results may be due to the fact that 
more hypertrophic cartilage developed in the subchondral area and less remodeling of 
bone tissue was observed in this group. Additionally, when compared to the group 
implanted with OPF scaffolds alone, the delivery of cells (OPF/MSC group) significantly 
improved scores for surface regularity [Figure IV-4 (c)]. 
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No significant difference was seen for chondrocyte clustering or cell and GAG 
content of adjacent cartilage among the formulations [Figure IV-4 (c)]. The values 
indicated that no severe degenerative changes occurred in the adjacent cartilage. However, 
the position within the defect was determined statistically to have an influence on cell and 
GAG content of adjacent cartilage. Specifically, significant differences in cell and GAG 
content of adjacent cartilage were seen between the lateral edge and the center of the 
defect. 
Discussion 
In this study, we investigated the delivery of MSCs, with or without TGF-pi, 
from biodegradable hydrogel composites on the repair of osteochondral defects in a 
rabbit model. Specifically, we investigated (1) whether the implantation of MSCs would 
influence the quality of new cartilage and bone tissue formation; and (2) whether the 
combined delivery of MSCs and TGF-|31 would affect the quality of new cartilage and 
bone tissue formation in a rabbit osteochondral defect model using OPF-based hydrogel 
composites as cell and growth factor carriers. 
At 12 weeks post-surgery, implants were not found to migrate from the defect, as 
reported previously using OPF constructs in the same model [81]. Hydrogel composites 
were found to be partially degraded and neo-tissue filling was observed within defects for 
all three formulations. Although scaffold degradation rate slightly varied among the 
animals, no signs of prolonged inflammatory response, osteoarthritis, or cartilage 
destruction were observed, which demonstrated the biocompatibility of OPF-based 
hydrogel composites and their degradation products. 
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Tissue formation and integration were seen in the group with the implantation of 
OPF/GMP scaffolds alone. As shown in Figure IV-1, hyaline cartilage with 
well-organized chondrocytes and intense GAG staining was seen to fill the chondral 
portion of the defect at 12 weeks, while hypertrophic cartilage with remodeling matrix 
was often observed filling the subchondral region. Many previous studies suggested that 
the post-injury response involves a rapid influx of donor MSCs and growth factors into 
the defect area and the fabrication of embryonic-like cartilage tissue throughout the 
defect [150, 158, 159]. This was confirmed by the results of the present study. Although 
this study did not include an experimental group of untreated defects (empty control), 
comparison of the current results with the results of a previous study using the same 
defect model suggests that the quality of neo-tissue is superior to that of untreated defects 
[81]. The normal cellularity and GAG deposition of neo-cartilage indicated that the 
OPF/GMP scaffold allowed for the recruitment, infiltration and differentiation of MSCs 
from the defect site or synovium. It has been reported that gelatin GMPs can bind with 
growth factors through polyionic interactions [69, 74, 160], therefore we speculate that 
GMPs incorporated in the hydrogel composites can adsorb and localize the growth 
factors from the defect site and synovial fluid. The subsequent release of these bioactive 
factors may contribute to the chondrogenic differentiation of the stem cells. 
Many investigators have reported that implantation of MSCs within scaffolds 
improves bone formation and to a lesser degree cartilage formation [161-164]. However, 
in the present study, differences in the three markers for subchondral bone formation 
were not significant among groups. The lack of difference could be due to a 
comparatively lower cell density in the scaffolds in the present study (10 million cells/ml) 
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as compared to some other studies using a seeding density of 50 million cells/ml [149, 
165]. 
For cartilage regeneration, implantation of MSCs significantly reduced cartilage 
thickness, which also provided evidence for faster erosion of hypertrophic cartilage and 
remodeling of subchondral bone in the presence of MSCs. It should also be noted that 
surface regularity was significantly improved with transplanted MSCs [see Figure IV-4 
(c)]. Previous reports suggested that cartilage fibrillation would proceed when immature 
surface cartilage lost sufficient mechanical support during the degradation of the scaffold, 
especially when experiencing vigorous repetitive loading at the weight bearing regions of 
articular cartilage [62, 163, 166]. Therefore, we hypothesize that the smoother articular 
surface observed in the OPF/MSC group was a result of faster subchondral bone 
formation in this group (as compared to the OPF group), which provided sufficient 
mechanical support for the articular surface. In addition to biomechanical considerations, 
implanted cells may also contribute to cartilaginous matrix secretion and remodeling, 
which result in better surface regularity and integration as other investigators reported 
[150, 164]. 
Histological scores of other neo-cartilage parameters did not reveal statistical 
differences for the implantation of MSCs. This is not an uncommon finding for the 
selected 12 week implantation time and the rabbit model used. For example, Solchaga et 
al. reported that the implantation of bone marrow in hyaluronan-based sponges 
accelerated the first stages of the osteochondral repair progress but did not significantly 
affect medium- (12 week) and long-term (24 week) outcomes of the repair process [138]. 
Several other studies, which involved cell implantation and cell tracking in osteochondral 
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defects also demonstrated that implanted cells can survive and participate in the initial 
repair process, but are finally replaced by host cells [163, 165, 167]. We hypothesize that 
a similar phenomenon occurred in our study, as we know from previous studies that the 
cells survive the crosslinking process [74, 75]. Additionally, cells from surrounding host 
tissues can migrate into the defect, thus explaining the dependence of cell and GAG 
content on position within the defect. Further research is necessary to elucidate the fate of 
encapsulated MSCs during implantation and the migration of host cells as well as their 
involvement in osteochondral tissue repair. 
TGF-pi has been reported to promote not only MSC chondrogenic differentiation, 
but also to induce osteogenic differentiation in vivo [168, 169]. Therefore, not 
surprisingly, the highest scores in bone filling and bone morphology occurred for the 
group including both TGF-J31 and MSCs [see Figure IV-4 (b)]. According to previous 
studies, TGF-|31 probably participates indirectly in vascularization, which controls the 
rate of bone formation [158]. Additionally, previous investigations suggested that 
TGF-J31 also affects chondro/osteoclasts and facilitates cartilage matrix resorption and 
bone remodeling during endochondral ossification [169]. This may explain the 
occurrence of more remodeled trabecular bone as seen in the group with TGF-J31 
compared to the other two groups. Although TGF-pi delivery to the bony tissue of 
osteochondral defects may elicit side effects, such as bone upgrowth into the 
cartilaginous region of the defects and inflammation [101, 158], such adverse effects 
were not observed in our study. 
Surprisingly, in the current study cell morphology and GAG production of 
neo-cartilage were not improved by the addition of MSCs or TGF-(31. In fact, a thick 
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fibrous layer was frequently noticed at the articular surface in the presence of TGF-|31, as 
shown in Figure IV-3. Since many studies indicated that a high dosage of TGF-pi is 
related to the occurrence of fibrosis and osteophyte formation in articular cartilage 
defects [11, 100], we hypothesize that the fibrous layer as seen in the MSC/OPF/TGF 
group may be linked to the high local concentration of TGF-|31. A previous in vitro study 
investigating the release of TGF-pi from similar OPF/GMP composites has shown that 
TGF-pl had a burst release within the first 3 days (65.5 ± 3.3% in PBS and 60.8 ± 3.4% 
in PBS containing collagenase), and a sustained release up to 28 days (84.6 ± 1.1% in 
PBS and 83.6 ± 1.5% in PBS containing collagenase) [81]. The TGF-|31 concentration 
was selected based on an in vitro study, where 600 ng TGF-|31/ml hydro gel achieved the 
best chondrogenic differentiation of MSCs in similar hydrogel composites [75]. However, 
the formation of fibrous tissue in vivo emphasizes the significant difference between the 
in vitro and in vivo environments. In addition to TGF-pi loaded on GMPs, some other 
bioactive agents from both the synovial joint and the defect site of the wound may also be 
involved in the repair process, as evidenced by the cartilage repair for the OPF and 
OPF/MSC groups. 
Comparing the results of this study to those from a previous study in our 
laboratory, where TGF-pi alone (200 ng/g gel) was delivered from a similar OPF/GMP 
composite to an osteochondral defect [81], we found that the combined delivery of both 
MSCs and TGF-pi did not exhibit significant improvement in neo-cartilage formation for 
the MSC seeding density and differentiation stage tested. Although MSCs are reported to 
be immunoprivileged and immunosuppressive [170-172], histoincompatibility may be a 
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factor that could affect neo-cartilage formation in the presence and absence of TGF-pi in 
this case. 
However, controversial results were found in some other studies, demonstrating 
that delivery of cells and growth factors enhanced cartilage repair as compared to the 
individual delivery of cells or growth factors. Sharma et al. injected PEG-DA and 
hyaluronic acid solution containing MSCs and 150 ng of TGF-(33 subcutaneously in nude 
mice, and they found that scaffolds with MSCs and TGF-J33 produced the highest quality 
cartilage [173]. Similarly, another study investigating the transplantation of periosteal 
cells in a fibrin gel to a full-thickness defect in rabbit knees showed that the addition of 
TGF-pi (5 ng/ml gel) resulted in better osteochondral integration and improved zonal 
architecture [164]. 
The different results for cartilage repair from similar strategies may be due to the 
differences in cellular microenvironment of defects, scaffold properties as well as growth 
factor release patterns. The complexity of the in vivo healing environment requires 
further understanding of the roles of cells and growth factors and their interactions during 
tissue repair. While OPF/GMP composites supported osteochondral tissue growth, further 
in vivo assessment (with and without cells) is necessary to optimize scaffold properties, 
stem cell seeding density and differentiation stage, growth factor dosage and release 
kinetics for the best osteochondral tissue regeneration. Design of an osteochondral 
construct of a layered architecture, which allows the delivery of suitable growth factors 
and cells to both cartilage and bone regions, may also be necessary. 
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Conclusions 
This study investigated the effect of MSC delivery with a biodegradable hydrogel 
composite in the presence or absence of TGF-pi on osteochondral tissue repair in a rabbit 
model. The results revealed that the OPF-based hydrogel composites partially degraded at 
12 weeks after implantation, which allowed for cartilaginous and bony tissue formation. 
The implantation of MSCs with the hydrogel composites did not elicit a persistent 
inflammation, and facilitated subchondral bone formation in the presence of TGF-pi. 
However, the delivery of MSCs either with or without TGF-pi did not improve cartilage 
morphology for the MSC seeding density and differentiation stage tested. 
Figures 
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Figure IV-1: Histological sections showing representative 12-week tissue repair at defect 
sites treated with OPF hydrogel composites alone. Sections stained with H&E (a), 
Safranin O (b), and Masson's trichrome (c) at 2x display cartilaginous tissue growth into 
the subchondral region. Small arrows define the edges of the defects. Boxed regions are 
shown at lOx magnification to illustrate clustered, spherical chondrocyte-like cells in the 
neo-surface (d) and hypertrophic cartilage with calcified matrix in the subchondral region 
(e). Bar is 1 mm for (a-c) and 250 um for (d, e). 
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Figure IV-2: Histological sections showing representative 12-week tissue repair at defect 
sites treated with OPF hydrogel composites containing MSCs. Sections stained with H&E 
(a), Safranin O (b), and Masson's trichrome (c) are demonstrated at 2x magnification. 
Small arrows define the edges of the defects. Boxed regions are shown at lOx 
magnification to illustrate a mixture of hyaline cartilage and fibrocartilage in the chondral 
region (d) and partially degraded composites remaining in the subchondral region (e). 
The big arrow indicates microparticles in a hydrogel composite remained in the defect. 
Bar is 1 mm for (a-c) and 250 urn for (d, e). 
73 
Figure IV-3: Histological sections showing representative 12-week tissue repair at defect 
sites treated with OPF hydrogel composites containing MSCs and TGF-pi. Sections 
stained with H&E (a), Safranin O (b), and Masson's trichrome (c) at 2x display a thick 
fibrous layer at the articular surface and significant restoration in the subchondral region. 
Small arrows define the edges of the defects. Boxed regions are shown at lOx 
magnification to illustrate the excessive fibrous tissue growth into the joint surface (d) 
and remodeling tissue in the subchondral region (e). Bar is 1 mm for (a-c) and 250 urn 
for (d, e). 
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Figure IV-4: Histological scoring for overall defect (a), subchondral region (b) and 
cartilage region (c). Data are shown as average scores with error bars representing 
standard derivation for n=12. The symbol (*) indicates a statistical difference between 
groups (PO.05). 
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Figure IV-5: Histological score distribution for subchondral morphology (a) and 
cartilage morphology (b). 
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Tables 
Table IV-1: Experimental groups tested in this study. 
Groups Scaffolds Cell seeding density Repetitions 
dose 
OPF OPF+GMPs — —- 12 
OPF/MSC OPF+GMPs
 i n ..!VlSCs „ . . — 12 
10 million cells/ml 
OPF/MSC/TGF OPF+GMPs
 1 n . . ^
S C s
 „ . . J ? ^ 1 , 12 
10 million cells/ml 600ng/ml 
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Table IV-2: Histological scoring system for evaluation of overall tissue filling (a), 
subchondral bone repair (b), and cartilage repair (c) in rabbit osteochondral defects. 
(a) Overall defect evaluation (throughout the entire defect depth) 
1. Percent filling with neo-formed tissue 
100% 
>50% 
<50% 
0% 
2. Percent degradation of the implant 
100% 
>50% 
<50% 
0% 
Score 
3 
2 
1 
0 
3 
2 
1 
0 
(b) Subchondral bone evaluation (within the bottom 2 mm of defect) 
3. Percent filling with neo-formed tissue 
100% 3 
>50% 2 
<50% 1 
0% 0 
4. Subchondral bone morphology 
Normal, trabecular bone 4 
Trabecular bone, with some compact bone 3 
Compact bone 2 
Compact bone and fibrous tissue 1 
Only fibrous tissue or no tissue 0 
5. Extent of neo-tissue bonding with adjacent bone 
Complete on both edges 3 
Complete on one edge 2 
Partial on both edges 1 
Without continuity on either edge 0 
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(c) Cartilage evaluation (within the upper 1 mm of defect) Score 
6. Morphology of neo-formed surface tissue 
Exclusively articular cartilage 
Mainly hyaline cartilage 
Fibrocartilage (spherical morphology observed with>75% of cells) 
Only fibrous tissue (spherical morphology observed with <75% of 
cells) 
No tissue 
7. Thickness of neo-formed cartilage 
Similar to the surrounding cartilage 
Greater than the surrounding cartilage 
Less than the surrounding cartilage 
No cartilage 
8. Joint surface regularity 
Smooth, intact surface 
Surface fissures (<25% neo-surface thickness) 
Deep fissures (>25% neo-surface thickness) 
Complete disruption of the neo-surface 
9. Chondrocyte clustering 
None at all 
<25% chondrocytes 
25-100% chondrocytes 
No chondrocytes present (no cartilage) 
10. Chondrocyte and GAG content of neo-cartilage 
Normal cellularity with normal Safranin O staining 
Normal cellularity with moderate Safranin O staining 
Clearly less cells with poor Safranin O staining 
Few cells with no or little Safranin O staining or no cartilage 
11 Chondrocyte and GAG content of adjacent cartilage 
Normal cellularity with normal Safranin O staining 
Normal cellularity with moderate Safranin O staining 
Clearly less cells with poor Safranin O staining 
Few cells with no or little Safranin O staining or no cartilage 
4 
3 
2 
1 
0 
3 
2 
1 
0 
3 
2 
1 
0 
3 
2 
1 
0 
3 
2 
1 
0 
3 
2 
1 
0 
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CHAPTER V: IN VITRO GENERATION OF AN OSTEOCHONDRAL CONSTRUCT USING 
INJECTABLE HYDROGEL COMPOSITES ENCAPSULATING RABBIT MARROW 
MESENCHYMAL STEM CELLS f 
Abstract 
Injectable, biodegradable hydrogel composites of crosslinked oligo(poly(ethylene 
glycol) fumarate) (OPF) and gelatin microparticles (MPs) were utilized to fabricate a 
bilayered osteochondral construct consisting of a chondrogenic layer and an osteogenic 
layer, and to investigate the differentiation of rabbit marrow mesenchymal stem cells 
(MSCs) encapsulated in both layers in vitro. The results showed that MSCs in the 
chondrogenic layer were able to undergo chondrogenic differentiation, especially in the 
presence of TGF-pi -loaded MPs. In the osteogenic layer, cells maintained their 
osteoblastic phenotype. Although calcium deposition in the osteogenic layer was limited, 
cells in the osteogenic layer significantly enhanced chondrogenic differentiation of MSCs 
in the chondrogenic layer. The greatest effect was observed when MSCs were 
encapsulated with TGF-pi -loaded MPs and cultured with osteogenic cells in the 
bilayered constructs. Overall, this study demonstrates the fabrication of bilayered 
hydrogel composites that mimic the structure and function of osteochondral tissue, along 
with the application of these composites as cell and growth factor carriers. 
Abbreviations 
ALP, alkaline phosphatase; APS, ammonium persulfate; BMP, bone morphogenetic 
protein; CM, chondrogenic medium; DMEM, Dulbecco's modified Eagle's medium; 
DMMB, dimethylmethylene blue; DMSO, dimethyl sulfoxide; ECM, extracellular matrix; 
FBS, fetal bovine serum; FGF, fibroblastic growth factor; GAG, glycosaminoglycan; 
t
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Kasper FK, Mikos AG. In vitro generation of an osteochondral construct using injectable hydrogel 
composites encapsulating rabbit marrow mesenchymal stem cells. Biomaterials 2009; 30:2741-2752. 
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GAPDH, glyceraldehyde-3-phosphatase dehydrogenase; GM, general medium; (3-GP, 
P-glycerophosphate; GPC, gel permeation chromatography; IGF, insulin-like growth 
factor; MP, gelatin microparticle; MSC, mesenchymal stem cell; OM, osteogenic 
medium; OPF, oligo(poly(ethylene glycol) fumarate); PBS, phosphate buffered saline; 
PEG, poly(ethylene glycol); PEG-DA, poly(ethylene glycol)-diacrylate; RT-PCR, reverse 
transcriptase-polymerase chain reaction; TEMED, 
N,N,N',f\P-tetram ethyl ethyl enediamine; TGF, transforming growth factor; VEGF, 
vascular endothelial growth factor. 
Introduction 
Articular cartilage and subchondral bone are two distinct tissues that contribute to 
the unique and important functions of the articular joint. Subchondral bone serves as a 
mechanical support for the articular surface [174], while articular cartilage protects bone 
from high stresses and allows for low-friction movements within the joint [174]. Due to 
its complex structure and poor access to progenitor cells, articular cartilage has limited 
ability to regenerate once injured [1, 2]. Thus, degenerative changes in cartilage and 
subchondral bone cause severe joint pain and progressive loss of joint function, which 
affects many people of different ages [2]. 
Recently, tissue engineering has become a promising strategy for tissue 
regeneration, by combining scaffolds, cells, and bioactive molecules [135]. In this 
approach, mesenchymal stem cells (MSCs) hold great promise because MSCs can be 
easily isolated from the bone marrow and expanded without losing their capacity to 
differentiate into cells of various mesenchymal lineages, including chondrocytes and 
osteoblasts [136]. Many studies have reported the successful generation of cartilage or 
bone tissue alone in vitro using MSCs [59, 95]. 
However, due to the different properties of articular cartilage and subchondral 
bone, a bilayered architecture with proper cell and extracellular matrix distribution is 
desirable because it mimics the complex structure of osteochondral tissue and contributes 
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to the function of the articular joint. Some attempts have been made to fabricate 
cartilaginous and bony layers independently before integrating the two components 
together by suturing or gluing [3, 84]. However, implantation of these bilayered 
constructs has typically revealed poor integration between layers, which may cause 
long-term device failure. Consequently, investigators are exploring methods to construct 
well-integrated bilayered scaffolds that can guide the chondrogenic and osteogenic 
differentiation of cells in different regions of the same scaffold during co-culture. The 
challenge lies in maintaining the appropriate chondrogenic and osteogenic phenotype 
under a single set of cell culture conditions [3, 5]. 
A degradable macromer, oligo(poly(ethylene glycol) fumarate) (OPF), has been 
developed in our laboratory and shown to be suitable as an injectable hydrogel carrier for 
cells and growth factors for both cartilage and bone tissue engineering [74, 78]. OPF can 
be synthesized from fumaryl chloride and poly(ethylene glycol) (PEG). The fumarate 
double bonds in the macromer chains allow this material to crosslink to form a hydrogel 
network, and the hydrolysis of ester linkages results in the degradation of the crosslinked 
hydrogel [73]. Previous work in our laboratory has demonstrated the cytocompatibility of 
OPF hydrogels with various cell types, including MSCs [74-76]. For example, rat MSCs 
encapsulated in OPF hydrogels and cultured in osteogenic medium have been shown to 
be viable and to differentiate down the osteogenic lineage, as evidenced by calcium 
deposition after 4 weeks [76]. Gelatin microparticles (MPs) can be incorporated into this 
hydrogel during the time of crosslinking for controlled release of growth factors [69, 70]. 
Previous studies have shown that MPs can be loaded with transforming growth factor-|31 
(TGF-pi), an important molecule for in vitro and in vivo chondrogenesis, through 
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polyionic complexation and encapsulated in OPF hydrogels. The hydrogel composites 
containing TGF-|31 -loaded MPs enable controlled release of the growth factor [69, 70]. 
Additionally, rabbit MSCs encapsulated with TGF-pi-loaded MPs in OPF hydrogels 
showed an increase in gene expression of type II collagen and aggrecan, indicating 
enhanced chondrogenic differentiation [75]. Further, the cellularity of the constructs and 
the distribution of the MPs in the OPF hydrogels were confirmed qualitatively via both 
light microscopy and histology [75]. It should also be noted that OPF allows the 
fabrication of a multi-layered structure with good integration between layers using a 
multi-step crosslinking procedure, as evidenced by swelling and mechanical studies [81, 
90]. All these features suggested that OPF hydrogel composites could be applied for 
fabrication of osteochondral constructs. 
The present study explored the fabrication of a bilayered OPF/MP composite 
consisting of a chondrogenic layer and an osteogenic layer; MSCs were encapsulated 
within these composites and MSC differentiation in both layers was investigated. 
Specifically, the study asked the following questions: (1) whether MSCs can undergo 
chondrogenic and osteogenic differentiation in the respective layers of a bilayered 
hydrogel composite; (2) how cells in the osteogenic layer affect MSC chondrogenesis in 
the chondrogenic layer; and (3) how cells in the osteogenic layer, in combination with 
TGF-pi-loaded MPs, influence MSC chondrogenesis in the chondrogenic layer. 
Materials and Methods 
Experimental Design 
The overall experimental design is shown in Figure V-l. In order to develop a set 
of cell culture conditions that is suitable for both osteogenic and chondrogenic 
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differentiation of MSCs, an osteogenic culture study and a chondrogenic culture study 
were first performed with single-layer OPF hydro gel composites. 
In the osteogenic construct culture study, MSCs were first cultured in a tissue 
culture flask with osteogenic medium for various periods of time (0, 3 and 6 days) to 
induce osteogenic differentiation (groups OS0, OS3, OS6 in Figure V-l). The precultured 
MSCs were then encapsulated in hydrogel composites with blank MPs and subsequently 
cultured in chondrogenic medium (CM) supplemented with (+) or without (-) 
P-glycerophosphate (P-GP); osteogenic differentiation was assessed. The purpose of this 
study was to examine whether the osteoblastic phenotype (induced by preculture) can be 
maintained within OPF hydrogel composites exposed to chondrogenic culture conditions 
with (or without) the osteogenic supplement p-glycerophosphate. 
In the chondrogenic construct culture study, MSCs were encapsulated in OPF 
hydrogel composites containing either blank MPs (group BLK) or TGF-pi-loaded MPs 
(group TGF in Figure V-l) to examine their effect on chondrogenic differentiation of 
encapsulated MSCs. Cell constructs were cultured in chondrogenic medium 
supplemented with P-GP. 
The next step was an osteochondral construct culture study, where bilayered 
hydrogel composites consisting of a chondrogenic layer at top and an osteogenic layer at 
bottom were fabricated. More specifically, in the top layer, MSCs were encapsulated in 
OPF hydrogels with either blank MPs (BLK) or TGF-pi loaded MPs (TGF), while in the 
bottom layer, OPF hydrogel composites with blank MPs were utilized to encapsulate 
either MSCs (MSC) or 6-day osteogenically precultured cells (OS). Four formulations of 
bilayered constructs [groups BLK(MSC), TGF(MSC), BLK(OS), TGF(OS) in Figure V-l] 
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were cultured in CM supplemented with (3-GP for 28 days. Samples from the top and 
bottom layers were analyzed to evaluate chondrogenic and osteogenic differentiation of 
the cells, respectively. 
OPF Synthesis and Characterization 
OPF was synthesized from fumaryl chloride and poly(ethylene glycol) with a 
nominal molecular weight of 10,000 g/mol (Sigma, St. Louis, MO) according to a 
previously established method [73]. Molecular weights of both the parent PEG and the 
resulting OPF were determined by gel permeation chromatography (GPC; Model 410; 
Waters, Milford, PA) using a refractive index detector (n=3). The purified macromer was 
stored at -20°C and sterilized prior to use by exposure to ethylene oxide for 14 h. 
Gelatin Microparticle Fabrication 
Gelatin microparticles were fabricated from acidic gelatin (Nitta Gelatin Inc., 
Osaka, Japan) and crosslinked with 10 mM glutaraldehyde (Sigma, St. Louis, MO) 
following established procedures [74]. After drying, MPs were sieved to obtain particles 
of 50-100 urn in diameter and sterilized with ethylene oxide for 14 h. 
Rabbit Marrow MSC Isolation and Preculture 
Rabbit marrow MSCs were isolated from the tibias of 4 month old New Zealand 
white rabbits as previously described [75]. Briefly, after anesthesia, the rabbit tibia was 
punctured with a 16-gauge needle and 4-5 ml of bone marrow were aspirated through a 
sterile tube into a 10 ml syringe containing 5000 U of heparin. The bone marrow was 
filtered through a cell strainer (40 urn) and cultured in general medium (GM) containing 
Dulbecco's modified Eagle's medium (DMEM), 10% v/v fetal bovine serum (FBS; 
Gemini, Calabasas, CA), 250 (ag/1 fungizone, 100 mg/1 ampicillin, and 50 mg/1 
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gentamicin for 2 weeks. In order to reduce any interanimal variation, a pool of rabbit 
marrow MSCs from a total of six rabbits was mixed together, and then cryopreserved in 
medium containing 20% FBS and 10% dimethyl sulfoxide (DMSO) in liquid nitrogen. 
Prior to use, MSCs were thawed at 37°C and expanded in T-75 flasks with GM up to 
passage three. For osteogenic preculture, cells were expanded in GM up to passage two, 
and then, for the third passage, cells were cultured in osteogenic medium (OM), which is 
DMEM supplemented with 10% v/v FBS, 50 mg/1 ascorbic acid, 10 mM 
P-glycerophosphate, 10" M dexamethasone, 250 jag/1 fungizone, 100 mg/1 ampicillin, and 
50 mg/1 gentamicin (all from Sigma), for 6 days (3 days in the OS3+ group in Figure V-l) 
before encapsulation. Cells from a single pool of rabbit marrow were used in all three 
studies and the cells used for each study were from each expansion of cryopreserved 
cells. 
Fabrication of Single-layer Hydrogel Composites 
Before encapsulation, sterile MPs were loaded with TGF-pi (R&D Systems, 
Minneapolis, MN) by swelling in an aqueous solution of the growth factor at pH 7.4 for 
15 h according to a previously reported method [79]. The volume of TGF-pi loading 
solution needed for equilibrium swelling of the MPs (110 ul) was combined with 22 mg 
of MPs. The loading solution had a concentration of 3.6 ug TGF-(31/ml phosphate 
buffered saline (PBS; Gibco) to achieve a final loading of 600 ng TGF-|31/ml in the 
crosslinked scaffolds. This growth factor amount has been shown to promote the 
chondrogenic differentiation of rabbit MSCs encapsulated in hydrogel composites in vitro 
[75]. Blank MPs were loaded with PBS in a similar fashion. 
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For fabrication of a single-layer hydrogel composite, 0.1 g of sterile OPF and 0.05 
g of sterile poly(ethylene glycol) diacrylate (PEG-DA; Nektar Therapeutics, Huntsville, 
AL) were first dissolved in 300 ul of PBS and mixed with swelled MP solution (either 
TGF-pi-loaded or blank). The mixture was then added to equal volumes (46.8 ul) of the 
thermal radical initiator solutions, 0.3 M ammonium persulfate (APS) and 0.3 M 
N,N,N\NMetramethylefhylenediamine (TEMED) in PBS. A cell suspension (6.7 million 
cells in 168 pi of PBS) was subsequently added to the polymer solution to achieve a 
concentration of 10 million cells/ml final suspension. After gentle mixing, the suspension 
was quickly injected into Teflon molds (6 mm diameter, 1 mm thickness), followed by 
incubation at 37°C for 8 min. In the osteogenic construct culture study, all hydrogel 
composites contained blank MPs, while in the chondrogenic construct culture study, 
hydrogel composites contained either blank MPs or TGF-|31 -loaded MPs, as shown in 
Figure V-l. 
Fabrication of Bilayered Hydrogel Composites 
Bilayered hydrogel composites were fabricated via a two-step crosslinking 
procedure. The desired composition for the osteogenic (bottom) layer (Figure V-l) was 
first injected into the bottom 1 mm of Teflon molds (6 mm diameter, 2 mm thickness) 
and incubated for 4 minutes, allowing for partial crosslinking. Meanwhile, another 
polymer-cell suspension was prepared, and then injected into the partially filled Teflon 
molds to form the chondrogenic layer. The resulting bilayered constructs were then 
incubated at 37°C for 8 minutes to achieve crosslinking. 
All hydrogel constructs were transferred into 12-well tissue culture plates. Each 
construct was cultured with 2.5 ml chondrogenic medium, which was DMEM 
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supplemented with ITS+ Premix (6.25 |ag/ml insulin, 6.25 jag/ml transferrin, 6.25 |J.g/ml 
selenous acid, 5.35 (J.g/ml linoleic acid and 1.25 p,g/ml bovine serum albumin) (BD 
Biosciences, Franklin Lakes, NJ), 1 mM sodium pyruvate (Sigma), 50 mg/1 ascorbic acid, 
10"7M dexamethasone, 250 mg/1 fungizone, 100 mg/1 ampicillin and 50 mg/1 gentamicin. 
In some of the groups, CM was supplemented with (3-glycerophosphate, as indicated in 
Figure V-l. The medium was changed every 3 days. In the osteogenic and chondrogenic 
construct culture studies, the hydrogel composites were cultured up to 14 and 21 days, 
respectively, while in the osteochondral construct culture study, samples were cultured up 
to 28 days. 
At the time points (days 0, 7, 14, 21 and 28), samples were removed from culture 
medium, rinsed in PBS and collected for quantitative reverse transcriptase-polymerase 
chain reaction (RT-PCR) (n=4) and for biochemical assays (n=4). Bilayered samples 
were dissected with a blade to separate the chondrogenic layer and osteogenic layer; 
samples from each layer were stored for analysis. 
Real-time PCR 
Samples from the chondrogenic construct culture study and the top layer of the 
osteochondral construct culture study were subjected to RT-PCR analysis to quantify 
MSC chondrogenic differentiation. Total RNA was extracted and reverse-transcribed to 
cDNA as described previously [75]. The final cDNA was then subjected to real time PCR 
(7300 Real-Time PCR System, Applied Biosystems, Foster City, CA) to determine the 
expression of genes for collagen type II, aggrecan and collage type I. 
Gene expression data were analyzed using the 2"AACt method as described 
previously [137, 147]. Briefly, all gene expression data were normalized to the 
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expression of a house-keeping gene, glyceraldehyde-3-phosphatase dehydrogenase 
(GAPDH) and expressed as the fold ratio compared to baseline gene expression of a 
control group at day 0. In the chondrogenic construct culture study, the control group 
contained a total of four samples from the BLK and TGF groups immediately after 
encapsulation. Similarly, in the osteochondral construct culture study, four top-layer 
hydrogels containing MSCs were collected from all the groups at day 0 and served as a 
control. The sequences of the primers for GAPDH, type II collagen, aggrecan, and type I 
collagen were as follows [75]: GAPDH: 5'-TCACCATCTTCCAGGAGCGA-3, 
5-CACAATGCCGAAGTGGTCGT-3' ; type II collagen: 
5' - AAC ACTGCC A ACGTCC AG AT-3', 5' -CTGC AGC ACGGTATAGGTGA-3'; 
Aggrecan: 5'-GCTACGGAGACAAGGATGAGTTC-3', 
5'-CGTAAAAGACCTCACCCTCCAT-3'; type I collagen: 
5' - ATGGATGAGGAA ACTGGC AACT-3', 
5 '-GCCATCGACAAGAACAGTGTAAGT-3'. 
Biochemical Assays 
Samples from the osteogenic construct culture study and the bottom layer of the 
osteochondral construct culture study were analyzed for DNA, alkaline phosphatase 
(ALP) enzyme activity, and calcium content to characterize osteogenic differentiation of 
the cells. In the osteochondral construct culture study, a total of four bottom-layer 
samples from the BLK(MSC) and TGF(MSC) groups were collected after encapsulation 
and analyzed to represent day 0 values for both groups. Similarly, the BLK(OS) and 
TGF(OS) shared bottom-layer samples for biochemical assays at day 0. 
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At each time point, samples were homogenized with a pellet grinder (Fisher 
Scientific) and stored in 500 ul of ddH20. The homogenates were then stored at -20°C 
until analysis, when they were subjected to three freeze-thaw-sonication cycles (30 min at 
-80°C, 30 min at room temperature, 30 min of sonication) for complete extraction of 
DNA from the cell cytoplasm. 
DNA content was determined using the PicoGreen assay (Molecular Probes, 
Eugene, OR) according to the manufacturer's instructions. ALP enzyme activity of each 
homogenized sample was measured by using an Alkaline Phosphatase Assay from Sigma 
(St. Louis, MO) as previously described [76]. After the DNA and ALP assays, each 
homogenized sample was mixed with an equal volume of 1 N acetic acid. Calcium 
content of the hydrogels was then determined using a calcium quantification assay 
(Diagnostic Chemicals; Charlottetown, PEI, Canada) as described previously [76]. 
Samples from the chondrogenic construct culture study and the top layer of the 
osteochondral construct culture study were subjected to DNA, glycosaminoglycan (GAG), 
and calcium assays to evaluate chondrogenic differentiation. In the chondrogenic 
construct culture study, a total of four samples from the BLK and TGF groups were 
collected after encapsulation and analyzed to represent day 0 values for both groups. 
Similarly, in the osteochondral construct culture study, the BLK(MSC) and BLK(OS) 
groups shared top-layer samples for biochemical assays at day 0, and the TGF(MSC) and 
TGF(OS) groups shared samples at day 0. 
The analysis of GAG content required samples to be homogenized and digested in 
500 ul of a proteinase K solution (1 mg/ml proteinase K, 10 (ig/ml pepstatin A, and 185 
ug/ml iodoacetamide in tris-EDTA solution (6.055 mg/ml tris(hydroxymethyl 
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aminomethane), 0.372 mg/ml EDTA, pH 7.6 adjusted by HC1); all from Sigma-Aldrich) 
at 56°C for 16 h. The homogenates were then frozen down and subjected to the same 
free-thaw-sonication cycles prior to analysis. DNA and calcium assays were performed 
on the lysate as described above. GAG content was determined using a biochemical assay, 
the dimethylmethylene blue dye (DMMB) assay (Sigma-Aldrich), as previously 
described [146]. 
Microplate readers (BIO-TEK Instrument, Winooski, VT) were utilized for all the 
absorbance/fluorescence measurements. Cell-free constructs were also fabricated, 
cultured, and analyzed with the samples. For all assays, fluorescence or absorbance of the 
cell-free hydrogels was subtracted from the values of experimental groups to account for 
fluorescence/absorbance caused by the scaffold material alone. 
Statistical Analysis 
DNA, GAG, calcium contents, ALP activity and gene expression data are 
reported as means ± standard deviation. Repetitive ANOVA and Tukey's multiple 
comparison tests were used to determine possible significant differences (p < 0.05) 
between groups. 
Results 
Osteogenic Construct Culture Study 
In the osteogenic construct culture study, we examined whether osteoblastic 
phenotype (induced by preculture) can be maintained within OPF hydrogel composites in 
the subsequent chondrogenic culture conditions, with an osteogenic supplement. DNA, 
ALP and calcium results are presented in Figure V-2 (a-c). For all the treatments, DNA 
content significantly decreased from day 0 to day 7, but the values remained similar after 
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day 7. At day 7, hydrogels with osteogenically precultured cells were found to have a 
higher DNA content than those with MSCs, and a significant difference was observed 
between OS0+ and OS6+ groups. However, by day 14, this difference among groups was 
no longer present. 
ALP results revealed a significantly higher ALP enzyme activity at days 7 and 14 
than at day 0 for all the treatments. However, there was no significant change in ALP 
activity between treatment groups. 
At day 14, there was higher calcium deposition in the hydrogels containing cells 
that were precultured in osteogenic medium for three or six days (and subsequently 
cultured in CM with P-GP), compared to hydrogels containing cells expanded in general 
medium. Specifically, 8.29 ± 3.62 \xg of calcium were deposited in the OS6+ samples 
(and 7.55 ± 7.84 jig in the OS3+ samples), compared to 0.38 ± 0.41 fig of calcium 
deposited in the OS0+ samples by day 14. The difference between the OS6+ and OS0+ 
groups was significant. Additionally, for MSCs precultured in osteogenic medium for 6 
days, a significant difference in calcium content was observed at day 14; constructs 
cultured in chondrogenic medium with P-GP (OS6+) had much higher calcium deposition 
than those cultured without P-GP (OS6-). 
Chondrogenic Construct Culture Study 
In the second study, we investigated whether MSCs will undergo chondrogenic 
differentiation when encapsulated in OPF hydrogel composites with blank MPs or 
TGF-pi-loaded MPs, and subsequently cultured in chondrogenic medium containing 
P-GP. The combined influence of P-glycerophosphate and TGF-pi on scaffold 
mineralization was also evaluated. 
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Quantitative gene expression data for collagen type II, aggrecan, and collagen 
type I at each time point are depicted in Figure V-3 (a-c). The results revealed an increase 
in collagen type II and aggrecan gene expression over time for both BLK and TGF 
groups. Specifically, a significantly higher collagen type II gene expression compared to 
day 0 was seen in the group containing blank MPs at day 28, while in the group with 
TGF-pi loaded MPs, significantly increased expression was observed at both day 14 and 
day 28 (and in the case of aggrecan gene expression, also at day 7). The presence of 
TGF-pi significantly affected the gene expression of chondrogenic markers, as evidenced 
by significant differences between the BLK and TGF groups in collagen type II gene 
expression at day 28 and in aggrecan gene expression at day 14 and day 28. 
For collagen type I gene expression, although the levels for TGF-(31 treated 
samples increased at day 7 and day 14 compared to day 0, gene expression subsequently 
decreased; the values on day 21 were found to be statistically equivalent to day 0. For the 
samples with blank MPs (no TGF-pi treatment), there was no significant change in 
collagen type I gene expression over time. 
Results for the biochemical assays, which quantified DNA, GAG and calcium 
content, are presented in Figure V-4 (a-c). For both BLK and TGF groups, there was a 
significant decrease in DNA content between day 0 and day 7, but the values on days 7, 
14 and 21 did not show any significant difference. At day 7, BLK samples had a 
significantly higher DNA amount than TGF samples, but there was no difference in DNA 
content between the two treatments at days 14 and 21. 
There was a trend of increasing GAG/DNA content for both BLK and TGF 
groups over the 21-day culture period; TGF samples had higher GAG/DNA values than 
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BLK samples at each time point. However, statistical analysis revealed no significant 
difference in GAG/DNA content between groups at each time point during the culture 
period. 
Little calcium deposition was observed for either BLK or TGF samples when 
cultured in the chondrogenic medium with (3-GP. The values for each treatment were 
found to be below 1 (j,g at each time point and statistically equivalent to those at day 0. 
Osteochondral Construct Culture Study 
After testing the effect of our set of culture conditions (specifically, CM + (3-GP) 
on both MSC chondrogenic and osteogenic differentiation in single-layer composites, we 
developed a bilayered hydrogel composite consisting of a chondrogenic layer at top and 
an osteogenic layer at bottom. Chondrogenic and osteogenic differentiation of the cells in 
each respective layer, as well as the signaling between layers, were examined in this 
study. 
RT-PCR analysis for gene expression of collagen type II, aggrecan, and collagen 
type I was performed on the top layer of the bilayered hydrogels to evaluate 
chondrogenic differentiation, as shown in Figure V-5 (a-c). For all the treatments, cells 
showed an increase in collagen type II and aggrecan gene expression over time. 
Significantly higher expression levels of both genes were found at days 14 and 28 
(compared to day 0) in the TGF(OS) treatment group. Samples with osteogenic 
precultured cells in the bottom layer (indicated by (OS) in Figure V-5) exhibited higher 
gene expression in both markers at every time point than those with MSCs in the bottom 
layer (indicated by (MSC) in Figure V-5); this trend was observed both in the presence 
and absence of TGF-(31. Interestingly, although there was a significant difference in gene 
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expression between BLK and TGF groups in the single-layer chondrogenic construct 
culture study, when the same formulations were co-cultured with MSCs encapsulated in 
the bottom layer, the difference in gene expression between BLK(MSC) and TGF(MSC) 
treatments at any time point was not significant (compare Figure V-5 (a-b) to Figure V-3 
(a-b)). However, when osteogenic precultured cells were seeded in the bottom layer, they 
seemed to have a synergistic effect with TGF-pi on chondrogenic differentiation of the 
cells in top layer, as evidenced by a significant increase in collagen type II gene 
expression at day 28 and in aggrecan gene expression at days 14 to 28 compared to all the 
other groups. Additionally, it should also be noted that samples without TGF-pi loading 
on the top layer but with osteogenic cells in the bottom layer (group BLK(OS) in Figure 
V-5) demonstrated a higher gene expression in the chondrogenic markers than the 
samples with TGF-pi and MSCs at bottom (group TGF(MSC) in Figure V-5). 
Although there was no significant difference in collagen type I gene expression 
among formulations at each time point, the trend over time was different between MSC 
and OS treatments. The samples with MSCs at bottom showed an increase in collagen 
type I gene expression at later time points as compared to day 0, whereas when the 
bottom layer contained osteogenic cells, collagen type I gene expression decreased or 
remained unchanged over time. 
DNA content of the top and bottom layers at each time point is shown in Figure 
V-6 (a) and Figure V-7 (a), respectively. For both layers, the results exhibited a 
decreasing trend over time with significant difference between day 0 and later time points. 
In the top layer, more DNA was seen in samples with OS cells at bottom than those with 
just MSCs at bottom. In particular, DNA content in the top layer of the BLK(OS) group 
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was found to be significantly higher than that for the BLK (MSC) or TGF(MSC) group at 
day 28. Similarly, a higher DNA content was seen in the bottom layer for OS treatment 
groups compared to MSC treatment groups at each time point, either with or without 
TGF-pi. There was significantly more DNA in the bottom layer of BLK(OS) or TGF(OS) 
samples than BLK(MSC) constructs at day 7. No significant difference in DNA content 
of the bottom layer was observed at days 14 and 28 among formulations. 
GAG content, indicative of chondrocytic phenotype, was measured for top layer 
hydrogels and is shown in Figure V-6 (b); GAG content was measured to further 
investigate chondrogenic differentiation of the encapsulated MSCs. For all four 
formulations, significantly higher GAG/DNA levels were observed at later time points 
(days 7, 14 and 28) compared to day 0. Significant differences in GAG/DNA values 
among groups were only found between the BLK(OS) group and both the BLK(MSC) 
and TGF(MSC) groups. However, this could be due to the artifact of higher DNA content 
in the BLK(MSC) group compared to the other two groups at this time point. The results 
of calcium content in top-layer hydrogels are depicted in Figure V-6 (c). All the 
formulations had little calcium deposition (less than 1 ug) in the top layer and the results 
showed no differences among the groups. 
For the bottom layer, ALP enzyme activity and calcium amount were measured to 
evaluate osteogenic differentiation of the cells, as shown in Figure V-7 (b) and (c). There 
was a general trend of increasing ALP activity over time for all the treatments. However, 
no significant differences were observed among the groups at any time point. A 
significant increase in ALP amount compared to day 0 was only observed for MSC 
treatment groups at day 28, likely because OS cells had a higher ALP level at day 0 than 
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MSCs. Compared to the results obtained from the single-layer study [Figure V-2 (b)], the 
ALP values in this study were in a similar range. 
Calcium content measurements indicated a generally low calcium deposition in 
the bottom layer of the bilayered scaffolds. At day 14, cells in BLK(OS) group produced 
2.04 ± 2.74 (j,g calcium, which was a little higher than the other treatments. However, due 
to the large standard deviation, no statistical difference was found among groups or over 
time. 
Discussion 
Guiding both osteogenic and chondrogenic differentiation of MSCs in different 
regions of the same composite scaffold is challenging. We hypothesized that 
osteogenically precultured MSCs can maintain their phenotype in OPF hydrogel 
composites that are subsequently cultured with CM containing P-GP. Additionally, we 
hypothesized that this medium would support chondrogenic differentiation of MSCs 
encapsulated in the hydrogel composites. These hypotheses were first examined with an 
osteogenic construct culture study and a chondrogenic culture study using single-layer 
OPF hydrogel composites. 
Bilayered hydrogel composites consisting of a chondrogenic layer and an 
osteogenic layer were then fabricated and cultured in CM containing (3-GP. We 
specifically investigated: (1) the differentiation of MSCs in both layers of the bilayered 
hydrogel composites; (2) the effect of cells in the osteogenic layer on MSC 
chondrogenesis in the chondrogenic layer; (3) the effect of cells in the osteogenic layer 
combined with TGF-{31-loaded-MPs on MSC chondrogenesis in the chondrogenic layer. 
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Osteogenic Construct Culture Study 
In the osteogenic construct culture study, we developed a protocol for osteogenic 
differentiation, which involved preculture of MSCs in osteogenic medium in a tissue 
culture plate, encapsulation of the MSCs in OPF/MP hydrogel composites and 
subsequent culture of cell constructs in a chondrogenic environment with 
P-glycerophosphate. 
Our results revealed a decrease in DNA content from day 0 to day 7, which was 
consistent with previous studies using the same scaffold for chondrogenic and osteogenic 
differentiation [75, 76]. As previously reported, although the radical initiators were 
biocompatible at the concentration used in the present study, the encapsulation process 
may still result in cell death at early time points; cell number remains the same at later 
time points [75, 76]. Alternatively, the decrease in DNA content could be due to the 
culture in the chemically defined, serum-free, chondrogenic medium. It has been shown 
that the serum-free condition is beneficial for MSC chondrogenic differentiation but not 
for cell proliferation [41]. During the process of chondrogenic differentiation, 
encapsulated MSCs may stop proliferating, resulting in a decrease in cell number. In the 
present study, after switching the cells to chondrogenic medium for 7 days, we found 
more DNA in the constructs with osteogenically precultured cells than in those with just 
MSCs, suggesting a more active role of the osteogenically precultured cells in the 
chondrogenic environment. Additionally, during the preculture in the tissue culture plate 
before encapsulation, we also observed a faster proliferation rate of the cells in the 
osteogenic medium than that of cells in general medium (data not shown). Based on these 
observations, we speculate that, during osteogenic preculture, cells may produce growth 
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factors that support cell survival and enhance proliferation. 
It has been shown that osteogenic differentiation of MSCs includes three periods: 
proliferation, extracellular matrix maturation, and mineralization [49]. ALP is considered 
as an early marker for osteogenic differentiation; it is expressed after cell proliferation 
and is involved in the onset of extracellular matrix mineralization [49]. The significant 
increase in ALP activity at days 7 and 14 compared to day 0 suggested that cells 
continued osteogenic differentiation in the chondrogenic environment, after preculture. 
This could be attributed to the chemical compounds common to both chondrogenic 
medium and osteogenic medium, including dexamethasone and ascorbic acid. However, 
little difference in ALP activity among the groups was observed. In a previous study 
investigating rabbit MSC osteogenic differentiation in osteoblast-conditioned medium, 
the authors found similar levels of ALP produced by cells in a control medium compared 
to cells in conditioned or chemically supplemented medium. They inferred that MSCs 
have a natural predisposition to differentiate into the osteogenic lineage in the absence of 
any growth factors and cytokines [175]. Alternatively, the lack of difference in ALP 
activity among groups could be due to the difficulty in extracting ALP, a cell 
membrane-associated molecule, from hydrogels, as reported in a similar study involving 
rat MSC osteogenic differentiation in OPF hydrogels [76]. 
In contrast to the ALP results, calcium deposition, which is a late marker of 
osteogenic differentiation, was observed to have higher values in OS3+ and OS6+ 
samples than in either OS0+ samples or OS6- samples at day 14. This underscores the 
importance of both osteogenic preculture, and the addition of P-GP to the subsequent 
culture medium, on cell osteogenic differentiation. A previous review on sequential gene 
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expression during osteoblast differentiation indicated that the onset of mineralization is 
associated with many factors besides ALP expression, such as co-expression of 
osteopontin and osteocalcin as well as the maturation of the extracellular matrix (ECM) 
[49]. Without osteogenic preculture, it is possible that the signals in chondrogenic 
medium with added (^-glycerophosphate were not enough for MSCs to undergo 
osteogenic differentiation, or that these conditions led to a delay in matrix mineralization, 
resulting in significantly lower calcium deposition in OS0+ samples compared to OS6+ 
samples. Similarly, the significant difference in calcium amount between OS6+ and OS6-
groups indicates that P-GP could have played an important role in providing further 
signals for maintaining osteoblastic phenotype and enhancing calcium deposition in 
chondrogenic medium. 
Both ALP and calcium results confirmed that the osteoblastic phenotype was 
maintained in a chondrogenic environment with the osteogenic supplement P-GP. This 
protocol provides an exciting new method for using the same culture medium for both 
chondrogenic and osteogenic differentiation of MSCs in different portions of a scaffold 
material. 
Chondrogenic Construct Culture Study 
It has been shown that when MSCs differentiate to chondrocytes, they start to 
express chondrocyte-specific marker genes such as collagen type II and aggrecan, along 
with downregulating the gene expression for collagen type I, which is produced by 
undifferentiated MSCs [137]. RT-PCR results from the chondrogenic construct culture 
study demonstrated general trends of increasing gene expression of collagen type II and 
aggrecan, and decreasing gene expression of collagen type I over time, which confirmed 
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the chondrogenic differentiation of MSCs encapsulated in OPF composites and cultured 
in chondrogenic medium supplemented with P-glycerophosphate in the absence or 
presence of TGF-pi. Additionally, the effect of TGF-pi on MSC chondrogenic 
differentiation was found to be significant, as evidenced by the earlier appearance of a 
marked increase in gene expression of chondrogenic markers, as shown in Figure V-3 
(a-b). 
DNA results showed a trend of decreasing DNA content over time in all studies, 
as reported, for instance, in the chondrogenic construct culture study [Figure V-4 (a)]. 
Significantly lower DNA content was found in the TGF group compared to the BLK 
group at day 7, indicating a possible inhibitory effect of TGF-pi on cell proliferation 
during the early portion of the culture period of the OPF hydrogel composites. Similar 
results were also seen in an osteogenic study by Roostaeian et al., in which the addition 
of TGF-pi resulted in a 44% decrease in cellular growth of rabbit MSCs when compared 
to medium alone [176]. 
GAG production, associated with chondrocytic phenotype of the cultured cells, 
exhibited higher values for both groups at later time points than at day 0, which together 
with gene expression results confirmed chondrogenic differentiation, particularly in the 
presence of TGF-pi [Figure V-4 (b), Figure V-3]. However, GAG production was 
comparatively low and there was no statistical difference between groups; this may be 
because of the tight polymer network surrounding cells, which may have limited the 
deposition of matrix. 
It should be noted that all the cell proliferation, gene expression and matrix 
production data in this study were comparable to those from a previous study where the 
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same formulations were cultured in chondrogenic medium [177]. This study indicated 
that the addition of |3-GP to chondrogenic medium did not significantly affect the 
chondrogenic potential of the medium. 
Little calcium deposition was observed in the present study, where constructs 
were cultured in chondrogenic medium supplemented with P-GP, either in the presence 
or absence of TGF-pi. Although P-GP has been reported to have a stimulatory effect on 
osteogenesis and calcification, its function with respect to mineralization seems to require 
the presence of other signals, such as those present in hypertrophic chondrocytes. Coe et 
al. reported that the addition of 10 mM P-GP to hypertrophic chondrocytes resulted in 
stimulation of type X collagen synthesis and the onset of mineralization. In contrast, the 
addition of P-GP to non-hypertrophic chondrocytes failed to induce expression of type X 
collagen or to induce calcium production [178]. Alternatively, serum could also be an 
important factor that synergizes with p-GP to induce calcification. Calcium deposition 
was noted when MSCs were encapsulated in OPF hydrogels and cultured in osteogenic 
medium, which has similar components to the medium used in the present studies, but 
also has serum [76]. Although an osteogenic supplement, P-GP, was utilized as one of the 
medium components in the present study, the results indicated that the chemically 
defined, serum-free medium seemed to provide a favorable environment for 
chondrogenic differentiation, without eliciting calcium deposition. 
Osteochondral Construct Culture Study 
Combining the results from the osteogenic and chondrogenic construct culture 
studies, we hypothesized that chondrogenic medium with P-GP would support both 
chondrogenic differentiation and osteogenic differentiation of MSCs in OPF/MP 
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composites in vitro. In the osteochondral construct culture study, we fabricated bilayered 
composites consisting of a chondrogenic layer and an osteogenic layer. 
Chondrogenic differentiation of the MSCs in the top (chondrogenic) layer was 
evaluated via gene expression of chondrocytic markers, collagen type II and aggrecan, as 
well as an MSC-associated marker, collagen type I. As expected, the results showed 
upregulation of chondrogenic markers and downregulation of collagen type I during the 
culture period for all the formulations, which further confirmed the chondrogenic 
potential of the culture medium. 
By comparing gene expression data from the MSC and OS treatment groups, it 
was apparent that the addition of osteogenic cells in the bottom layer of the composites 
enhanced the chondrogenic differentiation of the MSCs in the top layer. Samples without 
TGF-pi in the top layer, but with osteogenic cells in the bottom layer [BLK(OS)], 
demonstrated either similar or higher gene expression of chondrogenic markers and a 
lower gene expression of collagen type I, compared to the samples with TGF-(31 loaded 
MPs in the top layer and MSCs in the bottom layer. Thus, it is likely that the osteogenic 
cells in the bottom layer of the BLK(OS) group produced chondro-inductive signals and 
had a positive effect on the differentiation of the cells in the top layer. In fact, studies in 
our laboratory have shown that rat MSCs cultured in osteogenic medium either express 
genes for or secrete many molecules of bioactive factors related to cartilage and bone 
formation, including TGF-pi, fibroblastic growth factor-2 (FGF-2), vascular endothelial 
growth factor (VEGF), bone morphogenetic protein-2 (BMP-2), and insulin-like growth 
factor-1 (IGF-1) [93, 96]. These paracrine signals could have contributed to the 
chondrogenic differentiation of the cells in the top layer. 
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Similarly, bioactive molecules secreted by osteogenic cells in bilayered constructs 
may also explain the synergistic effect of OS cells and TGF-pl on chondrogenic 
differentiation of MSCs in the top layer. Numerous studies have reported that the 
combination of TGF-pi with other growth factors such as IGF-1, FGF-1, or BMP-2, has 
a synergistic effect on MSC chondrogenic differentiation in vitro, probably due to 
regulatory cross-talk between the signaling cascade of each growth factor [43, 44, 115, 
116]. 
In contrast, when MSCs were encapsulated in the bottom layer of the bilayered 
hydrogel, the effect of TGF-pi on cell differentiation in the top layer was not as obvious 
as in the chondrogenic construct culture study. In that single-layer study, where the same 
formulations as the top layers of the osteochondral construct culture study were cultured, 
the TGF group showed significantly higher collagen type II and aggrecan gene 
expression than the MSC group. Since the same amount of TGF-pi was loaded in the 
single-layer and bilayered constructs, the addition of a bottom layer with more MSCs (in 
the bilayered construct) could have resulted in each cell experiencing a lower TGF-pi 
concentration as compared to the conditions in the single-layer hydrogel. A previous 
study has shown that with a lower dosage of TGF-pi, gene expression of collagen type II 
and aggrecan by MSCs declined in OPF/MP composites [75]. 
The incorporation of OS cells in the bottom layer affected not only MSC 
chondrogenic differentiation in the top layer, but also influenced cell number for both the 
top and bottom layers. As shown in Figure V-7 (a), more cells were present in the bottom 
layer of the hydrogels for OS groups than MSC groups at day 7, which was in accordance 
with the results obtained from the osteogenic construct culture study [Figure V-2 (a)]. 
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The results of both studies indicated that after in vitro osteogenic preculture, the cells 
were more resilient than plain MSCs, and were able to survive the crosslinking procedure 
better and differentiate in OPF hydrogels. Additionally, the precultured cells in the 
bottom layer could have produced bioactive molecules that supported cell proliferation in 
the top layer through a paracrine effect, as speculated before. This was evidenced by 
higher DNA content in top layer hydrogels for OS treatment groups than MSC treatment 
groups at each time point [Figure V-6 (a)]. Similar results were also found in a study by 
Nakaoka et al., in which they demonstrated that proliferation and differentiation of 
chondrocytes were enhanced by soluble factors produced from osteoblasts in a co-culture 
system with both direct and indirect contact [130]. 
In fact, when comparing DNA results from the top and bottom layers to their 
corresponding single-layer culture results (chondrogenic and osteogenic construct culture 
studies, respectively), we found the values to be comparable. The results suggested that 
the increase in thickness of bilayered hydrogels did not affect cell growth, which further 
underscored the advantages of an OPF/MP crosslinked network for nutrient transport and 
cell growth. 
GAG production in the top-layer hydrogels also exhibited similar values to those 
obtained in the single-layer study for the same formulations [Figure V-4 (b) and Figure 
V6 (b)]. The increased GAG production compared to day 0 provided additional evidence 
of MSC chondrogenic differentiation. It is also important to see that no calcium was 
deposited in this layer under the influence of the osteogenic cells in the bottom layer 
[Figure V-6 (c)]. 
The continued osteogenic differentiation of the bottom-layer cells was confirmed 
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by the increased amount of ALP over time and the presence of some calcium deposits in 
the constructs [Figure V-7 (b-c)]. Although numerous studies have reported that 
chondrocytes have a positive effect on the osteogenic differentiation of MSCs in 
co-culture systems [50, 179], similar values for ALP secretion and calcium deposition 
were observed in our bilayered study and single-layer study for either MSCs or 
precultured cells (Figure V-2 and V-7), suggesting a limited effect of the top-layer cells 
on the osteogenic differentiation of the bottom-layer cells. Since the MSCs in the top 
layer were undergoing chondrogenic differentiation into chondrocyte-like cells, the 
bioactive factors produced by these cells could be limited in amount and thus explain the 
limited effect of these cells on osteogenic differentiation. Additionally, TGF-pi released 
from MPs in the top layer might have inhibited calcium deposition, explaining the 
difference between the calcium amount in the BLK(OS) group and the TGF(OS) group. 
Previous studies have also reported a similar inhibitory effect of TGF-P on osteogenic 
differentiation of both MSCs and osteoblasts differentiated from MSCs, as evidenced by 
reduced ALP activity and mineral deposition [108]. 
Conclusions 
In the current work, we developed a set of culture conditions, which not only 
promote chondrogenic differentiation of MSCs encapsulated in OPF hydrogel composites, 
but which also maintain the osteoblastic phenotype of precultured MSCs encapsulated in 
the same hydrogel composites. A bilayered osteochondral construct containing a 
chondrogenic layer and an osteogenic layer was fabricated using OPF hydrogel 
composites containing gelatin MPs and MSCs. The culture of the bilayered constructs 
showed that MSCs were able to undergo chondrogenic differentiation in the 
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chondrogenic layer. Although calcium deposition in the osteogenic layer was limited, the 
osteogenic cells in this layer enhanced MSC chondrogenic differentiation in the 
chondrogenic layer. Most importantly, osteogenic cells in the bone layer exhibited a 
synergistic effect with TGF-pi loaded MPs, promoting chondrogenesis in the 
chondrogenic layer, as evidenced by enhanced levels of gene expression for collagen type 
II and aggrecan. The present study demonstrated the fabrication of bilayered 
osteochondral constructs using biodegradable hydrogel composites for the co-delivery of 
growth factors and MSCs for cartilage tissue engineering. 
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Figure V-l: A schematic representation of the overall experimental design. Four groups 
were included in the osteogenic construct culture study, namely OS0+, OS3+, OS6+ and 
OS6- groups. Two groups were included in the chondrogenic construct culture study, 
namely BLK and TGF groups. In the osteochondral construct culture study, four groups 
were included, namely BLK(MSC), TGF(MSC), BLK(OS), and TGF(OS) groups. OS 
cells in this study were precultured with osteogenic medium for 6 days. CM: 
chondrogenic medium; GM: general medium; P-GP: P-glycerophosphate; MPs: gelatin 
microparticles; OM: osteogenic medium; OS: osteogenic; TGF-pi: transforming growth 
factor-pi. 
108 
(a) 
3 r 
21 
a. £ 2 
«j 
w 
< 
Z 
a 1 
3. 
(b) 
Q. 
£ 
o 
£ 
c 
10 
8 
6 
4 
2 
0 
(c) 
16 
a 
E 12 
V) 
03 
O 
8 
J« 
OS0+ OS3+ OS6+ 
D DO QD7 ED14 I 
OS6-
OS0+ OS3+ OS6+ OS6-
• DO0D7 ED14 
OS0+ OS3+ OS6+ ose-
QD7SD14 
Figure V-2: Biochemical assay results for single-layer OPF/MP hydrogel composites 
encapsulating rabbit marrow MSCs (OSO), 3-day osteogenically precultured MSCs (OS3) 
or 6-day osteogenically precultured MSCs (OS6); all composites were cultured in 
chondrogenic medium supplemented with (+) or without (-) p-glycerophosphate. DNA 
content (a), ALP enzyme activity (b), and calcium content (c) of the samples are 
presented. Within a given group, a significant difference (p<0.05) compared to day 0 
value (day 7 value for calcium assay) is noted with (*). Samples indicated with (#) had a 
significant difference from the other groups at the same time point (p<0.05). Error bars 
represent means ± standard deviation for n = 4. 
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Figure V-3: Quantitative gene expression of collagen type II (a), aggrecan (b), and 
collagen type I (c) for single-layer hydrogel composites encapsulating rabbit marrow 
MSCs and blank MPs (BLK) or rabbit marrow MSCs and TGF-01 -loaded MPs (TGF). 
Data are presented as a fold ratio after being normalized to GAPDH expression. The 
expression level of controls (Day 0, BLK group) is represented as one. Within a given 
group, a significant difference in gene expression (p<0.05) compared to day 0 value 
(control) is noted with (*). Samples indicated with (#) had a significantly higher gene 
expression than the other groups at the same time point (p<0.05). Error bars represent 
means ± standard deviation for n = 4. 
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Figure V-4: Biochemical assay results for single-layer OPF hydrogel composites 
encapsulating rabbit marrow MSCs and blank MPs (BLK) or rabbit marrow MSCs and 
TGF-pl-loaded MPs (TGF). DNA content (a), GAG content normalized to ug DNA (b), 
and calcium content (c) of the samples are presented. Within a given group, a significant 
difference (p<0.05) compared to day 0 value is noted with (*). Samples indicated with (#) 
had a significant difference from the other groups at the same time point (p<0.05). Error 
bars represent means ± standard deviation for n = 4. The BLK and TGF groups shared 
samples at day 0. 
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Figure V-5: Quantitative gene expression of collagen type II (a), aggrecan (b), and 
collagen type I (c) for the top layer of the bilayered OPF hydrogel composites. The top 
layer of each composite contained encapsulated rabbit marrow MSCs and blank MPs 
(BLK) or rabbit marrow MSCs and TGF-pl-loaded MPs (TGF), which were co-cultured 
with a bottom layer consisting of an OPF hydrogel/blank MPs composite encapsulating 
MSCs (MSC) or osteogenic cells (OS). Data are presented as a fold ratio after being 
normalized to GAPDH values. The expression level of controls [Day 0, BLK(MSC) 
group] is represented as one. Within a given group, a significant difference in gene 
expression (/?<0.05) compared to day 0 value (control) is noted with (*). Samples 
indicated with (#) had a significantly higher gene expression than the other groups at the 
same time point (/?<0.05). Error bars represent means ± standard deviation for n = 4. 
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Figure V-6: Biochemical assay results for top layer of the bilayered hydrogels. The top 
layer of each composite contained encapsulated rabbit marrow MSCs and blank MPs 
(BLK) or rabbit marrow MSCs and TGF-J31 -loaded MPs (TGF), which were co-cultured 
with a bottom layer consisting of an OPF hydrogel/blank MPs composite encapsulating 
MSCs (MSC) or osteogenic cells (OS). DNA content (a), GAG content normalized to ug 
DNA (b) and calcium content (c) of the samples are presented. Within a given group, a 
significant difference (p<0.05) compared to the day 0 value is noted with (*). Samples 
indicated with (#) had a significant difference from the other groups at the same time 
point (p<0.05). Error bars represent means ± standard deviation for n = 4. At day 0, the 
BLK(MSC) and BLK(OS) groups shared top-layer samples for all biochemical assays; 
and similarly the TGF(MSC) and TGF(OS) groups shared samples. 
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Figure V-7: Biochemical results for bottom layer of the bilayered hydrogels. The bottom 
layer of each composite consisted of an OPF hydrogel/blank MPs composite 
encapsulating MSCs (MSC) or osteogenic cells (OS); these were co-cultured with a top 
layer containing encapsulated rabbit marrow MSCs and blank MPs (BLK) or rabbit 
marrow MSCs and TGF-pl-loaded MPs (TGF). DNA content (a), ALP enzyme activity 
(b) and calcium content (c) of the samples are presented. Within a given group, a 
significant difference (p<0.05) compared to the day 0 value is noted with (*). Samples 
indicated with (#) had a significant difference from the other groups at the same time 
point (p<0.05). Error bars represent means ± standard deviation for n = 4. At day 0, the 
BLK(MSC) and TGF(MSC) groups shared bottom-layer samples for all biochemical 
assays; and similarly the BLK(OS) and TGF(OS) groups shared samples. 
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CHAPTER VI: THE EFFECTS OF TRANSFORMING GROWTH FACTOR-B3 AND 
PRECULTURE PERIOD OF OSTEOGENIC CELLS ON THE CHONDROGENIC 
DIFFERENTIATION OF RABBIT MARROW MESENCHYMAL STEM CELLS ENCAPSULATED 
IN A BLLAYERED HYDROGEL COMPOSITE F 
Abstract 
In this work, injectable, biodegradable hydrogel composites of crosslinked 
oligo(poly(ethylene glycol) fumarate) (OPF) and gelatin microparticles (MPs) were 
utilized to fabricate a bilayered osteochondral construct. Rabbit marrow mesenchymal 
stem cells (MSCs) were encapsulated with transforming growth factor-p3 
(TGF~p3)-loaded MPs in the chondrogenic layer and cocultured with cells of different 
periods of osteogenic preculture (0, 3, 6 and 12 days) in the osteogenic layer to 
investigate the effects of TGF-|33 delivery and coculture on the proliferation and 
differentiation of cells in both layers. The results showed that, in the chondrogenic layer, 
TGF-|33 significantly stimulated chondrogenic differentiation of MSCs. Additionally, 
cells of various osteogenic preculture periods in the osteogenic layer, along with TGF-P3, 
enhanced gene expression for MSC chondrogenic markers to different extents. In the 
osteogenic layer, cells maintained their alkaline phosphatase activity during the coculture; 
however, mineralization was delayed by the presence of TGF-P3. Overall, this study 
demonstrated the fabrication of bilayered hydrogel composites that mimic the structure 
and function of osteochondral tissue, along with the application of these composites as 
cell and growth factor carriers, while illustrating that encapsulated cells of different 
f
 This chapter was submitted to Acta Biomaterialia as: Guo X, Liao J, Park H, Saraf A, Raphael RM, 
Tabata Y, Kasper FK, Mikos AG. The effects of TGF-P3 and preculture period of osteogenic cells on the 
chondrogenic differentiation of rabbit marrow mesenchymal stem cells encapsulated in a bilayered 
hydrogel composite. 
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degrees of osteogenic differentiation can significantly influence the chondrogenic 
differentiation of cocultured progenitor cells in both the presence and absence of 
chondrogenic growth factors. 
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Introduction 
Articular cartilage is an avascular tissue with limited ability to self-repair once 
injured. Injured articular cartilage can lead to degeneration of subchondral bone, resulting 
in severe pain and loss of mobility of the affected joint [1, 2], Therefore, for long-term 
repair of articular cartilage, it is necessary to develop a construct consisting of both 
articular cartilage and subchondral bone to mimic the structure and fulfill the functions of 
native osteochondral tissue [3, 26, 82]. 
Mesenchymal stem cells (MSCs) are progenitor cells that reside in many tissues, 
including bone marrow [39, 136]. MSCs can be easily isolated and expanded without 
losing their ability to differentiate into different connective tissue cell types, such as 
chondrocytes and osteoblasts. Therefore, for the generation of an osteochondral construct, 
MSCs are an ideal candidate cell population, which circumvents the need for invasive 
isolation of chondrocytes and osteoblasts from limited sources [26]. However, 
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investigation of the chondrogenic and osteogenic differentiation of MSCs, especially in a 
coculture environment, stands as a fundamental aspect of the development of a cellular 
construct for osteochondral tissue repair. 
A three-dimensional network is known to be important for MSC proliferation and 
differentiation, since it mimics the in vivo environment [67]. Among the numerous 
scaffold materials available for tissue engineering approaches for osteochondral repair, 
hydrogels possess the key ability to allow for ample intake of nutrients and removal of 
wastes to support the viability of encapsulated cells [55, 141]. Recently, a biodegradable 
and injectable oligomer, oligo(poly(ethylene glycol) fumarate) (OPF), has been 
developed in our laboratory [73]. The double bonds in the OPF backbone allow it to 
crosslink to form a hydrogel network under physiological conditions; and the crosslinked 
material may degrade via ester hydrolysis. Additionally, gelatin microparticles (MPs) 
have been incorporated in OPF hydrogels as a digestable porogen and a drug delivery 
vehicle [70, 81]. The resulting hydrogel composites containing growth-factor-loaded MPs 
have been shown to support both chondrogenic and osteogenic differentiation of 
encapsulated MSCs [75, 76, 177]. 
In addition to a three-dimensional scaffold, chemical supplements and growth 
factors are also found to be crucial for guiding cell differentiation in vitro [41, 50]. 
Osteogenic differentiation of MSCs in vitro usually occurs with osteogenic supplements 
in a culture medium, including dexamethasone, ascorbic acid, and [3-glycerophosphate 
[50]; whereas chondrogenic differentiation requires not only a chemically-defined, 
serum-free medium but also the presence of chondrogenic growth factors, especially 
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members of the transforming growth factor-|3 (TGF-P) family [41], such as TGF-Ps and 
bone morphogenetic proteins (BMPs). 
Another strategy to enhance chondrogenesis is via coculture. Several studies have 
investigated the coculture of chondrocytes and osteoblasts in vitro, and they found that 
the proliferation and differentiation of chondrocytes were regulated by cell-cell contact 
and by soluble factors secreted by the osteoblasts [130, 131]. Similarly, the coculture of 
MSCs or embryonic stem cells (ES) with other cells types, such as chondrocytes and 
hepatic cells, also demonstrated enhanced levels of chondrogenic differentiation of the 
MSCs [39, 134]. Recently, a bilayered hydrogel coculture system has been developed in 
our laboratory for osteochondral tissue engineering applications [180]. The study found 
that TGF-P 1-loaded MPs in the chondrogenic layer of the hydrogel composites and 
MSC-derived osteogenic cells in the osteogenic layer synergistically enhanced MSC 
chondrogenesis in the chondrogenic layer. 
In the present work, we fabricated bilayered OPF hydrogel composites 
encapsulating MPs and MSCs in each layer; and we specifically asked the questions: (1) 
whether MSCs can undergo chondrogenic and osteogenic differentiation in the respective 
layers of a bilayered hydrogel composite; (2) whether TGF-P3-loaded MPs affect MSC 
chondrogenic differentiation in the chondrogenic layer; (3) whether TGF-P3-loaded MPs 
and cells of different periods of osteogenic preculture encapsulated in the osteogenic 
layer have a combined effect on MSC chondrogenic differentiation in the chondrogenic 
layer. 
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Materials and Methods 
Experimental Design 
In this study, bilayered hydrogel composites consisting of a chondrogenic layer at 
top and an osteogenic layer at bottom were fabricated, as shown in Figure VI-1. More 
specifically, in the top layer, MSCs were encapsulated in OPF hydrogels with either 
blank MPs (noted with -) or TGF-P3-loaded MPs (noted with +), while in the bottom 
layer, OPF hydrogel composites with blank MPs were utilized to encapsulate MSCs, 
3-day osteogenically precultured cells (OS3 cells), 6-day osteogenically precultured cells 
(OS6 cells), or 12-day osteogenically precultured cells (OS 12 cells). Eight formulations 
of bilayered constructs (groups OS0±, OS3±, OS6±, and OS12± in Figure VI-1) were 
cultured in chondrogenic medium (CM) supplemented with 10 mM P-glycerophosphate 
for 28 days. Samples from the top and bottom layers were analyzed to evaluate 
chondrogenic and osteogenic differentiation of the cells, respectively. Similar hydrogel 
composites containing TGF-pi-loaded MPs in the top layer were also fabricated for 
comparison (data shown in Appendix). 
OPF Synthesis and Characterization 
OPF was synthesized from fumaryl chloride and poly(ethylene glycol) (PEG) 
with a nominal molecular weight of 10,000 g/mol (Sigma, St. Louis, MO) according to a 
previously established method [73], and sterilized prior to use by exposure to ethylene 
oxide. 
Gelatin Microparticle Fabrication and Growth Factor Loading 
Gelatin microparticles were fabricated from acidic gelatin (Nitta Gelatin Inc., 
Osaka, Japan) and crosslinked with 10 mM glutaraldehyde (Sigma, St. Louis, MO) 
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following established procedures [74]. After drying, MPs were sieved to obtain particles 
of 50-100 /am in diameter and sterilized with ethylene oxide. 
Before encapsulation, sterile MPs were loaded with TGF-J33 (R&D Systems, 
Minneapolis, MN) by swelling in an aqueous solution of the growth factor at pH 7.4 for 
15 h according to a previously reported method [79]. The volume of TGF-P3 loading 
solution needed for equilibrium swelling of the MPs (110 ul) was combined with 22 mg 
of MPs. The loading solution had a concentration of 3.6 |ug TGF-f33/ml phosphate 
buffered saline (PBS; Gibco) to achieve a final loading of 600 ng TGF-|33/ml in the 
crosslinked scaffolds. This growth factor amount has been shown to promote the 
chondrogenic differentiation of rabbit MSCs encapsulated in hydrogel composites in vitro 
[75]. TGF-pi-loaded MPs were prepared in a similar fashion using a solution of the same 
growth factor concentration. Blank MPs were loaded with PBS alone. 
Rabbit Marrow MSC Isolation and Preculture 
Rabbit marrow MSCs were isolated from the tibiae of six 4-month-old New 
Zealand white rabbits as previously described [75]. The bone marrow was cultured in 
general medium (GM) containing Dulbecco's modified Eagle's medium (DMEM), 10% 
v/v fetal bovine serum (FBS; Gemini, Calabasas, CA), 250 jj.g/1 fungizone, 100 mg/1 
ampicillin, and 50 mg/1 gentamicin for 2 weeks, and then cryopreserved as described 
previously [180]. For MSC expansion, the cryopreserved cells were thawed at 37°C and 
cultured in T-75 flasks with GM up to passage three (12 days), as shown in Figure VI-1. 
Osteogenic cells were cultured from the same batch of cryopreserved MSCs for 12 days, 
as shown in Figure VI-1, with both GM and osteogenic medium (OM), which was 
DMEM supplemented with 10% v/v FBS, 50 mg/1 ascorbic acid, 10 mM 
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P-glycerophosphate, 10~8 M dexamethasone, 250 (j.g/1 fungizone, 100 mg/1 ampicillin, and 
50 mg/1 gentamicin (all from Sigma). Specifically, osteogenic cells for the bottom layer 
of OS3±, OS6± and OS12± groups were exposed to OM for 3, 6 and 12 days 
immediately prior to encapsulation, respectively. 
Fabrication of Bilayered Hydrogel Composites 
Bilayered hydrogel composites were fabricated via a two-step crosslinking 
procedure as described previously [180]. The desired composition for the osteogenic 
(bottom) layer was first prepared. Specifically, 0.1 g of sterile OPF and 0.05 g of sterile 
poly(ethylene glycol) diacrylate (PEG-DA; 4,000 Da nominal molecular weight, 
Monomer-Polymer & Dajac Labs, Feasterville, PA) were first dissolved in 300 ul of PBS 
and mixed with 110 ul of swelled MP solution (blank MPs). The mixture was then added 
to equal volumes (46.8 ul) of the thermal radical initiator solutions, 0.3 M ammonium 
persulfate (APS) and 0.3 M N,N,N\NMetramethylethylenediamine (TEMED) in PBS. A 
proper cell suspension (6.7 million cells in 168 ul of PBS) was subsequently added to the 
polymer solution to achieve a concentration of 10 million cells/ml final suspension. After 
gentle mixing, the suspension for the osteogenic layer was quickly injected into the 
bottom 1 mm of Teflon molds (6 mm diameter, 2 mm thickness) and incubated for 4 min, 
allowing for partial crosslinking. Meanwhile, another polymer-cell suspension was 
prepared, and then injected into the partially filled Teflon molds to form the 
chondrogenie layer. The resulting bilayered constructs were then incubated at 37°C for 8 
min to achieve crosslinking. 
Each hydrogel construct was then cultured with 2.5 ml chondrogenic medium, 
which was DMEM supplemented with ITS+ Premix (6.25 ug/ml insulin, 6.25 ug/ml 
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transferrin, 6.25 |j,g/ml selenous acid, 5.35 i^g/ml linoleic acid and 1.25 (^ g/ml bovine 
serum albumin) (BD Biosciences, Franklin Lakes, NJ), 1 mM sodium pyruvate (Sigma), 
50 mg/1 ascorbic acid, 10" M dexamethasone, 10 mM P-glycerophosphate, 250 mg/1 
fungizone, 100 mg/1 ampicillin and 50 mg/1 gentamicin. The medium was changed every 
3 days during a 28-day culture period. 
At various time points (days 0, 7, 14, and 28), samples were collected for 
quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) (n=4), 
biochemical assays (n=4), live/dead assay (n=l) and histological analysis (n=l). 
Bilayered samples for RT-PCR and biochemical assays were dissected with a blade to 
separate the chondrogenic layer and osteogenic layer [180]; samples from each layer 
were stored for analysis. Samples loaded with TGF-(31 were analyzed only for RT-PCR 
(n=4)atday28. 
Real-time RT-PCR 
Samples from the chondrogenic layer of the osteochondral constructs were 
subjected to RT-PCR analysis to quantify MSC chondrogenic differentiation as described 
previously [75]. Gene expression for collagen type II, aggrecan and collagen type I was 
determined, and data were analyzed using the 2"AACt method as reported previously [137, 
147]. All gene expression data were normalized to the expression of a house-keeping 
gene, glyceraldehyde-3-phosphatase dehydrogenase (GAPDH) and expressed as the fold 
ratio compared to baseline gene expression of a control group at day 0. In this study, the 
control group contained four top-layer hydrogels encapsulating MSCs that were collected 
immediately after encapsulation. 
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Biochemical Assays 
Samples from the osteogenic layer of the osteochondral constructs were analyzed 
for DNA, alkaline phosphatase (ALP) enzyme activity, and calcium content using 
microplate readers (BIO-TEK Instrument, Winooski, VT) to characterize osteogenic 
differentiation of the cells as described previously [180]. Bottom-layer samples 
containing MSCs, 3-day, 6-day and 12-day osteogenically precultured cells (n=4) were 
collected after encapsulation to represent day 0 values for the OS0±, OS3±, OS6± and 
OS12± groups respectively. 
Similarly, samples from the chondrogenic layer of the constructs were digested in 
a proteinase K solution and subjected to DNA, glycosaminoglycan (GAG), and calcium 
assays to evaluate chondrogenic differentiation as previously described [146, 180]. Four 
samples from top layer hydrogels containing MSCs and blank MPs were collected 
immediately after encapsulation and analyzed to represent day 0 values for all the groups. 
Confocal Fluorescence Microscopy 
A live/dead assay was performed at days 0 and 28 after encapsulation as reported 
previously [114]. After rinsing with PBS, each layer of the construct was then placed in 
dye solutions containing 4 uM ethidium homodimer-1 (EthD-1) and 2 uM calcein 
acetoxymethyl ester (Calcein AM) (Invitrogen) for 30 min. Cells encapsulated in the 
hydrogel composites were examined by confocal fluorescence microscopy (Zeiss LSM 
510, Thornwood, NY). Using argon laser excitation at 488 nm, the cells were imaged 
under a lOx objective, and the emitted light was collected using 505-526 nm and 612-644 
nm filters. 
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Histology 
At the various time points, bilayered hydrogel composites were fixed, dehydrated, 
and embedded in paraffin. Cross sections of 20 urn were prepared for Von Kossa staining 
using a method reported previously [76]. Briefly, the sections were exposed to 5% silver 
nitrate solution, exposed to UV light for 30 minutes to visualize calcium deposition, and 
counterstained with 0.1% Safranin O solution. 
Statistical Analysis 
DNA, GAG, calcium contents, ALP activity and gene expression data of the eight 
treatments (in Figure VI-1) at different time points are reported as means ± standard 
deviation. Repetitive ANOVA and Tukey's multiple comparison tests were used to 
determine possible significant differences (p < 0.05) between groups. Additionally, gene 
expression data of hydrogels containing TGF-(33- and TGF-pi-loaded MPs at day 28 
were compared similarly with repetitive ANOVA and Tukey's multiple comparison tests 
(p < 0.05). Statistical significance symbols for Figure VI-2, 3 and 4 are defined in Table 
VI-1. 
Results 
Cellularity in Both Chondrogenic and Osteogenic Layers 
DNA contents of the chondrogenic and osteogenic layers of the hydrogel 
composites are depicted in Figure VI-2 (A) and Figure VI-3 (A), respectively. For both 
layers of all the treatments, the DNA amount decreased from day 0 to day 7. 
In the osteogenic layer [Figure VI-3 (A)], samples containing osteogenically 
precultured cells (the OS3±, OS6±, and OS12± groups) generally showed higher DNA 
values compared to those containing plain MSCs (the OS0± groups), either in the 
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presence or absence of TGF-P3. Specifically, with blank MPs in the chondrogenic layer, 
a significantly higher DNA value was observed in the osteogenic layer of the hydrogels 
containing 6-day osteogenically precultured cells (the OS6- group) than in those 
encapsulating MSCs (the OS0- group) at day 28. Similarly, with TGF-P3-loaded MPs in 
the chondrogenic layer, significantly more DNA was found in the osteogenic layer of 
samples of the OS3+ and OS6+ groups than in those of the OS0+ group at day 28. 
As in the osteogenic layer, TGF-|33 did not show an effect on cell number in the 
chondrogenic layer [Figure VI-2 (A)]. However, cells in the osteogenic layer 
significantly influenced DNA content in the chondrogenic layer of the hydrogels. For 
example, MSCs in the chondrogenic layer that were cocultured with 3-day osteogenically 
precultured cells (the OS3± groups) demonstrated a significantly higher DNA amount 
than those cocultured with MSCs (the OS0± groups) at day 28, either with or without 
TGF-P3-loaded MPs. MSCs that were cocultured with 6-day osteogenically precultured 
cells (the OS6± groups) exhibited the highest DNA content compared to all the other 
groups (the OS0±, OS3±, and OS12± groups) during the culture with or without TGF-(33. 
However, the coculture with 12-day osteogenically precultured cells (the OS12± groups) 
did not result in a significant increase in DNA content in the chondrogenic layer when 
compared to the OS0± groups. 
Chondrogenic Differentiation of MSCs in the Chondrogenic Layer 
The chondrogenic differentiation of MSCs in the chondrogenic layer of the 
bilayered hydrogels was determined via gene expression of two chondrogenic markers, 
collagen type II and aggrecan, as well as the gene expression of an MSC-associated 
marker, collagen type I. Gene expression data are shown in Figure VI-4 (A-C). 
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For all the treatments, collagen type II gene expression was upregulated over time 
[Figure VI-4 (A)]. The presence of TGF-P3-loaded MPs enhanced collagen type II gene 
expression of MSCs encapsulated in the chondrogenic layer. At day 28, significantly 
higher levels of gene expression were observed in the groups with TGF-J33 (the OS0+, 
OS3+, OS6+ and OS 12+ groups) than in the corresponding groups without TGF-|33 (the 
OS0-, OS3-, OS6- and OS 12- groups, respectively). Additionally, 12-day 
osteogenically precultured cells had a combined effect with TGF-P3 (the OS 12+ group), 
resulting in the highest level of collagen type II gene expression among all the treatments 
at day 28. In similar hydrogel composites, where the same amount of TGF-(31 was loaded 
in the chondrogenic layer, a combined effect of osteogenic cells and the growth factor 
was also observed. Collagen type II gene expression of MSCs exposed to TGF-pi 
increased with the duration of osteogenic preculture of the cocultured osteogenic cells. 
However, with plain MSCs in the osteogenic layer, TGF-pi alone only resulted in a 357 
±211 fold increase in collagen type II gene expression at day 28, which was significantly 
lower than a 927 ±148 fold increase caused by TGF-P3 alone. 
Aggrecan gene expression levels also increased over time for all the treatments 
[Figure VI-4 (B)]. For the groups that were cultured with either osteogenic cells alone 
(the OS3-, OS6- groups) or with TGF-P3 alone (the OS0+ group), significant increases 
compared to a day 0 baseline were observed no earlier than day 28. However, when 
MSCs were cultured with both osteogenic cells and TGF-P3, significant increases relative 
to the day 0 baseline were observed as early as day 7 or 14 (day 14 for the OS3+ group, 
day 7 for the OS6+ group, and day 14 for the OS12+ group). Cells of 3-day and 6-day 
osteogenic preculture durations (the OS3± and OS6± groups) seemed to result in more 
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overall aggrecan gene expression of the MSCs in the chondrogenic layer than plain 
MSCs (the OS0± groups) or 12-day osteogenically precultured cells (the OS12± groups), 
with either TGF-P3-loaded or blank MPs in the top layer. 
Collagen type I gene expression was found to decrease significantly at day 28 
relative to day 0, when MSCs in the chondrogenic layer were cultured with either 
TGF-P3, or with osteogenic cells, or with both. It should be noted that samples treated 
with TGF-pi alone exhibited a significantly higher collagen type I gene expression than 
those treated with TGF-J33 alone. 
GAG content, indicative of the chondrogenic phenotype, was measured for the 
chondrogenic layer of the bilayered hydrogels to further investigate chondrogenic 
differentiation of the encapsulated MSCs, as shown in Figure VI-2 (B). For all the 
formulations, significantly higher GAG/DNA levels were observed at days 14 and 28 
compared to day 0. At day 28, significant differences in GAG/DNA values among groups 
were found between the OS0- group and the OS6- group; as well as between the OS0+ 
group and the OS3+, OS6+ and OS 12+ groups. 
Calcium deposition was determined for the chondrogenic layer of the hydrogels to 
ensure that no bone upgrowth to the chondrogenic layer occurred with the combined 
effects of TGF-P3 and P-glycerophosphate in the coculture medium. As illustrated in 
Figure VI-2 (C), all the formulations had a calcium content of less than 1.1 ug during the 
culture. No statistically significant difference was observed over time or among groups. 
Osteogenic Differentiation of Cells in the Osteogenic Layer 
ALP enzyme activity and calcium content were measured for the osteogenic layer 
of the hydrogels to evaluate the osteogenic differentiation of the encapsulated cells. ALP 
127 
results over time are shown in Figure VI-3 (B). Immediately after encapsulation, ALP 
activity of cells in the osteogenic layer of the hydrogels was found to be higher in 
samples containing cells of a longer osteogenic preculture period (not significantly). 
During the subsequent hydrogel culture, ALP values of the osteogenic cells (the OS3±, 
OS6± and OS12± groups) slightly increased or remained unchanged, either with or 
without TGF-P3 in the top layer. In contrast, the OS0± groups containing MSCs in the 
osteogenic layer both exhibited significant increases in ALP activity at later time points 
compared to day 0. In particular, in the OS0- group, ALP activity of the cells 
significantly increased from day 0 to day 7, and then significantly decreased by day 28 
relative to day 7. The OS0+ group had a significantly higher ALP activity at days 7, 14 
and 28 compared to day 0, with a peak at day 14. Additionally, the ALP values of the 
OS0+ group were found to be significantly higher than those of all the other treatments at 
days 7, 14 and 28. 
Calcium deposition in the osteogenic layer of the hydrogels for all the treatments 
is shown in Figure VI-3 (C). Although statistical analysis did not reveal any significant 
differences among the groups at each time point, significant increases in calcium 
deposition compared to day 0 values were found in some groups containing 
osteogenically preculrured cells, for example, in the OS3- group at days 14 and 28, in the 
OS 12- group at days 7, 14 and 28, and in the OS 12+ group at days 7 and 14. 
Confocal Fluorescence Microscopy 
Confocal fluorescence microscopy images of cells encapsulated in both layers of 
the hydrogels at day 0 and day 28 are presented in Figure VI-5. The cells were stained 
with a live/dead assay kit, where calcein AM stained the live cells with a green 
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fluorescence and ethidium homodimer-1 (EthD-1) stained dead cells with a red 
fluorescence. Immediately after encapsulation, most of the cells encapsulated in each 
layer were alive, and they were well distributed within the hydrogel composites [Figure 
VI-5 (A)]. After 28 days of culture, cells in each layer of the hydrogel composites 
retained their viability in all the treatments [Figure VI-5 (B-C)]. However, cells from 
different groups showed a different distribution in the top (chondrogenic) layer of the 
hydrogels. As shown in Figure VI-5 (B), cells of the OS0- group were sparsely 
distributed in the top layer; whereas in the groups treated with TGF-P3, more cell 
aggregation was observed in the top layer of the hydrogels [noted with small arrows in 
Figure VI-5 (C)]. No difference in cell distribution was observed for cells encapsulated in 
the bottom (osteogenic) layer of the hydrogels [Figure VI-5 (B-C)]. 
Light Microscopy and Histology 
A light microscopy image of a cross section of a bilayered hydrogel composite 
containing MSCs and MPs in both layers immediately after encapsulation is shown in 
Figure VI-6 (B). In the sample, cells (shown as small dots) and MPs (noted with a big 
arrow) were well distributed. No apparent border can be recognized between the layers, 
indicative of a good integration between layers. 
Figure VI-6 (A, C-J) depicts histological cross sections of the hydrogel 
composites after 0 and 28 days of culture. The sections were prepared with Von Kossa 
staining and counter stained with Safranin O, which collectively stain mineralized matrix 
with a black color and GAG, a cartilaginous matrix component, with a red color. MPs 
(noted with big arrows) and cells (aggregation noted with small arrows) in the samples 
appear in dark red in the images. Similar to the results from confocal fluorescence images 
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[Figure VI-5 (A)] and the light microscopy image [Figure VI-6 (B)], MPs and cells were 
found to distribute evenly in both layers of the hydrogel composites after encapsulation 
[Figure VI-6 (A)]. At day 28, most of the MPs were degraded, while cells maintained 
their rounded phenotype. There was a trend of increasing cell aggregation [noted with 
small arrows in Figure VI-6 (D, F, H)] in the TGF-P3-treated groups, especially with 
osteogenic cells cocultured in the bottom (osteogenic) layer of the hydrogels. Although 
no significant difference was observed for GAG staining among the samples, a more 
intense staining for mineralized matrix was noticed in the blank MP treatments [Figure 
VI-6 (C, E, G, I)] than in the TGF-p3-loaded MP treatments [Figure VI-6 (D, F, H, J)] at 
day 28. The hydrogel composites also seemed to have more calcium deposition in the 
center than in the top or bottom surfaces [Figure VI-6 (E, G, I)]. 
Discussion 
In the current work, bilayered composites consisting of a chondrogenic layer and 
an osteogenic layer were fabricated using OPF hydrogel networks containing gelatin MPs 
and MSCs. Specifically, we investigated: (1) the proliferation and differentiation of cells 
in both layers of the bilayered hydrogel composites; (2) the effect of TGF-P3-loaded MPs 
on the chondrogenic differentiation of MSCs in the chondrogenic layer; and (3) the 
combined effects of the duration of the osteogenic preculture of the cells in the 
osteogenic layer and TGF~p3-loaded MPs on MSC chondrogenesis in the chondrogenic 
layer. 
Previously, our laboratory has fabricated a similar bilayered OPF construct 
containing TGF-pi-loaded MPs and MSCs in the chondrogenic layer, and containing 
6-day osteogenically precultured cells in the osteogenic layer. The culture of the 
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bilayered construct showed that TGF-pi-loaded MPs in the chondrogenic layer and 
osteogenic cells in the osteogenic layer synergistically promoted chondrogenesis of 
MSCs encapsulated in the chondrogenic layer [180]. 
TGF-P3 was chosen for the current study because a previous study has shown that 
TGF-p3 was more effective than TGF-pi in terms of promoting the chondrogenesis of 
human MSCs in pellet culture, which was evidenced by an earlier and greater deposition 
of GAG and type II collagen [103]. Additionally, TGF-P3 was also reported to have a 
biphasic stimulatory effect on DNA synthesis of osteoblasts, and to inhibit osteogenic 
differentiation of MSCs or MSC-derived osteoblasts [104, 108]. 
In vitro osteogenic culture period of MSCs has been shown to significantly affect 
their osteogenic gene expression and extracellular matrix production levels [49, 51], and 
even to influence their osteogenic potential when implanted in vivo [51-53]. Based on 
these findings, we hypothesized that cells of different durations of osteogenic preculture 
can provide different signaling to the cocultured MSCs in a bilayered OPF hydrogel 
composite. Therefore, this study investigated how the osteogenic preculture duration of 
cells in the osteogenic layer in combination with TGF-p3-loaded MPs in the 
chondrogenic layer would affect cell proliferation and differentiation in both layers of a 
bilayered hydrogel composite. 
Cellularity in Both Chondrogenic and Osteogenic Layers 
DNA content of both the chondrogenic layer and the osteogenic layer was 
examined at different time points, as shown in Figure VI-2 (A) and Figure VI-3 (A), 
respectively. In both layers, there was a significant decrease in DNA content from day 0 
to day 7 for all the treatments. Previous studies using a similar single-layer hydrogel 
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composite for MSC chondrogenic and osteogenic differentiation have indicated that the 
encapsulation process may lead to some cell loss, especially at early time points [75, 76]. 
However, images of the live/dead assay in Figure VI-5 demonstrated that the majority of 
cells in both layers were alive after encapsulation [Figure VI-5 (A)] and that they 
maintained their viability during the subsequent culture [Figure VI-5 (B-C)], 
demonstrating the cytocompatibility of the macromer, crosslinker and initiators under the 
conditions explored in this study. 
Statistical analysis revealed that TGF-J33 did not influence the cellularity of either 
layer. However, the cells encapsulated in the osteogenic layer significantly affected the 
DNA content of both layers. In particular, more DNA was seen in both layers in the 
treatments with osteogenically precultured cells (the OS3±, OS6±, and OS12± groups) 
than the treatments with plain MSCs (the OS0± groups). This was in accordance with our 
previous findings that osteogenic cells (6-days of osteogenic preculture) were more 
resilient than plain MSCs when encapsulated in the osteogenic layer of an OPF hydrogel 
composite and that they supported the proliferation of the cells in the chondrogenic layer, 
possibly through a paracrine effect [180]. Furthermore, in this study, we found that 
osteogenic cells of various osteogenic preculture periods in the osteogenic layer 
supported the proliferation of MSCs in the chondrogenic layer to different extents. As 
shown in Figure VI-2 (A), MSCs in the chondrogenic layer that were cocultured with 
3-day osteogenically precultured cells (the OS3± groups) demonstrated a significantly 
higher DNA content compared to those cultured with plain MSCs (the OS0± groups) in 
the osteogenic layer at day 28; while MSCs that were cocultured with 6-day 
osteogenically precultured cells (the OS6+ groups) demonstrated the highest levels of 
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DNA, which were significantly higher than all the other treatments (the OS0+, OS3+ and 
OS 12+ groups) at days 14 and 28 in the presence of TGF-P3. In contrast to the OS3± and 
OS6± groups, MSCs cocultured with 12-day osteogenically precultured cells (the OS12± 
groups) did not show a significant increase in DNA content compared to the control 
groups (OS0±) at any time point. 
The difference in the ability of osteogenic cells to promote the proliferation of the 
cocultured MSCs may be related to their osteogenic differentiation levels. It is know that 
during the three stages of osteogenic differentiation (proliferation, matrix maturation, and 
mineralization), there is a reciprocal relationship between cell proliferation and the 
subsequent matrix maturation and mineralization [49, 51]. In this study, 3-day and 6-day 
osteogenically precultured cells can be considered as immature osteoblasts, which 
possess a great ability to proliferate. A previous review on osteogenic differentiation of 
osteoblasts indicated that immature osteoblasts actively express cell-cycle and 
cell-growth- regulated genes, which encode proteins that support proliferation [49], 
whereas 12-day osteogenically precultured cells represented more extensively 
differentiated osteoblasts, which express genes or extracellular matrix proteins associated 
with extracellular matrix maturation or mineralization and downregulate genes for 
proliferation [49]. Compared to 12-day osteogenically precultured cells, 3-day and 6-day 
osteogenically precultured cells may secrete more bioactive factors to support cell 
proliferation, thus resulting in a higher DNA amount of both layers due to autocrine and 
paracrine signaling. 
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Chondrogenic Differentiation ofMSCs in the Chondrogenic Layer 
It has been shown that when MSCs undergo chondrogenic differentiation, they 
start to express chondrocyte-specific marker genes such as collagen type II and aggrecan, 
along with downregulating expression of the gene for collagen type I, which is produced 
by undifferentiated MSCs [137]. Therefore, chondrogenic differentiation of MSCs 
encapsulated in the top (chondrogenic) layer of the constructs was determined by gene 
expression for collagen type II, aggrecan, and collagen type I. Gene expression data 
shown in Figure VI-4 (A-C) demonstrated upregulation of collagen type II and aggrecan 
gene expression and downregulation of collagen type I gene expression over time for all 
the treatments, indicating the chondrogenic differentiation of the MSCs encapsulated in 
the chondrogenic layer of the hydrogel constructs in the coculture environment. 
The stimulatory effect of TGF-P3 on MSC chondrogenic differentiation was 
apparent, as higher levels of collagen type II and aggrecan gene expression were 
observed in the TGF-p3-treated groups (the OS0+, OS3+, OS6+ and OS 12+ groups) than 
in the corresponding groups without TGF-P3 (the OS0-, OS3-, OS6- and OS 12- groups, 
respectively). Similar results have been reported in the literature, showing the important 
roles of TGF-P3 for MSC chondrogenic differentiation [103, 105]. Comparing the results 
of TGF-P3 and TGF-pi treatments at day 28 [Figure VI-4 (A-C)], where the same 
amount of TGF-P3 or TGF-pl was loaded on MPs and encapsulated with MSCs in the 
chondrogenic layer of the bilayered hydrogel composites, we found that TGF-P3 was 
more efficient than TGF-pi in enhancing MSC chondrogenic differentiation, when no 
osteogenic cells were involved in the bottom (osteogenic) layer. TGF-P3 resulted in 
higher levels of gene expression for collagen type II and aggrecan, as well as a lower 
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level of gene expression for collagen type I, than TGF-pi at day 28. The results agreed 
with the findings from some previous studies. For example, Barry et al. have compared 
the chondrogenic potential of three TGF-P isoforms on human bone marrow derived 
MSCs [103]. They found that TGF-P2 and TGF-p3 are more effective than TGF-pl in 
promoting chondrogenesis, as evidenced by an earlier and greater deposition of GAG and 
type II collagen. 
The incorporation of osteogenic cells of three different osteogenic preculture 
periods in the osteogenic layer of the hydrogels all resulted in an increase in chondrocytic 
gene expression of the chondrogenic-layer cells (not significant) [Figure VI-4 (A-B)], 
suggesting their stimulatory effect on MSC chondrogenesis. The results were expected, 
since studies in our laboratory have shown that MSCs cultured in osteogenic medium 
either express genes for or secrete many bioactive factors related to cartilage and bone 
formation, including TGF-P 1, BMP-2, fibroblastic growth factor 2 (FGF-2), vascular 
endothelial growth factor (VEGF), and insulin-like growth factor 1 (IGF-1) [93, 96]. 
Many studies including ours have suggested these paracrine signals could have 
contributed to the chondrogenic differentiation of the cocultured MSCs or chodnrocytes 
[130,134,180]. 
Osteogenic cells demonstrated a combined effect with both TGF-P 1 and with 
TGF-P3 on enhancing MSC chondrogenic differentiation in this study. It should be noted 
that the combined effects were more apparent in the TGF-P 1 treatments than the TGF-P3 
treatments at day 28, however, it was probably due to a more efficient potential of 
TGF-p3 alone for MSC chondrogenesis. Osteogenic cells of various osteogenic 
preculture periods, in combination with TGF-P3- (or TGF-P 1-) loaded MPs, enhanced 
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collagen type II and aggrecan gene expression of the MSCs at different levels. For 
collagen type II gene expression, there was a trend that longer osteogenic preculture 
periods of cells in the osteogenic layer resulted in a higher collagen type II gene 
expression of the cocultured MSCs in the chondrogenic layer in the presence of 
TGF-P3-loaded MPs. A more apparent trend was seen in similar hydrogel composites 
containing TGF-pi. In contrast, for aggrecan gene expression, 3-day and 6-day 
osteogenically precultured cells in the bottom (osteogenic) layer resulted in a more rapid 
and greater upregulation in gene expression of the top-layer MSCs compared to plain 
MSCs or 12-day osteogenically precultured cells in the bottom layer. This was true in all 
the cases, with blank MPs, TGF-p3-loaded MPs, or TGF-pi-loaded MPs in the 
chondrogenic layer. For collagen type I gene expression, although no difference was 
observed among the osteogenic treatments, all the values decreased at day 28 compared 
to day 0. Our previous study indicated that the synergistic effect of TGF-pi and 
osteogenic cells on MSC chondrogenic differentiation could be attributed to the 
cross-talk between the growth factor released from MPs and other growth factors secreted 
by osteogenic cells [180]. Therefore, the results of this study suggest possible differences 
in the soluble growth factors secreted by cells of various osteogenic preculture periods. 
In another study, Nakaoka et al. cocultured chondrocytes and osteoblasts in a 
culture medium with or without osteogenic supplements [130]. Their results also 
indicated that the differentiation level of osteoblasts (caused by the presence of 
osteogenic supplements) influenced collagen type II and aggrecan gene expression levels 
of the chondrocytes. Additionally the chondrocytes showed a significant increase in 
collagen type X gene expression, indicative of differentiation into a hypertrophic 
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phenotype, under the combined effects of osteoblasts and osteogenic supplements in the 
culture medium. Although the results are not directly comparable with the present study 
due to the differences in the cells types, culture medium, and the coculture system 
selected, both studies underscore the importance of the investigation of the cell 
differentiation stages on the cell signaling in osteochondral tissue. 
GAG production, associated with the chondrogenic phenotype of the cultured 
cells, exhibited higher values for all the groups at later time points than at day 0 [Figure 
VI-2 (B)], which provided additional evidence of MSC chondrogenic differentiation. 
However, GAG production was comparatively low, and no apparent difference was 
observed in the cross sections stained with Safranin O [Figure VI-6 (top layer of C-J)]. 
As previously reported, the tight polymer network may have limited the deposition of 
matrix [75]. Calcium content was low in the chondrogenic layer of bilayered hydrogels 
for all the treatments at all the time points [Figure VI-2 (C)], confirming that MSCs in the 
chondrogenic layer did not undergo osteogenic differentiation under the influence of both 
TGF-|33 and [3-glycerophosphate in the medium. 
Confocal microscopy images [Figure VI-5 (B-C)] and histological images [Figure 
VI-6 (C-J)] each showed differences in cell distribution in the top (chondrogenic) layer of 
hydrogels at day 28. Compared to the OS0- (control) group [Figure VI-5 (B) and Figure 
VI-6 (C)], where the cells were sparsely distributed, more cell aggregates were observed 
in the TGF-(33 treatments [noted with small arrows in Figure VI-5 (C) and Figure VI-6 (D, 
F, H)] at day 28. Previous studies have shown that MSC condensation is important for 
inducing chondrogenesis during joint development [26]. Thus, a higher extent of 
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chondrogenic differentiation of MSCs in the presence of TGF-P3 in the current study 
may be related to a better cell-cell contact. 
Osteogenic Differentiation of Cells in the Osteogenic Layer 
The osteogenic differentiation of the cells encapsulated in the bottom (osteogenic) 
layer was assessed by their ALP enzyme activity and calcium deposition. ALP activity 
has been regarded as an early marker for the osteogenic differentiation of MSCs or 
osteoblasts [49, 51, 76]. Many previous studies investigating osteogenic differentiation of 
cells have reported that ALP activity of the cells increased during their proliferation 
period, peaked before mineralization, and then decreased [49, 51]. ALP results of this 
study in Figure VI-3 (B) showed that MSCs (in the OS0± groups) encapsulated in the 
osteogenic layer followed the characteristic trend for ALP activity, indicative of their 
osteogenic differentiation. Although the OS0+ group (with TGF-P3 in the top layer) had 
higher ALP levels than the OS0- group (without TGF-P3 in the top layer) at days 7, 14 
and 28, the ALP peak in the OS0+ group was seen to shift to a later time point (day 14) 
compared to the ALP peak of the OSO- group at day 7. The results suggest that TGF-P3 
may prolong the immature stage of MSCs and delay the osteogenic process. 
ALP activity of osteogenic cells was higher than that of plain MSCs after the 
preculture at day 0. Additionally, there was a trend that longer exposure to the osteogenic 
medium resulted in higher ALP values (although the differences were not significant). 
During the subsequent culture in the hydrogel composites, ALP levels of the osteogenic 
cells slight increased or remained unchanged. This indicates that the peaks of their ALP 
values may have occurred during the osteogenic preculture in tissue culture flasks. 
However, the cells were able to maintain their osteoblastic phenotype in the hydrogels. 
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Calcium deposition is a marker for late-stage osteogenic differentiation [49, 51]. 
The results from the calcium assay on the osteogenic layer of the hydrogels did not reveal 
significant differences in calcium content among the groups, however significant 
increases in calcium content compared to the day 0 values were observed in some 
samples containing osteogenically precultured cells at later time points [Figure VI-3 (C)]. 
Von Kossa staining of the cross sections of the hydrogel composites at day 28 confirmed 
the deposition of mineralized matrix in the samples containing precultured osteogenic 
cells in the bottom (osteogenic) layer and blank MPs in the top (chondrogenic) layer [the 
OS3-, OS6- and OS 12- groups in Figure VI-6 (E, G, I)]. In those samples, a darker 
staining of calcium deposition was observed in the middle area of the hydrogel 
composites, some even spread to the top layer, as shown in Figure VI-6 (G, I). More 
calcium deposition in the middle area of the hydrogels could be due to a faster 
degradation rate in the center of the hydrogels (seen from cross sections of the hydrogel 
composites without cells, data not shown), giving the cells more space to lay down matrix. 
In contrast to the blank MP treatments, no staining of calcium was observed in either 
layer of the TGF-P3 treatments [Figure VI-6 (D, F, H, J)]. This finding, along with the 
results from the ALP assay showing the delay of peak ALP activity in the presence of 
TGF-P3, suggest that TGF-P3, or chondrocyte-like cells induced by TGF-P3 had an 
inhibitory effect on the maturation and mineralization of osteoblastic cells encapsulated 
in the bottom layer. In fact, other studies investigating the effect of TGF-P3 on osteogenic 
differentiation of MSCs, MSC-derived osteoblasts and osteoblast-enriched bone cells, 
have also shown that TGF-P3 suppressed osteogenic differentiation and matrix synthesis 
of the cells [104, 108]. 
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Conclusions 
We fabricated a bilayered osteochondral construct with good integration between 
layers, using OPF hydrogel composites containing gelatin MPs and MSCs. A live/dead 
assay revealed that cell viability was maintained in both layers during the coculture, and 
the cellularity of each layer was influenced by the osteogenic preculture period of the 
cells encapsulated in the osteogenic layer. TGF-P3-loaded MPs significantly stimulated 
chondrogenic differentiation of MSCs in the chondrogenic layer. Additionally, cells of 
various osteogenic preculture periods in the osteogenic layer, along with TGF-P3, 
enhanced chondrogenic gene expression of the MSCs in the chondrogenic layer to 
different extents. In the osteogenic layer, osteogenically precultured cells maintained 
their osteoblastic phenotype, as evidenced by a sustained ALP activity and some calcium 
deposition. However, TGF-P3 showed an inhibitory effect on cell mineralization by Von 
Kossa staining. The results demonstrated the fabrication of bilayered osteochondral 
constructs using biodegradable hydrogel composites and suggested their application for 
the co-delivery of growth factors and MSCs for cartilage tissue engineering, while 
illustrating that encapsulated cells of different degrees of osteogenic differentiation can 
significantly influence the chondrogenic differentiation of co-cultured progenitor cells in 
both the presence and absence of chondrogenic growth factors. 
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Figure VI-1: A schematic representation of the overall experimental design. During the 
plate preculture, rabbit marrow mesenchymal stem cells (MSCs) were cultured with 
either general medium (GM) or osteogenic medium (OM) or both for a total of 12 days. 
However, cells were exposed to OM for different time periods: 0, 3, 6 and 12 days, and 
were named MSCs, OS3 cells, OS6 cells, OS 12 cells, respectively. After cell 
encapsulation at day 0, bilayered hydrogel composites were cultured in chondrogenic 
medium (CM). Eight groups were included, namely the OS0±, OS3±, OS6± and OS12± 
groups. The top layer of the hydrogels encapsulated MSCs with blank microparticles 
(MPs) (indicated with - ) or with transforming growth factor-P3 (TGF-|33)-loaded-MPs 
(indicated with +). The bottom layer of the hydrogel composites contained blank MPs 
and cells of different preculture periods: MSCs in the OS0± groups, OS3 cells in the 
OS3± groups, OS6 cells in the OS6± groups, and OS 12 cells in the OS12± groups, 
respectively. 
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Figure VI-2: DNA content (A), GAG content normalized to |xg DNA (B) and calcium 
content (C) for the top layer of the bilayered hydrogel composites. Error bars represent 
means ± standard deviation for n = 4. At day 0, all groups shared top-layer samples for 
the biochemical assays. Statistical significance symbols are defined in Table VI-1. 
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Figure VI-3: DNA content (A), ALP enzyme activity (B) and calcium content (C) for the 
bottom layer of the bilayered hydrogel composites. Error bars represent means ± standard 
deviation for n = 4. At day 0, the OS0± groups shared bottom-layer samples for all 
biochemical assays; and similarly the OS3± groups, OS6± groups, and OS12± groups 
shared samples respectively. Statistical significance symbols are defined in Table VI-1. 
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Figure VI-4: Quantitative gene expression of collagen type II (A), aggrecan (B), and 
collagen type I (C) for the top layer of the bilayered OPF hydrogel composites. Data are 
presented as a fold ratio after being normalized to GAPDH values. The expression level 
of controls (Day 0, OS0- group) is represented as one. At day 28, gene expression levels 
were compared between top layer hydrogels encapsulating TGF-|33 and those 
encapsulating TGF-|31. Error bars represent means ± standard deviation for n = 4. 
Statistical significance symbols are defined in Table VI-1. 
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Figure VI-5: Confocal fluorescence microscopy images of cells encapsulated in top and 
bottom layers of the bilayered composites after encapsulation (A) and after 28 days of 
culture (B-C) with live/dead reagents. A green fluorescence (calcein AM) designates live 
cells, whereas a red fluorescence (EthD-1) indicates dead cells. Arrows indicate 
aggregated rabbit marrow MSCs in OPF hydrogel composites. Scale bar represents 100 
urn. 
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Figure VI-6: Histological sections stained with Von Kossa and Safranin O stainings 
illustrating cells encapsulated in top and bottom layers of the bilayered composites after 
encapsulation (A) and after 28 days of culture (C-J). (B) shows a light microscopy image 
of a cross section of a bilayered hydrogel encapsulating MSCs and blank MPs in each 
layer at day 0. Small arrows indicate aggregated cells in OPF hydrogel composites. Big 
arrows indicate MPs. Scale bar represents 1 mm in (B), and 250 um in the histological 
images (A, C-J). 
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Tables 
Table VI-1: Definition of statistical significance symbols in Figures VI-2, 3, 4 and 
Figures A-2, 3, 4. 
Symbols Statistical Significance (p<0.05) 
* A significant difference between the values at a later time point and day 0 within a 
given group 
** A significant decrease compared to a previous time point within a given group 
t A significant difference between a TGF-p3-loaded MP treatment and its blank MP 
control at the same time point 
# A significant difference compared to another group within the TGF-P3 -treated 
groups or within blank MP groups at the same time point 
§ A significant difference between the TGF-p3 and TGF-pi groups, of the same 
bottom layer formulation at the same time point 
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CHAPTER VII: SUMMARY 
Articular cartilage has limited ability to repair itself. Therefore, the overall 
objective of this research was to develop a biodegradable hydrogel composite as a cell 
and growth factor carrier for the repair and regeneration of articular cartilage in an 
osteochondral defect. 
An initial study demonstrated that OPF hydrogel composites containing 
TGF-J31 -loaded MPs supported MSC chondrogenic differentiation in vitro. Additionally, 
hydrogel composites of higher swelling ratios (larger mesh sizes) resulted in enhanced 
upregulation of chondrocyte-specific genes of the encapsulated MSCs, such as collagen 
type II and aggrecan. 
Next, these hydrogel composites containing MSCs were implanted in an 
osteochondral defect in rabbits. After 12 weeks, OPF hydrogel composites partially 
degraded. Histological analysis revealed that the implantation of MSCs with the hydrogel 
composites facilitated subchondral bone formation in the presence of TGF-pi. However, 
the delivery of MSCs either with or without TGF-pi did not improve cartilage 
morphology. 
Accordingly, further investigation explored the fabrication of a bilayered 
construct to mimic native osteochondral tissue. An osteochondral construct was 
successfully fabricated using OPF/MP hydrogel composites and MSCs, consisting of a 
chondrogenic layer and an osteogenic layer. In vitro culture of the bilayered constructs 
showed good integration between layers. MSCs were able to undergo chondrogenic 
differentiation in the presence of TGF-|31 in the chondrogenic layer, while osteogenic 
cells maintained osteoblastic phenotype in the osteogenic layer. Most importantly, the 
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osteogenic cells exhibited a synergistic effect with TGF-pi-loaded MPs, promoting 
chondrogenic differentiation of MSCs in the chondrogenic layer. 
A following study further investigated the combined effects of TGF-(33 and 
osteogenic cells of different preculture periods on the chondrogenic differentiation of 
co-cultured MSCs in a similar bilayered hydrogel composite. Compared to TGF-pi, 
TGF-J33 loaded on the MPs was more effective in stimulating chondrogenic 
differentiation of MSCs in the chondrogenic layer. Additionally, cells of various 
osteogenic preculture periods in the osteogenic layer, along with TGF-P3, enhanced 
chondrogenic gene expression of the MSCs in the chondrogenic layer to different extents. 
Overall, these studies demonstrated the applications of OPF hydrogel composites 
as an injectable scaffold for MSC differentiation, suggesting their great potential for the 
co-delivery of growth factors and cells for osteochondral tissue engineering. 
Future studies may involve investigation of the release kinetics of different 
bioactive molecules released from multilayered cell-laden hydrogels on the structure and 
function of osteochondral tissue. Additional investigation may focus on the effects of the 
mechanical properties of multilayered cell-laden hydrogels on their capacity to regenerate 
osteochondral tissue. Further investigation may emphasize the effects of the 
differentiation stage of cell populations encapsulated in different layers of multilayered 
cell-laden structure on osteochondral tissue formation and regeneration. 
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Figure A-l: A schematic representation of the overall experimental design for a 
supplemental study. This study was performed using the same conditions as those in 
Chapter VI, except that TGF-|31 instead of TGF-P3 was used in the top layer of the 
hydrogel composites. In particular, during the plate preculture, rabbit marrow 
mesenchymal stem cells (MSCs) were cultured with either general medium (GM) or 
osteogenic medium (OM) or both for a total of 12 days. However, cells were exposed to 
OM for different time periods: 0, 3, 6 and 12 days, and were named MSCs, OS3 cells, 
OS6 cells, OS 12 cells, respectively. After cell encapsulation at day 0, bilayered hydrogel 
composites were cultured in chondrogenic medium (CM). Eight groups were included, 
namely the OS0±, OS3±, OS6± and OS12± groups. The top layer of the hydrogels 
encapsulated MSCs with blank microparticles (MPs) (indicated with -) or with 
transforming growth factor-pi (TGF-pi)-loaded-MPs (indicated with +). The bottom 
layer of the hydrogel composites contained blank MPs and cells of different preculture 
periods: MSCs in the OS0± groups, OS3 cells in the OS3± groups, OS6 cells in the OS6± 
groups, and OS 12 cells in the OS12± groups, respectively. 
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Figure A-2: DNA content (A), GAG content normalized to \ig DNA (B) and calcium 
content (C) for the top layer of the bilayered hydrogel composites containing blank MPs 
(-) or TGF-pi-loaded MPs (+). Error bars represent means ± standard deviation for n = 4. 
At day 0, all groups shared top-layer samples for the biochemical assays. Statistical 
significance symbols are defined in Table VI-1. 
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Figure A-3: DNA content (A), ALP enzyme activity (B) and calcium content (C) for the 
bottom layer of the bilayered hydrogel composites containing blank MPs (-) or 
TGF-pi-loaded MPs (+). Error bars represent means ± standard deviation for n = 4. At 
day 0, the OS0± groups shared bottom-layer samples for all biochemical assays; and 
similarly the OS3± groups, OS6± groups, and OS12± groups shared samples respectively. 
Statistical significance symbols are defined in Table VI-1. 
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Figure A-4: Quantitative gene expression of collagen type II (A), aggrecan (B), and 
collagen type I (C) for the top layer of the bilayered OPF hydrogel composites containing 
blank MPs (-) or TGF-P1-loaded MPs (+). Data are presented as a fold ratio after being 
normalized to GAPDH values. The expression level of controls (Day 0, OS0- group) is 
represented as one. Error bars represent means ± standard deviation for n = 4. Statistical 
significance symbols are defined in Table VI-1. 
